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ABSTRACT 
 
 
New Mechanism-Based Anticancer Drugs That Act as Orphan Nuclear Receptor 
Agonists. (May 2006) 
Sudhakar Reddy Chintharlapalli, B.V.M., College of Veterinary Science,  
Acharya N.G.Ranga Agricultural University, India;  
M.S., Texas A&M University-Kingsville 
Chair of Advisory Committee: Dr. Stephen Safe 
 
 1,1-Bis(3'-indolyl)-1-(p-substitutedphenyl)methanes containing p-
trifluoromethyl (DIM-C-pPhCF3), p-t-butyl (DIM-C-pPhtBu), and phenyl (DIM-C-
pPhC6H5) substituents have been identified as a new class of peroxisome proliferator-
activated receptor γ (PPARγ) agonists that exhibit antitumorigenic activity. In this study, 
the PPARγ-active compounds decreased HT-29, HCT-15, RKO, HCT116 and SW480 
colon cancer cell survival and KU7 and 253JB-V33 bladder cancer cell survival. In HT-
29, HCT-15, SW480 and KU7 cells, the PPARγ agonists induced caveolin-1 expression 
and this induction was significantly downregulated after cotreatment with the PPARγ 
antagonist GW9662. Since overexpression of caveolin-1 is known to suppress cancer 
cell and tumor growth, the growth inhibitory effects of the DIM compounds in these cell 
lines are associated with PPARγ-dependent induction of caveolins. These PPARγ-active 
compounds did not induce caveolin-1 in HCT-116 cells. However, these compounds 
induced NSAID-activated gene-1 (NAG-1) and apoptosis in this cell line. This 
represents a novel receptor-independent pathway for C-DIM-induced growth inhibition 
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and apoptosis in colon cancer cells. In SW480 colon cancer cells 2.5-7.5 μM C-DIMs 
induced caveolin-1 whereas high concentrations (10 μM) induced pro-apoptotic NAG-1 
expression. In athymic nude mice bearing SW480 cell xenografts DIM-C-pPhC6H5 
inhibited tumor growth and immunohistochemical staining of the tumors show induction 
of apoptosis and NAG-1 expression. Thus, the PPARγ-active compounds induce both 
receptor-dependent and-independent responses in SW480 cells which are separable over 
a narrow range of concentrations and this dual mechanism of action enhances their 
antiproliferative and anticancer activities. Similar results were obtained for another 
structural class of PPARγ agonists namely 2-cyano-3,12-dioxoolean-1,9-dien-28-oic 
acid (CDDO) and the corresponding methyl (CDDO-Me) and imidazole (CDDO-Im) 
esters. Structure-activity studies show that 1,1-bis(3'-indolyl)-1-(p-
substitutedphenyl)methanes containing p-trifluoromethyl (DIM-C-pPhCF3), hydrogen 
(DIM-C-pPh) and p-methoxy (DIM-C-pPhOCH3) substituents activate Nur77 and induce 
apoptosis in pancreatic, prostate, and breast cancer cell lines. Nur77 agonists activate the 
nuclear receptor, and downstream responses include decreased cell survival, induction of 
cell death pathways including tumor necrosis factor related apoptosis-inducing ligand 
(TRAIL) and PARP cleavage. Nur77 agonists also inhibit tumor growth in vivo in 
athymic nude mice bearing Panc-28 cell xenografts. 
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CHAPTER I 
 
INTRODUCTION 
Nuclear Receptors 
 Nuclear receptors comprise a large family of ligand-dependent and independent 
transcription factors responsible for processes as diverse as organogenesis during 
development, to governing cyclicity in reproductive tissues. These transcription factors 
act by transducing the effects of small, lipophilic hormones, synthetic compounds and 
other endogenous ligands into transcriptional responses (1-4). Nuclear receptors 
comprise the largest evolutionarily conserved family of transcription factors, found in a 
variety of animal kingdoms from nematodes to man. More than 5% of our genes are 
predicted to encode transcription factors underscoring the importance of this family in 
biology.  
 In humans, 48 nuclear receptors (Table 1.1) (5) and in mouse 49 nuclear 
receptors (6) have been identified; this can be compared to 21 nuclear receptor genes in 
the complete genome of the fly Drosophila melanogaster (7) and unexpectedly more 
than 270 nuclear receptor genes in the worm Caenorhabditis elegans (8). This diversity 
has been organized into a phylogeny-based nomenclature of the form NRxyz, where x is 
the sub-family, y is the group and z is the gene (9). The nuclear receptor superfamily 
 
__________________ 
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 2
includes receptors for steroid hormones [(estrogen receptor (ER), androgen receptor 
(AR), adrenal glucocorticoid receptor (GR), mineralocorticoid receptor (MR), and 
progesterone receptor (PR)], nuclear hormones [(vitamin D receptor (VDR), retinoic 
acid receptor (RAR) retinoid X receptor (RXR), thyroid receptor (TR)], and several 
orphan nuclear receptors such as [(peroxisome proliferator activated receptors (PPAR)] 
have also been characterized. Orphan receptors have diverse functions in cells, during 
development and in adult physiology, however their endogenous ligands are not 
completely defined. Some orphan receptors such as PPARs are activated by endogenous  
 
Fig. 1.1. Schematic illustration of the structural and functional organization of nuclear receptors. The 
evolutionary conserved regions C and E are indicated as boxes and a black bar represents the divergent 
regions A/B, D and F. Domains functions are described above and below the scheme. Two transcription 
activation functions(AFs) have been described in several nuclear receptors, a constitutively active AF-1 in 
region A/B and a ligand inducible AF-2 in region E. Within these activation functions, autonomous 
transactivation domains (ADs) have been defined in the ER and PR N-terminal regions. In the case of the 
ER, RXR, TR an autonomous activation domain encompassing helix H12 has been detected at the C-
terminal end of the ligand binding domain E (10). 
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Table 1.1. Human nuclear receptors (10). 
 
Class Receptor Subtype Nomenclature Ligand Half-site1 Configuration2 
       
I Thyroid 
hormone 
receptor 
TRα 
 
TRβ 
 
 
NR1A1 
 
NR1A2 
Thyroid 
hormone 
Thyroid 
hormone 
RGGTCA IR-0, DR4, 
ER6,8 
I Retinoic 
acid 
receptor 
RARα 
RARβ 
RARγ 
 
NR1B1 
NR1B2 
NR1B3 
Retinoic acid 
Retinoic acid 
Retinoic acid 
AGTTCA IR-0,DR2,5, ER-
8 
I Peroxisome 
proliferators 
activated 
receptor 
PPARα 
 
 
PPARβ 
PPARγ 
 
 
NR1C1 
 
 
NR1C2 
NR1C3 
Fattyacids, 
leukotrieneB4, 
fibrates 
Fattyacids 
Fattyacids, 
prostaglandin 
J2 
AGGTCA DR-1 
I Reverse 
erbA 
Rev-erbα 
Rev-erbβ 
 
NR1D1 
NR1D2 
Orphan 
Orphan 
WAWNAG
GTCA 
NR 
I RAR-
related 
orphan 
receptor 
RORα 
RORβ 
RORγ 
 
NR1F1 
NR1F2 
NR1F3 
Cholesterol 
Retinoic acid 
Retinoic acid 
WWCWRG
GTCA 
NR 
I Liver X 
receptor 
LXRα 
 
 
LXRβ 
 
NR1H3 
 
 
NR1H2 
 
Oxysterols, 
T0901317, 
GW3965 
Oxysterols, 
T0901317, 
GW3965 
RGKTCA DR-4 
I Farnesoid X 
receptor 
FXRα 
 
FXRβ 
 
NR1H4 
 
NR1H5 
Bile acids, 
Fexaramine 
Lanosterol 
AGGTCA IR-1, DR-5 
I Vitamin D 
receptor 
VDR 
 
 
NR1I1 1,25-dihydroxy 
vitamin D3, 
litocholic acid 
RGKTCA DR-3 
I Pregnane X 
receptor 
PXR 
 
 
NR1I2 Xenobiotics, 
pregnenolone 
16α–
carbonitrile 
(PCN) 
AGTTCA DR-3 
I Constitutive 
androstane 
receptor 
CAR 
 
 
 
NR1I3 Xenobiotics, 
Phenobarbital 
RGKTCA DR, IR, ER 
II Human 
nuclear 
factor 4 
HNF-4α 
HNF-4γ 
 
NR2A1 
NR2A2 
Orphan 
Orphan 
AGGTCA DR-1 
 4
Table 1.1. Continued. 
 
Class Receptor Subtype Nomenclat
ure 
Ligand Half-site1 Configuration2 
II Testis 
receptor 
TR2 
TR4 
 
NR2C1 
NR2C2 
Orphan 
Orphan 
 
AGGTCA DR-1 
II Taillless TLL 
 
NR2E2 Orphan 
 
AAGTCA NR 
II Photo-
receptor-
specific 
nuclear 
receptor 
PNR 
 
 
 
NR2E3 Orphan 
 
  
II Chicken 
ovalbumin 
upstream 
promoter-
transcriptio
n factor 
COUP-
TFI 
 
COUP-
TFII 
 
 
NR2F1 
 
 
NR2F2 
Orphan 
 
 
Orphan 
RGGTCA DRs, IRs 
II ErbA2-
related 
gene-2 
EAR2 
 
 
NR2F6 Orphan 
 
  
III Estrogen 
receptor 
Erα 
 
 
Erβ 
 
NR3A1 
 
 
NR3A2 
Estradiol-17β, 
tamoxifen, 
raloxifene 
Estradiol-17β, 
various 
synthetic 
compounds 
 
RGGTCA IR-3 
III Estrogen 
receptor–
related 
receptor 
ERRα 
ERRβ 
 
 
ERRγ 
 
NR3B1 
NR3B2 
 
 
NR3B3 
Orphan 
Diethylstilbestr
ol, 4-OH 
tamoxifen 
Diethylstilbestr
ol, 4-OH 
tamoxifen 
 
TCAGGTC
A 
NR 
III Glucocortic
oid receptor 
GR 
 
 
NR3C1 Cortisol, 
dexamethasone
, RU486 
 
AGAACA IR-3 
III Mineralocor
ticoid 
receptor 
MR 
 
 
NR3C2 Aldosterone, 
spirolactone 
AGAACA IR-3 
 
 
 
 
 5
Table 1.1. Continued. 
 
Class Receptor Subtype Nomenclat
ure 
Ligand Half-site1 Configuration2 
III Androgen 
receptor 
AR 
 
 
NR3C4 Testosterone, 
flutamide 
AGAACA IR-3 
IV NGF-
induced 
factor B 
NGFI-B 
 
 
NR4A1 Orphan AAAGGTC
A 
NR, DR-5, 
IR-0 
IV Nurr related 
factor 1 
NURR1 
 
 
NR4A2 Orphan AAAGGTC
A 
NR, DR-5, 
IR-0 
IV Neuron-
derived 
orphan 
receptor 1 
NOR1 
 
 
 
NR4A3 Orphan AAAGGTC
A 
NR, DR-5, 
IR-0 
V Steroidogen
ic factor 1 
SF1 
 
 
NR5A1 Orphan YCAAGGY
CR 
NR 
V Liver 
receptor 
homologous 
protein 1 
LRH1 
 
 
 
NR5A2 Orphan YCAAGGY
CR 
NR 
VI Germ cell 
nuclear 
factor 
GCNF 
 
 
NR6A1 Orphan TCAAGGT
CA 
DR-0 
0 Dosage-
sensitive 
sex reversal 
adrenal 
hypoplasia 
congenita 
critical 
region on 
the 
chromosom
e, gene 1 
 
DAX-1 
 
 
 
 
NR0B1 Orphan   
0 Short 
hetero-
dimeric 
partner 
SHP NR0B2 Orphan   
 
1 R, purine (adenine or guanine); Y, pyrimidine (thymine or cytosine); W, adenine or thymine; K, guanine 
or thymine. 2Hormone response elements are configured as direct repeats (DR), inverted repeats (IR), 
everted repeats (ER) or nonrepeats (NR) and are spaced by the given number of nucleotides. 
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and synthetic ligands and these have been referred to as adopted orphan receptors where 
the identity of true natural ligands in most instances remains to be elucidated. 
 Despite their functional diversity, molecular cloning and structure/function 
analyses have revealed that members of the superfamily have a common functional 
domain structure. This includes a variable N-terminal domain A/B, a well conserved 
DNA-binding domain (DBD) or region C, a not well conserved linker region D, a 
conserved domain E that contains the ligand binding domain (LBD) and insome 
receptors a C-terminal region F whose functions have not been defined (Fig. 1.1).  
The hypervariable A/B region often contains an autonomous transcriptional 
activation function (AF-1) that contributes to constitutive ligand-independent activation 
by the receptor. The DBD is crucial for recognition of specific DNA sequences and 
protein:protein interactions. A second transcriptional activation domain (AF-2) in the 
LBD is essential for ligand-dependent transactivation. The D domain serves as a hinge 
between the DBD and the LBD and allows rotation of the DBD with respect to the LBD 
and also often contains nuclear localization signals. 
Structural features of specific domains of the nuclear receptor superfamily 
The N-Terminal Domain (NTD) 
The NTD of many members of the nuclear receptor superfamily contains a 
powerful transactivation domain, AF-1. Molecular and genetic evidence indicates that 
this NTD plays an important role in gene regulation (11, 12). Circular dichroism and 
nuclear magnetic resonance (NMR) studies have shown that the AF-1 region of GR, 
which is rich in acidic amino acid residues, is largely unstructured in aqueous solution 
 7
under a variety of pH conditions (13). However, as many as three segments at the C-
terminal end of the AF-1 region exhibit α-helical characteristics in the presence of the 
strong α-helix stabilizing agent trifluroethanol (TFE). The ability to activate a reporter 
gene in vivo correlates with the ability to form an α-helical conformation, in addition, 
introduction of helix-breaking proline residues in the potential helix-forming regions of 
the AF-1 domain of GR greatly disturb the transactivation capacity, suggesting that α-
helical structure is important for receptor activity (13, 14). The importance of induction 
of the α-helical structure in the AF-1 region by TFE is a topic of considerable interest 
since TFE not only induces α-helical structure in peptides (15) but can also force helicity 
in peptides. Nevertheless it is unclear whether and under what conditions analogous 
conformational changes in nuclear receptors occur in vivo.  
It is not clear how any part of N-terminal region or AF-1 interacts with other 
proteins to induce transcription. Hypothetically, the transactivation domain is 
unstructured (16) until it is bound to its putative target factors and interaction of the 
transactivation domain with these factors by an induced fit mechanism leads to a 
stabilized structure(17). Functional and physical interaction with the basal transcriptional 
machinery by the AF-1 domain of GR have been reported (18, 19) and mutants of the 
AF-1 domain affected these interactions. Interactions with other coactivators, mediators 
and adaptors are also important (20-22). The data support the idea that conditional 
folding of the activation domain is an important requirement for its interaction with 
target factors and subsequent roles in gene regulation (18, 21, 22). However these 
 8
concepts are only inferred from experimental data since X-ray crystal structure analysis 
on the AF-1 domains of nuclear receptors have not been reported. 
The DNA-Binding Domain (DBD) 
The DBD has the most conserved amino acid sequence among the members of 
the nuclear receptors superfamily. The DBD consists of two zinc-finger motifs, each 
containing four highly conserved cysteine residues coordinating binding of a zinc atom 
(Fig. 1.2). This results in formation of  a tertiary structure containing helices that interact 
specifically with DNA sequences that are organized appropriately in response elements 
(23-25). In addition to the two zinc fingers that span 60-70 amino acids, this domain is 
also comprised of a COOH-terminal extension (CTE).  
With the use of NMR spectroscopy, the structures of the DBDs of the ER, GR 
RAR-β, and RXR in solution have been determined (26-29). Crystal structures of the 
DBDs of the GR and ER complexed with DNA have been reported (16, 23). The central 
feature of the secondary structure elements within the GR DBD is found in three helical 
regions. Helices I and III are oriented perpendicular to each other and form the base of a 
hydrophobic core. NMR studies indicate that helices I and III are both regular α–helices, 
whereas helix II is somewhat distorted (26). The DBD may be considered as two 
interdependent subdomains, each consisting of a zinc ion, tetrahedrally coordinated to 
the sulphurs of four cysteine residues, and an amphipathic helix. The two subdomains 
differ both structurally and functionally. The helix of the first domain is mainly involved 
in site-specific recognition based on its interaction with certain bases in the cognate 
response element hexamer. Also within this helix are the amino acids responsible for 
 9
 
Fig. 1.2. Schematic structure of a nuclear receptor DBD. Amino acid sequences of orphan nuclear receptor 
DNA-binding domain are shown. The two zinc finger modules as well as CTE are identified. Amino acids 
in P-box and D-box that are important for the DNA recognition and dimerization, respectively are 
highlighted (30). 
 
 
 
site-specific discrimination of DNA binding. These 3-4 amino acids have been termed 
the P box (23, 29). 
A loop formed in the second subdomain, the so-called D box provides the DBD 
homodimerization interface, and the helical region is important for less specific DNA 
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COOH terminus of the second Zinc finger forms a right angle with the recognition helix. 
The hinge region 
This region is less conserved in nuclear receptors than the surrounding C and E 
region. The hinge domain allows DBDs and LBDs to adopt several different 
conformations without creating any steric hindrance problems. The D region also 
contains a nuclear localization signal (31). The intracellular localization of nuclear 
receptors is a result of dynamic equilibrium between nuclear cytoplasmic and 
cytoplasmic-nuclear shuttling (32). At equilibrium, some steroid receptors (GR, MR and 
AR) reside in the cytoplasm of cells in absence of ligands and translocate into the 
nucleus in a ligand-induced fashion. Many other nuclear receptors are in the nucleus in 
the unbound state and the addition of ligand facilitates interactions with the promoter 
DNA and transactivation (33, 34). 
The Ligand-Binding Domain (LBD) 
The LBD is a multifunctional domain that, in addition to the binding of ligand, 
mediates receptor homo- and heterodimerization, interaction with heat-shock proteins, 
ligand-dependent transcriptional activity and in some cases, hormone reversible 
transcriptional repression. For 20 out of the 48 human nuclear receptors the crystal 
structure of the LBD has been solved (35). These studies have demonstrated that the 
overall structures of the different receptors are rather similar, suggesting a canonical 
structure for the different members of the nuclear receptor superfamily (36).  
The LBDs are generally composed of a series of 11-12 α-helices (H1-H12) 
closely folded in a similar manner. There are slight differences in the specific helix 
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number given for topologically analogous sites when LBDs from different receptors are 
compared since no universal numbering convention has been adopted. Inspection of 
helices within the LBDs, show conservation of helical arrangement, with only slight 
differences, regardless of the numbering system. The structure of the unliganded LBD of 
the RXR-α revealed that about 65% of the total volume is occupied by 11 α-helices 
organized in a three layer, antiparallel sandwich and a conserved β–sheet between H5 
and H6 (37). A central core layer of three helices is packed between two additional 
layers to create a cavity, the ligand binding pocket, which accomodates the ligand. This 
domain is mainly hydrophobic and is buried within the bottom half of the LBD. Contacts 
with the ligand can be extensive and include different structural elements throughout the 
LBD.  
Similar overall folding was also observed for the structures of the ligand-bound 
LBDs of TR, RAR-γ, and ERα (38-40) and with the exception of the C-terminal helix 
their secondary structural features are superimposable (41). However, PPARγ is unique 
in its overall structure and contains an extra helix designated H2′, and the VDR contains 
a poorly structured insertion between helices H1 and H3 for which no functional role has 
been defined (42). Although the secondary structure elements in the unliganded and 
ligand bound RXR-α and RXR-γ are similar, the bound receptor is more compact. The 
ligand-bound LBDs of the TR and ER also reveal a more compact structure compared to 
unliganded RXR-α. Presumably, these differences are due to ligand-induced 
conformational changes that stabilize the conformation of a large portion of the LBD. 
The extensive involvement of amino acids from many parts of the LBD to make the 
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ligand-binding pockets is consistent with the data showing that mutation of several 
amino acid mutations within the LBD interfered with ligand binding. 
The ER LBD was the first nuclear receptor LBD in which the structure of both 
agonist and antagonist bound complexes have been determined (38). The binding cavity 
of the LBD bound to the agonist 17 β-estradiol is completely partitioned from the 
external environment, occupying a relatively large portion of the hydrophobic core of the 
ER-LBD. This is formed by segments of H3, H6 and H8 and the loop formed by H11 
and H12. The antagonist raloxifene binds at the same site but significantly alters the 
position of helix 12. When the antagonist is bound, the positioning of H12 inhibits 
interaction of the LBD with coactivators. Thus, the altered LBD surface presumably 
changes critical protein:protein contacts involving AF2 (H12) and 
coactivators/corepressors and this accounts for the antagonist activity of raloxifene. 
The ligand-inducible activation function has been attributed to the C-terminal 
part of the LBD (43, 44). For this function to manifest itself, ligand-dependent 
interactions with a number of putative transcriptional coactivators must occur (45). The 
region shown by molecular genetics to be essential for AF2 function adopts a helical 
structure, which corresponds to the C-terminal helix H11 in the unliganded RXR-α LBD 
structure. This helix is often known as the AF2 activation helix which extends from the 
core of the LBD, pointing away from the dimer axis at an angle of about 450. This 
orientation may be optimal for facilitating interactions with putative intermediary factors 
(46). The equivalent AF2 activation helix corresponds to the C-terminal amphipathic 
helix H12 in the liganded RAR, TR, and ER LBDs, and it is positioned as a tight part of 
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the globular LBD that is different in position from its counterpart in the unliganded RXR 
(37-40). Deletion and mutational studies have shown that the AF2 activation helix is 
essential for ligand induced transcriptional activation. It appears that ligand-dependent 
activation of AF2 induces major conformational changes, required for efficient 
interactions with transcription factors (47, 48). 
The C-terminal F region 
The C-terminal F region is not evolutionary conserved and only some receptors 
possess this domain. The function of the C-terminal sequence is poorly understood, 
however, recent data suggest that the F-region might play a role in coactivator 
recruitment to the E-domain and in determining the specificity of the LBD coactivator 
interface (49, 50). 
Hormone Response Elements (HREs) 
HREs are specific DNA sequences in target genes that are bound by nuclear 
receptors in response to steroid hormones to regulate transcription. These elements are 
normally present in the 5′ regulatory sequences of target genes. HRE’s can be located 
proximal to the translational start site in the distal enhancer region up to several 
kilobases upstream of the transcriptional start site. The glucocorticoid response element 
(GRE) was the first HRE identified by mutational analysis of the glucocorticoid-
responsive mouse mammary tumor virus (MMTV) gene (51). A deletion or mutation of 
that sequence eliminated hormone responsiveness. Later it was demonstrated that a short 
oligonucleotide corresponding to the identified sequence conferred glucocorticoid 
binding and responsiveness to a heterologous promoter (52). The GRE consisted of two 
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short, imperfect inverted repeats separated by three nucleotides. Later, response elements 
for PR, MR and AR were shown to be similar to that of GR (53-57). 
 A large number of synthetic and naturally occurring HREs were analyzed and a 
sequence of 6 bp that constitutes the core recognition motif was determined. Two 
consensus motifs have been recognized, the sequence AGAACA is preferentially 
recognized by steroid receptors except ER, whereas AGG/TTCA serves as recognition 
motif for other receptors of the nuclear receptor superfamily (1). Both consensus and 
variable nonconsensus HREs have been identified. Some monomeric receptors bind to a 
single hexameric motif, but most nuclear receptors bind as homo- or heterodimers to 
HREs composed principally of two hexameric half-site core sequences. Modifying the 
location of the half-sites relative to one another creates diversity among HREs. For 
dimeric HREs, the half-sites can be configured as palindromes, inverted palindromes or 
direct repeats (DR) and this influences the receptor dimerization pattern on an HRE.  
The nuclear receptor superfamily can be subclassified into at least four categories 
based on their protein-protein and protein-DNA (HRE) interactions (Fig. 1.3). Class I 
steroid hormone receptors, form symmetrical head to head arranged homodimers bound 
to a palindromic HRE (23). Class II receptors are ligand-activated receptors that always 
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Fig. 1.3. Classification of nuclear receptor family transcription factors. Nuclear receptors can be grouped 
into four classes according to their ligand binding, DNA binding, and dimerization properties: Steroid 
receptors, RXR:Nuclear Receptor (NR) heterodimers, RXR heterodimers, homodimeric orphan receptors, 
and monomeric orphan receptors. Shown are representative receptors for each group (30). 
  
 
bind to the DR elements arranged asymmetrically in head to tail orientation as a 
heterodimer with RXR. Class III receptors bind primarily to direct repeats as 
homodimers and Class IV receptors typically bind to extended core sites as monomers. 
Most orphan receptors fall into the Class III and IV categories. Further selectivity is 
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created between HREs by varying the number of neutral base pairs separating the half-
site repeats. According to inter-half-site spacing (1-5 bp), these elements are also known 
as DR1-DR5 (4, 58-60). This is the key identity factor contributing to the binding 
specificity of different RXR heterodimer pairs and it provides the geometry required for 
two subunits to specifically interact. Even a single base pair insertion in the inter-half-
site spacing displaces the interacting subunits by nearly 3.4 A0 and reorients them by 
~350, leading to disruption of important protein-protein and protein-DNA interactions 
(61). Sequence composition of the spacer nucleotides plays a less critical role in the 
recognition of HREs by receptors (60, 61). 
Molecular mechanisms of transcriptional regulation by nuclear receptors 
Nuclear receptor activation is often represented by initial ligand binding to a 
cytoplasmic receptor complexed with heat shock proteins, which then translocates to the 
nucleus and binds HREs to activate gene expression. This model is valid only for some 
steroid hormone receptors (62). Most unbound nuclear receptors are constitutively 
nuclear and bound to DNA in the absence of ligand, many nuclear receptors act as strong 
repressors of gene expression (63-67). 
Gene expression can be regulated at several different levels, including 
transcription, translation and posttranslation. Transcription can also be regulated at 
multiple levels. The transcriptional activity of a gene can be controlled epigenetically via 
methylation, at the level of its chromatin structure and at the level of the assembly and 
activity of the initiating and elongating polymerase complexes. The reported effects of 
nuclear receptors on transcription are so far restricted to the initiation of transcription by 
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RNA polymerase II (Pol II).  Pol II begins transcription with the formation of 
preinitiation complex in which general transcription factors and Pol II are assembled at 
the promoter in a defined order. It has been demonstrated that nuclear receptors increase 
the formation rate of the complex of basal transcription factors and Pol II at the promoter 
by interacting with specific basal transcription factors including TFIIB, TFIID, and 
TATA binding protein associated factors (TAFs); however it is evident that a multitude 
of other factors are involved in these interactions.  
Overexpression of the GAL4 transcription factor in yeast squelches the 
transcription of genes lacking GAL4 response elements. The observation of 
transcriptional interference or squelching between nuclear receptors provided evidence 
for the existence of limiting common transcriptional cofactors or adaptors. Meyer et al 
(68) first demonstrated squelching for nuclear receptors by showing that stimulation of 
transcription of reporter genes by the PR can be decreased by coexpression of ER in the 
same cell. They also showed that overexpression of ER inhibited transactivation by GR 
and, as expected these steroid hormone receptors were activated by common 
coactivators. Squelching experiments also suggested that different types of AFs exist. 
The two AF domains that were identified in ER and GR differed in their ability to 
squelch one another (46, 69, 70). For example, the AFs of ER will squelch one another, 
but the AF-1 of GR will not squelch AF-2 of ER. 
Nuclear receptor coactivators, a growing family 
Genetic studies demonstrated that transcription cofactors with no specific DNA-
binding activity are essential components of transcriptional regulation, and these studies 
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led to identification of a series of nuclear receptor-interacting coregulator proteins (71). 
It has been shown that coactivators exhibit some characteristic features. First they must 
interact with the activation domain of a nuclear receptor directly in a ligand-dependent 
manner, leading to the enhancement of the receptor activation function. Secondly, a 
coactivator should also interact with components of the basal transcriptional machinery. 
Thirdly, some coactivators also exhibit critical enzymatic functions linked to gene 
regulation, such as the nucleosomal remodeling histone acetyltransferase (HAT) or 
deacetylase (HDAC) activities. Finally, coactivators alone should not enhance basal 
transcriptional activity even though they may contain an autonomous activation function 
(72, 73).  
The p160/SRC family 
 Ligand-induced transactivation function of several nuclear receptors were 
enhanced by a group of conserved adaptor proteins termed as p160/SRC coactivators. 
Three distinct but related family members from different species, with each member 
having a number of splice variants have been identified. These include SRC-1/NCoA-1 
(74-76), TIF2/GRIP1/NCoA-2 (74, 76), and p/CIP/ACTR/AIB1/TRAM1/RAC3 (77-79). 
All three members of the p160/SRC family interact with a broad range of nuclear 
receptors in a ligand-dependent and independent fashion and enhance nuclear receptor-
dependent transcription both in vitro and in vivo (80).  
 The p160/SRC proteins contain three distinct functional domains (Fig 1.4). The 
central nuclear receptor-interaction domain contains three copies of a consensus leucine  
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Fig. 1.4. Structural representation of SRC1a. The structure of SRC1a is representative of a class of highly 
homologous coactivators. These are divided into three subgroups (i, ii, iii) based on more stringent 
homology. Asterisks denote LXXLL motifs. bHLH, basic helix-loop-helix; PAS, period/aryl hydrocarbon 
receptor/single minded; S/T, serine/threonine rich; AB, acidic base; HAT, histone acetyl transferase 
activity; QQQ, glutamine rich (81). 
 
 
rich LXXLL signature motifs (NR box) (75, 82). Biochemical and crystallographic 
studies reveal that the AF2 core (helix 12) undergoes major conformational change upon 
ligand binding, forming part of a “charged clamp” that accommodates p160/SRC 
coactivators within a hydrophobic cleft of the receptor LBD, through direct contacts with 
the LXXLL motifs (83, 84). The N-terminal region of p160 proteins contains a basic 
helix-loop-helix/Per-Arnt-Sim (bHLH/PAS) domain. This domain plays a role in DNA 
binding and homo and heterodimerization between proteins containing these motifs (85). 
These domains have been implicated as potential target sites for other non-nuclear 
receptor activators (80). The central and the carboxy-terminal regions contain two 
intrinsic transcriptional activation domains (AD1 and AD2) that retain their activity 
when transferred to a heterologous DNA binding domain. The AD1 region is responsible 
for interactions with HAT enzymes, p300 and CREB binding protein (CBP) (76, 86, 87), 
but does not interact with nuclear receptors (88). The second activation domain (AD2) 
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located in the C-terminal region of SRC proteins is responsible for interaction with 
histone methyltransferases, CARM1 and PRMT1 (86, 89).  
 p160/SRC family members SRC1 and SRC3 (ACTR) possess an intrinsic 
acetyltransferase activity in their carboxy terminal that is primarily specific for histones 
H3 and H4 (78, 90). This weaker HAT activity does not appear to be essential for the 
nuclear receptor-coactivation function (91). Taken together, the data suggest that 
p160/SRC coactivators effectively target histone modifying enzymes (HATs or histone 
methyltransferases (HMTs)) to nuclear receptors in a ligand-dependent manner. This 
results in chromatin remodeling and results in formation of the preinitiation complex, to 
enhance transcription of target genes. 
The CBP/p300 coactivators 
 CBP and p300 exhibit significant homology and are functionally interchangeable 
(92), and are referred  to as CBP/p300. Although these proteins lack direct DNA-binding 
activity, they are recruited to specific promoters by forming complexes with sequence-
specific transcription factors such as nuclear receptors (80, 93). CBP/p300 coactivators 
contain several distinct and functionally important domains (Fig. 1.5), including a 
conserved HAT domain, a centrally located bromodomain that is frequently found in 
mammalian HATs, three cysteine/histidine (CH)-rich zinc finger domains (CH1, CH2 
and CH3), an Ada2 homology domain, which shares extensive homology with the yeast 
transcriptional coactivator, Ada2p (94) and an SRC/p160 interacting domain (SID). The  
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Fig. 1.5. Structural representation of  p300/CBP.  Factors known to interact with these proteins are shown 
below the structures. HAT, histone acetyl transferase activity; QQQ, glutamine rich; C/H, cysteine rich; 
Bromo, bromodomain (81). 
 
 
CBP/p300 nuclear receptor coactivation function primarily depends on its intrinsic HAT 
activity (95, 96) since mutations in the HAT domain abolishes its ability to enhance 
transactivation in vitro and in vivo (87, 97). CBP/p300 proteins can acetylate all four 
core histones (98) and form complexes with other HATs, such as p300/CBP associated 
factor (p/CAF) (99) TFIIB and Pol II via its CH domains (92, 93). The bromodomain 
plays a role in recognizing different acetylation motifs to facilitate stable CBP/p300 
interactions with chromatin (100). The amino terminal regions of CBP/p300 also contain 
two LXXLL-like motifs that facilitate direct interactions with nuclear receptors (22, 
101). However several studies indicate that CBP/p300 is recruited to nuclear receptors 
by binding to p160/SRC coactivators through its SID domain (102). The recruitment of 
the nuclear receptor-p160/SRC-CBP/p300 complex to specific target genes results in 
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histone acetylation of the proximal promoter and this facilitates the ordered recruitment 
of other types of transcriptional regulatory complexes (103-105). 
CARM1 
The coactivator arginine methyltransferase 1 (CARM1) enhances transcriptional 
activation of a broad range of nuclear receptors by physically interacting with the AD2 
domain of p160/SRC coactivators (86, 89). CARM1 belongs to a conserved family of 
protein arginine methyltransferases (PRMT). PRMT catalyzes formation of asymmetric 
dimethyl arginine residues in proteins by transferring the methyl moiety from S-
adenosyl-L-methionine (AdoMet) to the guanidine group of arginine. CARM1 harbors 
several distinct domains (Fig. 1.6), including the highly conserved central core 
methyltransferase domain containing the AdoMet and arginine binding sites (106). 
Mutational analyses shows that a p160/SRC binding site and homo-oligomerization 
domain significantly overlap with the methyltransferase domain (107). The C-terminal 
region of CARM1 also contains a strong autonomous activation domain. Recent studies 
have demonstrated that CARM1 is recruited to promoters through its interaction with 
CBP/p300 to stimulate nuclear receptor dependent transcription (108). The autonomous 
C-terminal activation domain synergistically acts with methyltransferase activity to 
mediate CARM1 coactivator function. The recruitment of CARM1 and arginine-specific 
H3 methylation results in chromatin remodeling and enhancement of gene transcription 
(105). 
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TRAP/DRIP complex 
 
The thyroid hormone receptor-associated protein (TRAP) and vitamin D receptor 
interacting protein (DRIP) complexes have been isolated based on their ligand-
dependent interactions with TR (109, 110) or VDR (111, 112) respectively. Among the 
several subunits, the 220 kDa component of the TRAP/DRIP complex is unique in that it 
demonstrates direct ligand-dependent binding to several nuclear receptors, including 
TRα, VDR, RXRα, RARα, PPARα, PPARγ, ERα and GR (113-115). TRAP220 protein 
contains three distinct domains (Fig. 1.6) (114). The central nuclear receptor-interaction 
domain has two LXXLL motifs (NR Box). The two NR boxes show different ligand-
dependent affinities for nuclear receptors. NR box 2 preferentially interacts with TRα, 
VDR and PPARα whereas NR box 1 binds the heterodimerization partner RXRα    (114, 
116, 117). Although NR box motifs are critical structural features that facilitate ligand-
dependent nuclear receptor coactivator interactions (118, 119), a recent study 
demonstrates that coactivation of ERα by DRIP205 in ZR75 breast cancer cells is 
complex and involves multiple regions of DRIP205 and ERα (120). Moreover, 
coactivation of ERα by DRIP205 and interaction of these proteins do not require the NR 
box motifs of DRIP205 (120). A serine-rich domain followed by a cluster of mixed-
charged amino acids is present in the C-terminal of TRAP220 which is responsible for 
oligomerization and DNA binding. The DRIP complex and p160/CBP share similar 
nuclear receptor binding determinants but do not bind nuclear receptors simultaneously 
and constitute functionally distinct complexes (116).  A proposed general mode of action 
is that ligand-mediated association of HAT-containing or HAT- interacting coactivators 
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Fig. 1.6. Structural representation of CARM1, PGC-1 and TRAP220. The functional domains/regions are 
depicted. Asterisks denote LXXLL motifs. AD, transcriptional activation domain; RRM, RNA recognition 
motif (81). 
 
 
are exchanged with the TRAP complex which subsequently recruits the transcription 
factors and Pol II to form a functional preinitiation complex (121). 
PGC-1 
Peroxisome proliferator-activated receptorγ coactivator-1 (PGC-1) was initially 
isolated as a coactivator of PPARγ. An isoform of PGC-1, PGC-1α, is preferentially 
expressed in brown adipose tissue and skeletal muscle and plays a role in adaptive 
thermogenesis and energy metabolism (122). PGC-1α enhances the transcriptional 
activation of the uncoupling promoter-1 (UCP-1), and these promoter specific 
coactivator functions are controlled by external environmental stimuli. PGC-1α contains 
several distinct domains (Fig. 1.6). A transcriptional activation domain (AD) and an 
LXXLL motif are present in the amino-terminal region of the protein (123, 124). The 
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LXXLL motif of PGC-1α mediates ligand-dependent interactions with nuclear receptors, 
such as ERα (125), ERRα (126), GR (127), PPARα (123), RXR (128), PPARγ (129) and 
TR (129). PGC-1α also interacts with the SRC-1 and CBP through its N-terminal region 
(124). An inhibitory domain that represses its transcriptional activation function is also 
present in PGC-1α. Interactions with transcription factors induces a conformational 
change in PGC-1α to relieve the inhibitory activity, and enable interaction with other 
effectors. PGC-1α also associates with Pol II and another isoform of PGC-1, PGC-1β, 
which is predominantly expressed in heart, adipose tissue, skeletal muscle and brain, and  
functions as a coactivator for TRβ, PPARα, PPARγ and GR. (130). Unlike PGC-1α, 
PGC-1β is not induced in response to environmental stimuli. 
Other coactivators 
 In addition to the above mentioned coactivators, nearly 50 other putative 
coactivators have been identified. Many coactivators have been extensively studied 
including nuclear receptor interacting factor 3 (NRIF3) (131), nuclear receptor 
coregulator (NRC) (132), also referred to as activating signal cointegrator-2 (ASC-2) 
(133), 250-kDa receptor associated protein (RAP250) (134), thyroid hormone receptor-
binding protein (TRBP) (135), and PPAR-interacting protein (PRIP) (136). Some of the 
coactivators such as E6-associated protein (E6-AP), 70-kDa androgen receptor abrogate 
(ARA70), nuclear receptor coactivator (NCoA62) or NRIF3 interact with AF-2 domain 
of nuclear receptors in a ligand dependent manner whereas other coactivators such as, 
p68 interact with AF-1 domains. Recent studies also suggest that cell-specific 
coactivators may play an important role in gene-specific transcriptional activation. Some 
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coactivators exhibit a relative preference for a determined group of nuclear receptors. 
For instance, ARA70 specifically enhances androgen receptor transcriptional responses 
(137), and four and half LIM domains 2 (FHL2), which has a unique tissue-specific 
expression pattern, selectively increases androgen receptor-dependent transactivation 
(138).  
 One of the more intriguing coactivators is steroid receptor RNA activator (SRA), 
which selectively enhances the transcriptional activity of the steroid hormone receptors 
PR, ER, GR and AR but not other nuclear receptors such as TR or RXR (139). 
Moreover, SRA functions as an RNA transcript and not as a protein. SRA enhances 
steroid receptor activity in presence of cycloheximide, while other coactivators such as 
SRC-1 do not. SRA works exclusively through the amino-terminal AF-1 domain and can 
be detected in a large complex which contains SRC-1 and several other proteins (139).   
 Although biochemical and functional data strongly suggest that coactivators play 
a key role in transcriptional regulation by nuclear receptors, coactivator knock-out 
studies indicate that in addition to their coactivator function they have several other 
physiological roles. For example, SRC-3 knock-out studies indicate that SRC-3 may 
play a critical role in overall growth and sexual maturation (140). The organization or 
expression of nuclear receptor coregulators is also altered in diseases such as X-linked 
dementia and hypothyroidism, further indicating that they play important physiological 
roles (141). 
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Nuclear receptor corepressors 
 
Unliganded nuclear receptors such as RAR and TR bind cis-element in target 
genes and repress the basal transcription and this led to the discovery of nuclear receptor 
corepressors. Nuclear receptor corepressor (NCoR) (64) and silencing mediator for 
retinoic acid and thyroid hormone receptors (SMRT) (63) were originally isolated as 
factors associated with the hinge domain of the unliganded TR and RAR. These 
interactions are disrupted upon binding of their respective ligands. Other studies have 
shown that NCoR and SMRT interact with other nuclear receptors, including VDR, 
PPARδ, and LXR, and with orphan nuclear receptors such as COUP-TF, RORα and 
DAX (80). NCoR and SMRT also interact with steroid hormone receptors, including 
AR, ER and PR (142-146) but only when these receptors are bound to their 
corresponding antagonists. These studies demonstrate that NCoR and SMRT are 
common corepressors of nuclear receptors.  
NCoR and SMRT contain distinct functional domains including C-terminal 
receptor interaction domains (RIDs) that are responsible for nuclear receptor binding 
(Fig. 1.7). RIDs contain a consensus sequence of LXXI/HIXXXI/L (CoRNR box) (147, 
148), representing an extended helix compared to the coactivator LXXLL helix (75, 82), 
which interacts with specific residues in the same receptor pocket required for 
coactivator binding. Multiple distinct domains responsible for repression are also present 
in the amino-terminal ends of corepressors and through these repression domains (RD),  
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Fig. 1.7. Structural representation of corepressors, NCoR and SMRT. The N-terminal region contains 
multiple repression domains (RDs). The receptor interacting domains (RIDs) in the C-terminal region each 
contain a conserved CoRNR are shown with the conserved LXXXIXXXL sequence in bold. The N-
terminal portion of the corepressors also harbors the two matched SANT domains in the DAD and HID 
(81). 
 
 
NCoR and SMRT associate with HDAC leading to targeted hypoacetylation of histones 
and repressed gene expression (147, 149). Two distinct SANT 
(SWI/ADA2/NCoR/TFIIIB) domains have been identified in the amino-terminal regions 
of corepressor proteins such as SWI/SNF, Ada, NCoR and TFIIIB and both NCoR and 
SMRT also contain a SANT domain. In addition NCoR and SMRT have a conserved 
deacetylase domain (DAD) which is critical for interaction of corepressors with HDAC3 
and for activating the HDAC enzyme complex (150). The conserved SANT domain is a 
part of a histone interaction domain (HID) and serves to increase the affinity of the 
active corepressor/HDAC complex for histones (151). 
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Fig. 1.8. Coactivator and corepressor complexes and histone acetylation. In the absence of ligand, the 
nuclear hormone receptor heterodimer is associated with corepressor complexes. The corepressors 
(NCoR/SMRT) recruit histone deacetylases (HDACs) either directly or through interaction with Sin3. 
Deacetylation of histone tails leads to chromatin compaction and transcriptional repression. Ligand 
binding causes the release of corepressor cmplex and the AF-2-dependent recruitment of a coactivator 
complex that contains at least p160 coactivators (SRC-1) and CBP/p300. All of these proteins possess 
histone acetyltransferase (HAT) activity that allows chromatin decompaction and gene activation (30). 
 
 
NCoR and SMRT use multiple complimentary mechanisms to repress 
transcription. Both NCoR and SMRT are not only associated with multiple members of  
the HDAC family (HDACs 3,4, 5, and 7), but also interact with HDAC 1 and 2 via Sin3 
(152). These interactions combined with HDAC activating and enhancing functions of 
the DAD and HID domains, cooperatively repress nuclear receptor interactions with 
specific response elements by antagonist bound nuclear receptors or by unliganded 
nuclear receptors. 
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Coactivators and corepressors have an important function in ligand-dependent  
activation of nuclear receptors. In brief, ligand binding results in the release of HDAC-
containing corepressor complexes and recruitment of SRC-1, which then serves as a 
platform to recruit CBP. These factors and associated proteins induce HAT-dependent 
remodeling of nucleosomal structures and facilitate replacement of SRC-1/CBP with 
TRAP/DRIP complexes which in turn recruit the Pol II complex required for nuclear 
receptor mediated transactivation (Fig. 1.8). 
Orphan Nuclear Receptors 
Most nuclear receptors are orphan receptors for which endogenous ligands were 
not initially identified. Orphan nuclear receptors are often defined as gene products that 
embody structural features of nuclear receptors and these genes were identified without 
any prior knowledge of their association with a putative ligand (153). Recently novel 
ligands have been identified for a number of these receptors including RXR (154), 
PPAR (155), farnesoid X receptor (FXR) (156, 157), liver X receptor (LXR) (158) and 
pregnane X receptor (PXR) (159) and this has led to characterization of their functional 
roles and an understanding their significance in metabolic regulation (160). It is not 
known whether unliganded orphan receptors exert their diverse actions in a ligand-
independent manner or if they are regulated by unidentified endogenous compounds. 
Since orphan nuclear receptors occur in nearly all species examined and outnumber the 
steroid/nonsteroid hormone receptors, they probably represent an ancient and complex 
class of regulatory proteins that participate in multiple physiological functions. 
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Most orphan nuclear receptors possess the functional domains that have been 
characterized for other nuclear receptors, however, some orphan receptors have very 
short N-terminal regions, and lack an AF-1, while Rev-Erbα and –β lack the conserved 
AF-2. Some members possess either a conserved DBD or LBD, but not both. Both 
DAX-1 and SHP lack a “typical” nuclear receptor DBD (161), however, DAX-1 binds 
hairpin loop structures via its unique amino-terminal domain (161). Other serum and 
cellular binding proteins (such as retinol-binding protein, cellular retinoic acid binding 
protein) and intracellular receptors (such as aryl hydrocarbon receptor) bind small 
lipophilic ligands using structures unrelated to the LBD of nuclear receptors. 
The PPAR family 
Peroxisome proliferator-activated receptors (PPARs) are a subgroup of ligand-
activated orphan nuclear receptors responsible for regulation of diverse cellular events 
ranging from glucose and lipid homeostasis to cell differentiation and apoptosis (162). 
Peroxisome proliferation occurs only in rodents as a consequence of the activation of 
PPARs by specific molecules called peroxisome proliferators (PPs) (163). Three related 
PPAR isotypes have been identified in vertebrates, including xenopus, mouse, rat, 
hamster, and human (164-170). They have been named PPARα, PPAR β, and PPAR γ 
based on their initial identification in Xenopus (171) and the mammalian PPARα and 
PPAR γ equivalents were easily identified (Fig. 1.9). The third PPAR isotype exhibited 
lower homology to xenopus PPAR β and was alternatively called PPARδ, FAAR, or 
NUCI. The chromosomal localization of human (hu) PPARα was mapped to 
chromosome 22 slightly telomeric to a linkage group of six genes and genetic markers 
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that are located in the general region 22q12-q13.1(169). The huPPAR γ gene is located 
on chromosome 3 at position 3p25, close to RARβ and TRβ, which are at positions 3p24 
and 3p21, respectively(170). Finally, huPPAR β has been assigned to chromosome 6, at 
position 6p21.1-p21.2 (172). These three isotypes have distinct tissue distribution and 
biological activities. PPARα is expressed in liver, intestine, pancreas, kidney, muscle, 
heart, skeletal muscle, adrenals and cells from the vascular wall, and regulates fatty acid 
uptake and oxidation in the liver  (173). PPAR γ is mainly expressed in adipose tissues 
where it plays a role in lipid metabolism, and expression has been observed in intestine, 
mammary gland, endothelium, liver, skeletal muscle, prostate, colon and other cell types, 
including monocytes, macrophages/foam cells and type2 alveolar pneumocytes. PPARγ 
regulates not only systemic glucose and lipid homeostasis, but also has a role in the 
biology of monocytes, cell-cycle regulation, cancer development and treatment (163, 
173, 174). PPAR β is expressed in a wide range of tissues including embryonic kidney, 
small intestine, heart, adipose tissue, skeletal muscle and developing brain, with a less-
defined function (163). PPARγ is involved in keratinocyte differentiation, wound 
healing and in mediating very low-density lipoprotein (VLDL) signaling of macrophages 
(175). 
The PPAR response element (PPRE) was first characterized using synthetic 
oligonucleotides and was defined as a direct repeat of two core recognition motifs 
AGGTCA separated by one nucleotide, DR1 (176). All PPREs fulfill these DR1 criteria, 
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Fig. 1.9. General structure of PPARs. Schematic representation of the domain structure of PPARs, which 
is similar to other members of the nuclear receptor family. The numbers within each domain correspond to 
the percentage of aminoacid sequence identity of human PPARβ and PPARγ relative to PPARα (177). 
 
 
 
and this distinguishes PPREs from other direct repeat response elements for the TR/RAR 
class of receptors. PPARs do not bind as a monomer or homodimer but are dependent on 
RXR as DNA-binding partner. Based on more extensive analysis of PPREs in several 
gene promoters (178-181) three additional properties can be added to the definition of a 
DR1; an extended 5′ half-site, an imperfect core DR1, and an adenine as the spacing 
nucleotide between the two hexamers giving the following consensus PPRE 5′-
AACTAGGNCA A AGGTCA-3′. These properties most likely add discriminating 
parameters that contribute to PPAR:RXR binding selectivity vs. the homo- and 
heterodimers formed by other members of the superfamily, some of which also 
recognize a DR1 type element. PPAR interacts with the upstream extended core hexamer 
of the DR1, whereas RXR occupies the downstream motif  (179, 182). This represents a 
reversed polarity compared to the VDR:RXR bound to DR3, where RXR occupies the 
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upstream core hexamer of the direct repeat. This difference in binding polarity between 
PPAR:RXR and VDR:RXR is determined in part by the 5’-extended half-site in the 
PPRE. The inability of PPARs to bind as monomers has been attributed to the N-
terminal region of these proteins since PPARα in which the A/B domain has been 
deleted binds as a monomer to a PPRE. These changes in the DNA binding of this 
truncated PPAR might reflect evolutionary changes in which PPAR has functionally 
diverged from its monomeric cousins such as NGFI-B, ROR and RevErbAα (183). 
PPARγ 
PPARγ is the most extensively studied of the three PPAR subtypes (Fig.1.10), 
and there is a remarkable conservation of this receptor across different species (184). In 
contrast to the mouse which has only two PPARγ isoforms (185) humans express three 
PPARγ isoforms, namely i.e. PPARγ1, PPARγ2 (186) and PPARγ3 (187). Alternate 
transcription start sites and alternate splicing generate three PPARγ mRNAs, which 
differ at their 5’ ends.  
The three PPARγ mRNAs have specific and distinct expression patterns (186, 
187). PPARγ1 and PPARγ3 mRNAs give rise to an identical protein product, (i.e. 
PPARγ1), and PPARγ2 encodes for the PPARγ2 protein, which in humans contains 28 
additional amino acids at the N-terminus. PPARγ1 is broadly expressed but at low 
levels. Both PPARγ2 and PPARγ3 are highly expressed in adipose tissue, and PPARγ3 
is also expressed in macrophages. To date, functional differences between PPARγ 
isoforms have not been determined. 
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Fig. 1.10. Structural representation of PPARγ. A. Structure of PPARγ gene and the PPARγ mRNA and 
protein. The three promoters and the different exons are indicated. The three mRNA species give rise to 
two different PPARγ proteins. B. Basic mechanism of action PPARs. Upon ligand binding, PPARs form 
heterodimeric complex with RXR, that binds to the PPRE and drives the transcription of target genes 
(177). 
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PPARγ ligands 
 
Natural PPARγ ligands. Endogenous PPARγ ligands include a variety of 
lipophilic compounds such as long-chain polyunsaturated fatty acids and several 
eicosanoids. PPARγ is bound and activated by essential fatty acids like arachidonic acid, 
gamolenic acid, docasahexanoic acid, and eicosapentaenoic acid, as well modified 
oxidized lipids 9- and 13-hydroxyoctadecadienoic acid (9- and 13-HODE) and 12- and 
15- hydroxyeicosatetraenoic acid (12- and 15- HETE) (Fig.1.11) (184). 
15-deoxy-Δ12, 14-PGJ2 (15d- PGJ2) is the naturally occurring PPARγ agonist that 
has been most commonly used experimentally (188). This cyclopentenone-derived 
prostaglandin (PG) was first discovered in 1983, following incubation of PGD2 for 
extended periods in the presence of albumin (189). In 1995 two groups simultaneously 
reported that PGJ2 activated PPARγ and it was subsequently hypothesized that 15d- 
PGJ2 may serve as an endogenous PPARγ ligand.  
15d- PGJ2 activates PPARγ but in order for this compound to be an endogenous 
ligand it has to induce PPARγ-dependent responses at physiological concentrations. 
However, the concentrations of 15d- PGJ2 required to activate PPARγ are generally in 
the low μM range whereas physiological levels of 15d- PGJ2 are in the low nM range 
(190). It has been demonstrated in vitro that albumin-catalyzed dehydration of PGD2 
yields PGJ2, and further dehydration of PGJ2 results in formation of 15-dPGJ2. However, 
there is no evidence for enzymatic formation of these prostaglandins in vivo. Bell-Parikh 
and his colleagues used a highly sensitive liquid chromatography/tandem mass  
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Fig. 1.11. Chemical structures of naturally occuring PPARγ ligands (191). 
 
 
spectrometry assay for detecting 15-dPGJ2.  They reported that 15dPGJ2 can be 
synthesized in vivo but the levels are not sufficient for this compound to be an 
endogenous PPARγ ligand (192). However 15-dPGJ2 is the most potent natural ligand 
for this receptor and commonly used as a PPARγ agonist (188).  
15-dPGJ2 has been used extensively to define PPARγ-dependent responses 
however, it is important to note that 15-dPGJ2 can induce a variety of PPARγ-
independent effects and induce many growth inhibitory responses in cells devoid of the 
receptor (193). Many of the PPARγ-independent effects are mediated through covalent 
binding of 15-dPGJ2 to proteins; the cyclopentenone ring of 15-dPGJ2 readily reacts with 
nucleophiles such as cysteinyl thiol groups of proteins. For example, 15-dPGJ2 not only 
inhibits NF-κB activation via PPARγ but also through two distinct PPARγ-independent 
mechanisms. First, 15-dPGJ2 inhibits nuclear factor (NF)-κB activation by inhibiting the  
binding of NF-κB to promoter elements (194). Secondly, 15-dPGJ2 also interrupts NF-
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κB-dependent gene transcription by covalently binding to IκB kinase thus preventing 
IκB degradation and nuclear uptake of NF- κB (194, 195). 
 Synthetic PPARγ ligands.  In addition to the natural PPARγ agonists, a wide 
range of synthetic ligands have also been developed. The most widely used synthetic 
agents belong to the thiazolidinedione (TZD) class of antidiabetic drugs, also referred 
to as glitazones and these include ciglitazone, troglitazone, pioglitazone, 
rosiglitazone and LY171.833 (Fig.1.12). Pioglitazone (Actos), rosiglitazone 
(Avandia) and troglitazone (Rezulin) sensitise patients to insulin and lower blood 
glucose levels and have been used clinically to treat type 2 diabetes (196). 
Troglitazone was recently removed from the market due to idiosyncratic 
hepatotoxicity, which resulted in liver failure in extreme cases. Several other 
structurally distinct ligands, such as the derivative of 2,3-disubstituted indole-5-
acetic acid called GW0207 or non- thiazolidinedione tyrosine based compounds are 
potent and selective PPARγ agonists (184).  
Non-steroidal anti-inflammatory drugs such as indomethacin, ibuprofen, 
fenoprofen and fulfenamic acid are also PPARγ agonists, and this might explain the anti-
inflammatory effects of these drugs at concentrations that are substantially higher than 
those required to inhibit prostanoid synthesis (197). The synthetic triterpenoid 2-cyano-
3,12-dioxooleana-1,9-dien-28-oic acid (CDDO) binds PPARγ and induces 
differentiation and inhibits proliferation of a variety of cancer cells and CDDO also 
exhibits anti-inflammatory activity (198). Our laboratory has characterized a series of 
1,1-bis(3’-indolyl)-1-(p-substitutedphenyl)methanes (C-DIM) containing  
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Fig. 1.12. Chemical structures of synthetic PPARγ ligands (199). 
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p-triflouromethyl, p-t-butyl and p-phenyl substituents that also activate PPARγ and these 
compounds inhibit MCF-7 breast cancer cell growth and Go/G1-S phase progression and 
induce differentiation in 3T3-L1 preadipocytes and apoptosis (200). 
PPARγ ligands activate transcription of many genes that are important for lipid 
metabolism and transport, and these includes lipoprotein lipase (LPL), adipsin, fatty acid 
binding protein, acyl-CoA synthase, and fatty acid transport protein-1 (FATP-1). 
Furthermore ligand-activated PPARγ mediates differentiation of preadipocytes to 
adipocytes (201-203). PPARγ ligands also repress expression of some genes. For 
example, in monocytes and macrophages, PPARγ agonists decrease expression of 
cytokines such as IL-4, proinflammatory molecules including TNF, IL-1, as well as 
inducible nitric oxide synthase (193, 204-207). Proinflammatory transcription factors 
such as AP1, Stat, and NF-κB are also inhibited by PPARγ agonists. The mechanisms 
for these responses are unclear, however gene repression induced by these compounds 
may be PPARγ -independent. 
The activity of PPARγ is controlled by ligands and interactions with various co-
factors. In the inactive (unliganded) state PPARγ is complexed with corepressors such as 
NCoR and SMRT. Upon ligand binding PPARγ undergoes conformational changes that 
lead to release of repressors and subsequent binding to coactivators. Many PPARγ 
interacting coactivators have been identified including SRC-1, TIF-2, CBP/p300, 
TRAP220  and PGC-1 (208). Kodera et al showed that the endogenous ligand 15-dPGJ2 
induced a different set of coactivator interactions compared to the synthetic ligand 
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troglitazone and this may explain some of the ligand-dependent selective activation of 
PPARγ (209).  
X-ray crystal structure of PPARγ LBD 
Nuclear receptors exhibit a common structural three-dimensional fold, which 
consists of an antiparallel α-helical sandwich of 12 helices organized in three layers with 
a central hydrophobic pocket. Upon ligand binding, the swinging of helix 12 or 
activation function helix (HAF) closes the ligand binding pocket like a lid, in a so-called 
“mouse trap model” (37, 39, 40). The x-ray crystal structure of the human apo-PPARγ 
reveals an overall fold similar to that of the above mentioned LBDs from helix 3 to the 
C-terminus (84, 210, 211). However there are certain distinct differences. Similar to the 
holoforms of PPAR and other nuclear receptors, the core AF-2 activation domain in the 
apo-PPARs is folded against the ligand binding pocket. An additional helix, called helix 
2′, which is found between the first β-strand and helix 3 together with the helix 2, 
provides an easy access to the hydrophoblc pocket for ligands (212). The region between 
the helix 2′ and helix 3 is the most thermally mobile loop and undergoes structural 
changes upon ligand binding. The ligand binding pocket is buried in the bottom half of 
the LBD and is unusually large, approximately 1300 Å3 (84, 211), and the ligand 
occupies only 30-40% of this pocket. The LBD of PPARs is large and more accessible 
than observed for other known LBDs. For example the cavity in TR is approximately 
600 Å3 and most of this volume is occupied by T3 which has a volume of 530 Å3 (40)). 
Two histidine residues, H323 and H449, participate in fixation of the thiazolidinedione 
head group (84). These key interactions along with the relatively free non-specific 
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interactions associated with the hydrophobic regions of the ligands can occur within the 
large binding cavity and may explain the promiscuous ligand binding behavior of 
PPARγ. Therefore the different functional activities of a specific ligand may be related 
to different conformations in the ligand binding cavity (210). The extra helix 2′ and the 
tertiary placement of helix 2 provides ready access of PPARγ to structurally diverse 
ligands and this is consistent with the low affinity interactions of this receptor with 
multiple natural ligands (84). 
Four amino acids, namely aspartic acid 243 (D243) at the N terminus of the first 
β-sheet, arginine 288 (R288), glutamic acid 291 (E291) and glutamic acid 295 (E295) in 
helix 3, are the critical determinants of the ligand entry site (84). E291 and E295 are 
conserved in all known PPARs, whereas D243 and R288 are only conserved in the γ-
isotype, suggesting that these latter positions might be involved in isotype- and species 
specific ligand selectivity. The crystal structure also shows coiled-coil interactions 
between helix 10 of two PPARγ molecules forming a homodimer, which is reinforced by 
salt bridges involving helices 9 and 10. While PPARγ homodimers do not occur in vivo, 
these observations are similar to those described for RXR homodimers (37) and reflect 
the type of contacts involved in formation of the PPARγ:RXR heterodimer. Consistent 
with these observations, a deletion of helix 10 and HAF of PPARα abolishes 
heterodimerization with RXRα (213). 
Alternative pathways for activation of PPARγ 
 Activation by phosphorylation. In addition to ligand-dependent activation, 
many nuclear receptors including PPARγ are activated by phosphorylation. Transfection 
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studies in CV1 and HepG2 cells revealed that insulin increases the transcriptional 
activity of PPARγ by nearly two-fold (214). Insulin induces phophorylation of two 
mitogen-activated protein (MAP) kinase sites in the A/B domain of PPARγ (215). The 
results of cotransfection experiments in chinese hamster ovary (CHO) cells that express 
the insulin receptor, showed the insulin and the PPARγ  agonist TZD synergistically 
induced expression of the PPARγ –responsive target gene aP2 and this effect was 
partially inhibited by addition of a MAP kinase inhibitor (216). Enhanced PPARγ –
dependent activity was observed in cells transfected with purified MAP kinase (216). In 
contrast the growth factors such as epidermal growth factor (EGF) and platelet-derived 
growth factor (PDGF) decrease the transcriptional activity of PPARγ while increasing 
the phosphorylation of PPARγ through MAP kinase signaling (217, 218). How the same 
changes in phosphorylation can result in activation or inhibition of PPARγ signaling, 
depending on the action of either insulin or growth factor is unclear but may involve 
either specific pleiotropic actions or activation of different kinase pathways by these 
hormones. For example, the insulin mediated up-regulation of phosphoenolpyruvate 
carboxykinase (PEPCK) gene expression does not require the activation of MAP kinase 
but relies on the phosphatidylinositol 3-kinase (PI3K) signaling pathway (219). 
 Activation by RXR agonists. PPARγ forms a permissive heterodimer with RXR 
in which either partner can regulate the transcriptional activity of the DNA-bound 
complex by interacting with its own cognate ligand, or both ligands. The response of 
ligands in both receptors is essentially additive. Thus, both the natural (9-cis-retinoic 
acid (9-cis-RA)) and synthetic RXR ligands,( LG1069, LG 100268), activate a PPRE-
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dependent liver fatty acid binding protein or aP2, in a PPAR:RXR dependent manner 
(176, 220-223). Activation of PPAR:RXR by the RXR agonist 9-cis-RA signal is 
consistent with the observation that RXR agonists also display antidiabetic activities 
comparable to those observed thiazolidinediones (224). The in vivo actions of RXR 
ligands are not PPARγ-specific since these compounds also activate PPARα inducible 
genes (225).  
Physiological effects of PPARγ 
PPARγ is necessary and sufficient for differentiating adipocytes. PPARγ 
regulates adipocyte-specific expression of the fatty acid-binding protein aP2 by directly 
interacting to the cis PPRE aP2 gene promoter (226). Ligand activated PPARγ induces 
differentiation of fibroblasts into adipocytes (202). PPARγ heterozygous null mice have 
decreased amounts of adipose tissue (227-229) and expression of PPARγ dominant-
negative mutants in 3T3-L1 cells inhibited their differentiation into adipocytes (230, 
231). PPARγ regulates numerous genes involved in lipid metabolism in adipocytes 
including aP2 (201), PEPCK (232), acyl-CoA synthase (233) and LPL (203). PPARγ 
also controls the expression of genes involved in lipid uptake into adipocytes such as 
FATP-1 (234) and CD36 (235) and all these genes contain a PPRE in their regulatory 
regions. 
PPARγ is also associated with several genes that affect insulin action. PPARγ 
agonists inhibit expression of TNFα, a pro-inflammatory cytokine, in adipocytes of 
obese rodents (236) and also inhibit TNFα-induced insulin resistance (237). PPARγ 
agonists also induce expression of c-CBL-associated protein which plays a positive role 
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in insulin signaling (238). Thus PPARγ agonists enhance or partially mimic certain 
actions of insulin and these activities form the basis for their use as antidiabetic agents 
(239). Although TZDs show a positive correlation between their binding affinity for 
PPARγ and their antihyperglycaemic activity, their activation of PPARγ is not sufficient 
to explain their biological effects. For example, PPARγ is predominantly expressed in 
adipose tissue compared to liver or muscle suggesting that adipose tissue is a major site 
of action of PPARγ agonists. However in aP2/DTA mice, whose white and brown fat is 
virtually eliminated by fat specific expression of diphtheria toxin A chain, troglitazone 
alleviated hyperglycaemia, and decreased elevated insulin levels without affecting 
PPARγ mRNA levels in liver, suggesting an adipose tissue-specific and PPARγ-
independent response (240). 
PPARγ agonists also induce rapid effects that do not correlate with their affinity 
for PPARγ, suggesting a PPARγ independent mechanism. For example, rosiglitazone 
and troglitazone rapidly inhibited LPL activity in adipocyte cell lines, increased lipase 
mRNA levels in undifferentiated adipocytes but had no effect on mRNA or protein 
expression of LPL in differentiated cells (241). The effects of PPARγ agonists on 
cholesterol levels may be receptor independent. TZDs inhibit cholesterol biosynthesis in 
CHO ovary cells, HepG2 hepatocarcinoma cells, 3T3-L1 adipocytes within 2 hr after 
treatment and these effects are reversed within 1 hr after the drug was withdrawn. 
Neither actinomycin D nor cycloheximide affected the inhibition of cholesterol synthesis 
by TZDs, suggesting that this inhibitory response did not require de novo mRNA or 
protein synthesis (242). 
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 PPARγ and inflammation 
 
The potential involvement of PPARγ in inflammatory processes was first 
suggested by the inhibition of the pro-inflammatory cytokine TNFα. PPARγ agonists 
also inhibit macrophage (differentiated monocyte) activation and limit their production 
of cytokines. Treatment of monocytes with PPARγ agonists inhibits production of 
TNFα, IL-1β and IL-6 (204) and PPARγ agonists induce a resting phenotype and down-
regulate inducible nitric oxide synthase (iNOS) (207, 243), gelatinase B and scavenger 
receptor A genes in macrophages (207). These processes may be mediated by a direct 
transcriptional effect of PPARγ, which interferes with NF-κB, activating protein-1 (AP-
1), and signal transducers and activators of transcription (STAT) transcription factors 
that regulate cytokine gene expression (207, 243).  
The anti-inflammatory effects of PPARγ agonists in these studies are often 
observed at concentrations higher than their EC50 values for binding to or activating 
PPARγ (184). For example, concentrations of troglitazone and rosiglitazone required for 
inhibition of  iNOS were 15- to 60-fold (for troglitazone) and 650-fold (for 
rosiglitazone) higher than their corresponding EC50 values for activating PPARγ (244). 
Although this suggests that these responses are PPARγ-independent more direct 
evidence comes from studies which show that PPARγ antagonists do not block the anti-
inflammatory effects of these TZDs. For example, high concentrations of rosiglitazone 
increased lipopolysaccharide stimulated prostanoid synthesis; however, PPARγ 
antagonists did not reverse this effect (245). Moreover studies from PPARγ null cells 
provide additional evidence that TZD-induced anti-inflammatory responses were 
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PPARγ-independent since inhibition of iNOS by TZDs were obsereved in both PPARγ 
null cells and macrophages (246). 
PPARγ and atherosclerosis 
Treatment of monocytic cells with PPARγ agonists induce lipid accumulations 
reminiscent of those found in foam cells of the atherosclerotic plaque and activation of 
PPARγ /RXR heterodimer enhances macrophage differentiation. Exposure of human 
monocytes or monocytic cell lines to oxidized LDL (oxLDL) but not regular LDL not 
only induces PPARγ expression (247) but also provides the cells with two PPARγ 
ligands i.e 9-HODE and 13-HODE, both oxidative metabolites of linoleic acid present in 
oxLDL (248). Activated PPARγ induces oxLDL receptor, CD36 and fatty acid 
translocase (FAT) expression through a PPRE in CD36/FAT gene promoter thereby 
establishing a positive feedback loop leading to foam cell formation (248). Consistent 
with this hypothesis PPARγ is expressed at moderately high levels within the 
atherosclerotic plaques of mice (248) and humans (249, 250) and mice carrying the 
targeted deletion of CD36 are partially protected from atherosclerosis (251). These data 
suggest a complex function of PPARγ in macrophage and foam cell formation with a 
predominantly pro-atherogenic activity. However, this pro-atherogenic activity may be 
neutralized by the effects of PPARγ in vascular smooth muscle cells, where PPARγ 
inhibits expression of metalloproteinase 9 and reduces cell migration (252). 
Furthermore, using LDL receptor knockout mice as a model for atherogenesis, LDL-
deficient mice, like their human counterparts, are hypercholesterolemic and prone to 
atherosclerosis when fed diets rich in fat and cholesterol. However administration of two 
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different classes of synthetic PPARγ ligands, rosiglitazone and a non-TZD tyrosine 
analog decreased atherosclerotic lesions (34). These studies provide direct experimental 
evidence that PPARγ activation can inhibit or reverse atherosclerosis in a well-
characterized model for this disease. 
PPARγ and cancer 
The proliferation advantage of cancer cells over their normal counterparts is at 
least, in part, because of their inability to undergo terminal differentiation, they remain 
in a proliferative state and continue to grow. The effects of PPARγ agonists on cancer 
was based on results showing that PPARγ ligands inhibited cell proliferation while 
inducing adipocyte differentiation (253-256). Moreover PPARγ is overexpressed in most 
tumor samples and cancer cells lines (257). PPARγ agonists inhibit proliferation of 
transformed cells mainly by cell cycle arrest or by inducing differentiation and/or 
apoptosis. 
 Cell cycle. Studies based in several tumor cell lines have implicated a role for 
PPARγ in cell cycle arrest. It was initially observed that ligand activation of PPARγ 
induces cell cycle withdrawal of preadipocytes via suppression of the transcriptional 
activity of E2F/DP DNA-binding complex (258). Decreased E2F/DP activity is in part 
mediated by PPARγ through down-regulation of the protein phosphotase 2A (PP2A) 
(259). E2F/DP activity can also be inhibited by the activation of retinoblastoma protein 
(RB) and PPARγ ligands inhibit phosphorylation of RB in vascular smooth muscles 
cells, therefore maintaining RB in its hypophosphorylated form and abrogating the G1 to 
S phase transition (260).  
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Morrison and Farmer also suggested a role for PPARγ in up-regulating the 
cyclin-dependent kinase inhibitors (CDKIs) p18 and p21 during adipogenesis (261). 
Thus PPARγ ligands control genes that are involved in the negative regulation of cell 
cycle and similar responses were also observed in pancreatic cancer cell lines (262). 
However, the specific growth regulatory pathways that are affected by PPARγ agonists 
are highly variable even among cells derived from a common tumor type. TGZ inhibited 
growth of six of nine pancreatic cancer cell lines, by G1 phase cell cycle arrest through 
the up-regulation of p21 mRNA and protein expression (262). In the Panc-1 pancreatic 
cancer cell line , TZD-dependent growth inhibition of G1 phase arrest was accompanied 
by increased expression of p27 but not p21 (262, 263). A dose dependent cytostatic 
effect of TZD was observed in different hepatoma cell lines including HLF, HuH-7, 
HAK-1B, and HAK-5 cells, and the G0 to G1 cell cycle arrest was related to alterations 
in p21 protein expression. HLF hepatoma cells, which are deficient in RB, responded 
more profoundly to TGZ, which induced expression of p21, p27 and p18, suggesting that 
these CDKIs may be involved in TGZ-induced cell cycle arrest in human hepatoma cell 
lines (264).  
Hupfeld and Weiss reported that TZDs inhibit vascular smooth muscle cell 
growth by decreasing cyclin D1 and cyclin E levels, suggesting another possible 
mechanism for TZD action (265). MCF-7 breast cancer cell growth and G1-S phase 
progression was inhibited by troglitazone treatment, and cells accumulated in the G1 
phase by modulating RB phosphorylation and decreasing cyclin D1 expression (266). 
CDK-dependent activity was also decreased by troglitazone and overexpression of 
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cyclinD1 partially rescued MCF-7 cells from troglitazone mediated G1 cell cycle arrest 
(266). PPARγ activation inhibits proliferation of several other malignant cells from 
different lineages such as liposarcoma (267), prostate carcinoma (268), colorectal 
carcinoma (269-271), non-small cell lung carcinoma (272), bladder cancer cells (273) 
and gastric carcinoma cells (274). 
 Differentiation. PPARγ induces differentiation pathways beyond adipocytes and 
overexpression of PPARγ induces differentiation of hepatocytes, myoblasts and several 
other cell types including mammary and colon epithelium (202). Furthermore, treatment 
of human primary liposarcoma cells with pioglitazone induced terminal differentiation 
(275).  PPARγ agonists induce upregulation of several differentiation markers such as 
carcinoembryogenic antigen, E-cadherin and alkaline phosphotase in pancreatic cancer 
cell lines (276). Ligand-dependent activation of PPARγ induced apoptosis in malignant 
rat and human glioma cells and also induced transient expression of the glioma 
redifferentiation marker N-cadherin (277).  
In the colon, levels of PPARγ mRNA are nearly equivalent to that found in 
adipocytes (186) with the highest levels of receptor expressed in the post-mitotic, 
differentiated epithelial cells facing the lumen (278). Consistent with this expression 
pattern, exposure of human colon cancer cells to PPARγ agonists induces growth 
inhibition associated with a delay in G1 phase of the cell cycle and an increase in several 
markers of differentiation, including caveolin-1 and caveolin-2, which exhibit tumor 
suppressor activity, and some members of the keratin and CEA families (269, 270, 279). 
Levels of caveolin-1 and 2 also increase during differentiation of pre-adipocytes to 
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adipocytes (280, 281). Breast adenocarcinoma and colon adenocarcinoma cells, where 
caveolin expression is normally downregulated, express a functional PPARγ with 
transcriptional activity (278, 282). These cells undergo differentiation in vitro upon 
treatment with PPARγ agonists (271, 283, 284). The ability of PPARγ to promote 
lineage-specific differentiation and the fact that caveolins are characteristic markers for 
terminally differentiated cells raised the hypothesis that PPARγ transcriptionally 
regulates caveolin expression. Burgermeister et al. have shown that PPARγ induces 
caveolin gene expression in human adenocarcinoma cells and this may have important 
applications in the context of cancer differentiation therapy (285). 
 Apoptosis. PPARγ ligands induce apoptotic cell death in a wide variety of 
experimental cancer models both in vitro and in vivo (286-289) including ER negative 
MDA-MB-231 and ER positive MCF-7 breast cancer cells (290). Treatment of MCF-7 
cells with troglitazone irreversibly inhibited the growth and induced apoptosis, and this 
was accompanied by a dramatic decrease of anti apoptotic bcl-2 protein levels (291). 
Inhibition of RNA or protein synthesis abrogates apoptosis induced by 15d-PGJ2 in 
breast cancer cells. Additionally, 15d- PGJ2-induced caspase activation is inhibited by 
caspase inhibitors, showing that de novo gene transcription was necessary for induction 
of apoptosis in breast cancer cells (292). 
PPARγ ligands such as 15d- PGJ2, LY171 833 and ciglitazone inhibited 
proliferation and induced cell death in human (U87MG and A172) and rat (C6) glioma 
cell lines. This cell death was characterized by DNA fragmentation and nuclear 
condensation which are the hallmarks of apoptosis. In contrast, primary murine 
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astrocytes were not affected by treatment with ciglitazone (293). PPARγ ligand-induced 
apoptotic cell death in the glioma cells was accompanied by transient upregulation of 
proapoptotic proteins Bax and Bad. Upregulated expression of Bad and Bax induce 
apoptosis by enhanced release of mitochondrial cytochrome C and subsequent activation 
of several effector caspases. In addition, inhibition of Bax expression by specific 
antisense oligonucleotides protected glioma cells against PPARγ mediated apoptosis, 
indicating an essential role of Bax in this process (293). PPARγ activation by 
troglitazone also leads to increased caspase 3 activity in human liver-cancer cells (294) 
and in human malignant astrocytoma cell lines (277). 
  Shimada and coworkers noted that troglitazone-induced cell death in colon 
cancer cells was inhibited by pan-caspase inhibitors (295). Furthermore, ciglitazone -
induced apoptosis in human pancreatic cell lines is blocked by the pan-caspase inhibitor 
ZVAD-FMK but not by a specific caspase-3 inhibitor (296). Moreover, treatment of 
human liver cancer cell lines (294) and human thyroid carcinoma cells (297) with 
PPARγ agonists did not increase in Bax protein levels, suggesting that PPARγ agonists 
induce several different apoptotic pathways. TNF related apoptosis inducing ligand 
(TRAIL) is a member of TNF family of cytokines that induces apoptosis and both 
natural and synthetic PPARγ agonists sensitize tumor cells but not normal cells to 
apoptosis induction by TRAIL. PPARγ ligands selectively reduce levels of FLICE-
inhibitory protein (FLIP), an apoptosis-suppressing protein that blocks early events in 
TRAIL/TNF family death receptor signaling. PPARγ ligands induced ubiquitination and 
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proteasome-dependent degradation of FLIP, without concomitant decreases in FLIP 
mRNA (298). 
 PPARγ-independent actions. PPARγ agonists inhibit proliferation of several 
types of cancer cells, however, the role of PPARγ remains controversial and in many 
cases the compounds induce receptor-independent effects. The sensitivity of cancer cell 
lines to PPARγ agonist induced growth inhibition does not correlate with levels of 
PPARγ protein in these cells. For example glitazone resistance occurs even in tumors 
with high PPARγ concentration (eg, breast-tumor cells) (284). Homologous 
recombination was used to create embryonic stem cells with a null mutation for PPARγ 
and these stem cells could be differentiated into macrophages when treated with 
glitazones (193). Troglitazone induced cell cycle arrest and subsequent cell death and 
this was associated with downregulation of c-myc, c-myb and cyclin D2 expression. 
These genes lack a PPRE in their promoter regions , indicating that these responses were 
not directly mediated through PPARγ (299). Similar results were observed in human 
leukemia cell line (KU812) suggesting that troglitazone-mediated growth suppression 
was PPARγ-independent and was associated with decreased cyclin E levels and 
hyperphosphorylation of RB (300). 
In human glioblastoma T98G cells, TZD induced cell cycle arrest and apoptosis, 
and the fomer response was associated with increased p27 levels, whereas apoptosis was 
mediated by downregulation of anti-apoptotic Bcl2 and upregulation of pro-apoptotic 
Bax and caspase-3 activation. None of these responses were blocked in cells treated with 
a specific PPARγ antagonist (301). The mechanisms by which PPARγ agonists induce 
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glioma toxicity were also investigated in another study using rosiglitazone and 
ciglitazone. The rapidity of the mitochondrial damage caused by PPARγ agonists and the 
failure to revert the cytotoxic effects using the specific PPARγ antagonist GW9662 
suggested a receptor-independent action (302). 
Troglitazone inhibited growth of HCT-116 colon cancer cells by expression of 
nonsteroidal anti-inflammatory drug-activated gene-1 (NAG-1), most likely via direct 
activation of the transcription factor early growth response-1 (EGR-1) (303). This 
induction was not blocked by a PPARγ antagonist, thus providing another mechanism by 
which TZD can cause growth inhibition. In MCF-7 breast cancer cell lines, troglitazone-
induced apoptosis was dependent upon GADD45 expression. Regulation of GADD45 by 
troglitazone occurred at the transcription level and was associated with MAPK 
activation. In the same studies neither rosiglitazone nor pioglitazone induced GADD45 
expression indicating a receptor independent action (304). 
The triterpenoid CDDO inhibits the growth of ovarian cancer cells that express 
PPARγ, but the effects of CDDO were not blocked after co-treatment with a PPARγ 
antagonist T007, suggesting that the growth inhibition was a PPARγ independent 
response (305). Another PPARγ agonist, methylene-sustituted diindolylmethane 
inhibited the G0/G1-S phase progression in MCF-7 and several cancer cell lines by 
downregulation of cyclin D1. The PPARγ inhibitor T007 did not affect downregulation 
of cyclin D1 indicating that this response was also PPARγ independent (200). 
More direct evidence of PPARγ independent effects comes from receptor 
knockout studies. Embryonic stem cells induced tumor growth was inhibited by 
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troglitazone and ciglitazone in both PPARγ (-/-) and PPARγ (+/+) mice, confirming the 
receptor independent actions of PPARγ agonists. These compounds blocked the G1/S 
phase transition by inhibiting translation initiation as a consequence of partial depletion 
of intracellular calcium stores. This  resulted in activation of PKR, a kinase that 
phosphorylates the alpha subunit of eukaryotic initiation factor 2, thus rendering it 
inactive (306).  
Indirect and direct evidence suggest that many of the anticancer activities of 
PPARγ ligands are PPARγ-independent, however the mechanisms of receptor-
independent pathways warrant further study. Although PPARγ is well characterized, 
there are still numerous challenges ahead before modulators of this receptor will be 
adopted for therapeutic applications in treating cancer. This will require development of 
selective PPARγ modulators with minimal side effects and an increased understanding 
of both receptor-dependent and independent pathways. 
Nerve growth factor-inducible gene B (NGFI-B) family 
Three orphan receptors, (Nur77 (NGFI-Bα, TR3, NAK1), Nurr1 (NGFI-Bβ), 
NOR-1 (NGFI-Bγ)) (Fig.1.13) have been characterized as a distinct family (NGFI-B) 
based on their strong sequence homologies. Since different nomenclature has been used 
to describe these genes, for convenience this group will be referred as the Nur77 receptor 
subfamily and use the terminology for the mouse homolog genes for Nurr77 and Nurr1 
and the human homolog for NOR-1. The rat homolog of Nur77, NGFI-B was the first of 
these proteins discovered when it was identified in the rat pheochromocytoma cell 12 
(PC12) following differentiation after treatment with nerve growth factor (NGF) (307). 
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Later, the mouse homolog Nur77 (nuclear receptor-77) was identified in fibroblasts 
(308). Nurr1 (Nor-related factor-1), was the second gene in this subfamily discovered 
while screening a mouse brain cDNA library with COUP-TF, another orphan nuclear 
receptor as a probe (309). Subsequently, other Nurr1 homologs were identified in the rat 
(RNR-1 and Hzf-3) (310, 311) and the human (NOT) (312). The final member of this 
subclass, NOR-1 (nuclear derived orphan receptor-1), was isolated from cultured rat 
forebrain neurons undergoing apoptosis (313).  
Nur77 receptor subfamily members are highly expressed in adult nervous system 
where they are induced as part of the immediate early response to stimuli such as growth 
factors, membrane depolarization, and seizures (308, 309, 314, 315). The pattern of 
expression of the Nur77 subfamily members is broad. In adult rodents, Nur77 is 
expressed in the adrenal, thyroid, and pituitary glands, as well as the liver, testis, ovary, 
thymus, muscle, lung, and ventral prostate (307, 316, 317). Nur77 expression is 
upregulated in T cells undergoing apoptosis (318, 319). Nurr1 is expressed in the adult 
liver (310) as well as the pituitary gland, thymus, and osteoblasts (312, 317). NOR-1 is 
expressed at high levels in the pituitary gland and at intermediate or low levels in the 
adrenal glands, heart, skeletal muscle, thymus, kidney, epididymis, and submandibular 
glands (313, 320, 321). 
Similar to other nuclear receptors, Nur77 family members consists of an N-
terminal AF1 transactivation domain, a DBD with two zinc fingers, and a C-terminal 
putative LBD. While Nur77, Nurr1 and NOR-1 share this tripartite structure and a high 
degree of structural homology. Strong sequence homologies are found in central DBD 
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where all the three receptors share greater than 90% homology (307, 309, 313). Strong 
homologies (59-65%) are also found in the putative LBD (307, 309, 313). The N-
terminal regions of these receptors are more distinctive and only approximately 30% 
homology is found (307, 309, 313). In comparison, these three proteins only share 
homologies of 40-60% and 20-30% in the DBD and LBD respectively with other 
members of the nuclear receptor superfamily (307, 308).  
Nur77 subfamily members bind DNA as monomers, as homodimers, or as 
heterodimers with RXR. Nur77 binds to monomeric response elements (NBREs) 
containing the 5’-extended core motif, AAAGGTCA. This is an artificial DNA sequence 
selected from random oligomer library on the basis of the ability of this sequence to bind 
Nur77 (322). Nur77 site specificity is determined by DNA-protein contacts between 
nucleotides located 5’ to the core motif contained in the NBRE and the CTE (323-325). 
On the contrary Nur77 binds the Nur response element (NuRE) palindromic DNA motif 
as homo- and heterodimers with other Nur77 subfamily members. NuRE was initially 
identified in the pro-opiomelanocortin (POMC) gene promoter (326). The homodimer 
binding site consists of two inverted NBREs separated by 6 bp that confer high 
responsiveness to Nur77.  
Ligands for members of the Nur77 subfamily have not been identified. However 
Nur77 and Nurr1 (but not NOR-1) bind to DR5 response elements as heterodimers with  
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Fig. 1.13. Domain structure and the percent of amino acid identity with the corresponding region of human 
Nur77 (327). 
 
 
RXR and, the heterodimer complex is efficiently induced by rexinoids (328, 329). 
Transcription of Nurr1-RXR heterodimers by rexinoids has been reported when 
synthetic reporters containing multiple copies of monomeric NBRE are used in 
cotransfection assays (330). In this case, activation by the heterodimeric complex occurs 
in the absence of direct DNA binding by the RXR moiety. In addition, the activity of 
Nur77 subfamily members appears to be regulated by posttranslational modifications, 
which may be induced via ligand-independent pathways activated by growth factors. 
Nur77 nuclear localization, DNA-binding affinity, and transcriptional activity can be 
modulated by phosphorylation of the receptor protein (331-335). Regulation of the 
NGFI-B heterodimeric complexes activity by rexinoids and covalent modifications does 
not exclude the existence of the NGFI-B-specific ligands since other RXR-receptor 
heterodimers can be activated by ligands for both receptors. Recent studies reports that 
6-mercaptopurine activates both Nurr1 and Nor-1 through their respective N-terminal 
Nur77
Nurr1
NOR1
A/B C ED F
Zn Zn
1 265 353 598
1 265 369 598
1 292 378 626
28 95 65
26 94 58
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AF-1 domains (336, 337). These results suggest that some activities of 6-mercaptopurine 
and other antimetabolite drugs may be mediated through NGFI-B proteins.  
The physiological roles for NGFI-B proteins are not fully understood; however, 
gene targeting knockout experiments demonstrate several important functions for these 
proteins which correlate, in part, with other in vitro and in vivo studies.  For example 
mice lacking Nurr1 die soon after birth and Nurr1 mutant mice fail to generate midbrain 
neurons with a dopaminergic phenotype, and midbrain dopamine precursor cells 
degenerate as brain development progresses (338, 339).  Since loss of midbrain 
dopaminergic neurons is associated with the etiology of Parkinson’s disease, the use of 
the putative NGFI-B ligands or specific rexinoids could provide a novel therapeutic 
avenue for treatment of this disease. A recent study reports that NOR-1 knockout 
animals die at gestation day 5, demonstrating an important role for this protein in early 
embryogenesis (340).  In contrast, Nur77 knockout mice do not exhibit a specific 
phenotype, and this may be related to coexpression of both Nur77/Nor1 which exhibit 
some overlapping functions (341). 
Nur77 and T-cell apoptosis 
Immature T-cells expressing a T cell receptor (TCR) that binds to self peptides 
and major histocompatibility complexes undergo apoptosis during T-cell development. 
The removal of potentially autoreactive T-cells from the population of T-cells by 
apoptosis is defined as negative selection. Nur77 was rapidly induced in T-cell 
hybridomas undergoing TCR-mediated cell death. Expression of dominant negative 
Nur77 protein or antisense Nur77 mRNA blocked the TCR-mediated apoptosis of these 
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cells (318, 319). Furthermore, thymocytes undergoing TCR-mediated apoptosis also 
express high levels of Nur77, suggesting that Nur77 might play a role in thymocytes 
negative selection. Transgenic mice expressing a dominant negative Nur77 protein 
blocked TCR mediated apoptosis and prevented clonal deletion of self-reactive T cells 
(342, 343). In contrast, overexpression of full-length Nur77 in the thymus resulted in 
massive apoptosis. These results suggest that thymocyte negative selection depends on 
Nur77. However Nur77 deficient mice did not show any defect in thymocyte negative 
selection (341). The normal thymic phenotype in Nur77 -/- mice may be due to functional 
redundancy of NOR-1 in the thymus. NOR-1 and Nur77 exhibit similar tissue expression 
patterns and overexpression induces massive thymocyte apoptosis (344). A clear 
functional role of Nur77/NOR-1 in thymocyte negative selection requires the generation 
of mice lacking both Nur77 and NOR-1. Besides its role in TCR-mediated lymphocyte 
cell death, Nur77 is also involved in T cell hybridoma cell death induced by thapsigargin 
(345), suggesting that Nur77 may regulate some shared death pathways in both types of 
apoptosis.  
TCR activation, Nur77/NOR-1 expression and apoptosis are calcium-dependent 
and treatment with calcium ionophores and phorbol esters mimics TCR activation while 
inhibition of calcineurin, a calcium/calmodulin-dependent phosphotase, by cyclosporine 
A blocks apoptosis (346). Using promoter deletional analysis, two myocyte enhancer 
factor 2 (MEF2) sites were identified as TCR-regulated transcriptional elements in the 
Nur77 promoter region (346). Studies have shown that TCR activation elevates 
intracellular calcium levels that cause dissociation of MEF2 from Cabin1, an inhibitor of 
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MEF2 activity. After dissociation from Cabin1, MEF2 binds MEF2 sites in the Nur77 
promoter and induces expression of Nur77 (347). 
Nur77 and cancer 
Nur77 is involved in induction of apoptosis in various cancerous cell types. 
Nur77 is not only rapidly induced during apoptosis of immature thymocytes and T-cell 
hybridomas but also in lung cancer cells treated with synthetic retinoids (348) and 
prostate cancer cells (LNCaP) treated with different retinoids  and apoptotic inducers 
such as  phorbol-12-myristate-13-acetate (TPA) and TNFα (349). Li and coworkers 
demonstrated that Nur77 regulates apoptosis through a mechanism that is independent of 
transcriptional regulation (350). In response to apoptotic stimuli, Nur77 is translocated 
from the nucleus to the cytoplasm, where it targets mitochondria and induces 
cytochrome c release and apoptosis. It was also shown that Nur77 lacking the DBD 
localized exclusively in the cytoplasm where it is associated with mitochondria and 
induced apoptosis indicating that this response was independent of activation of the 
nuclear receptor (350). Lin et al showed that Nur77 interacts with Bcl-2 through its LBD 
and this interaction is required for Nur77-dependent mitochondrial targeting and 
apoptosis. Interestingly, Nur77 binds to the Bcl-2 N-terminal loop, resulting in a 
conformational change in Bcl-2, which converts it from a pro-apoptotic to an anti-
apoptotic protein (351). 
The role Nur77 plays in apoptosis in colon carcinoma cells appear to be different 
from that reported in prostate cancer cells. Apoptosis induced by butyrate, the anti-
inflammatory drug, sulindac and 5-flourouracil (5-FU) in colon cancer cells results in 
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nuclear-cytosol translocation of Nur77 which does not associate with mitochondria 
(352). Thus, although Nur77 translocation from the nucleus may be an apoptotic signal 
for colon cancer cells, it appears that the mitochondria are not directly targeted. Instead, 
the trigger for the apoptotic cascade may involve recruitment of other proapototic 
molecules.  
In contrast, other studies support a role of nuclear Nur77 in mediating the effects 
of apoptosis inducers. For example, TPA induces Nur77 expression in LNCaP cells and 
the apoptotic response is linked to the induction of E2F1 through direct interaction of 
Nur77 with a NBRE in the E2F1 promoter (353). Overexpression of E2F1 through 
induction by Nur77 can induce apoptosis in several systems (353). Thus it is clear that 
Nur77 can induce apoptosis by multiple mechanisms which not only depend on cell 
context but also on the apoptosis-inducing agent. 
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CHAPTER II 
1,1-BIS(3'-INDOLYL)-1-(p-SUBSTITUTEDPHENYL)METHANES INDUCE 
PEROXISOME PROLIFERATOR-ACTIVATED RECEPTOR γ-MEDIATED 
GROWTH INHIBITION, TRANSACTIVATION AND DIFFERENTIATION 
MARKERS IN COLON CANCER CELLS* 
Introduction 
Peroxisome proliferator-activated receptors (PPARs) are ligand-activated 
transcription factors and members of the nuclear receptor (NR) family (354-356).  
Ligand-bound PPARs form nuclear heterodimers with retinoid X receptors (RXRs) 
which modulate transcription by interactions with cognate PPAR response elements in 
target gene promoters.  PPARγ has been extensively investigated and ligands for this 
receptor typically induce adipocyte differentiation and mediate tissue-specific anti-
inflammatory responses.  Synthetic thiazolidinediones (TZDs), such as rosiglitazone and 
pioglitazone, are PPARγ agonists that have been developed for treatment of insulin-
resistant Type 2 diabetes (354-357). 
 Ikezoe and coworkers (257) reported expression of wild-type PPARγ mRNA in 
tumors from multiple tissues including lung, breast, colon, prostate, osteosarcomas, 
____________________ 
*Reprinted with permission from “1,1-Bis(3'-indolyl)-1-(p-substitutedphenyl)methanes 
induce peroxisome proliferator-activated receptor gamma-mediated growth inhibition, 
transactivation, and differentiation markers in colon cancer cells” by  Chintharlapalli S, 
Smith R, 3rd, Samudio I, Zhang W, Safe S. Cancer Res 2004;64:5994-6001. Copyright 
2004 by American Association for Cancer Research, Inc., 
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 acute myelogenous leukemia, adult T-cell leukemia, glioblastomas, B-cell acute 
lymphoblastic leukemia, non-Hodgkin's lymphoma, and myelodisplastic syndrome.  In 
 addition, PPARγ mRNA was also expressed in 71 different cancer cell lines derived 
from hematopoietic and non-hematopoietic (lung, duodenal, prostate, breast, 
glioblastomas and colon) tumors.  Surprisingly, the reported PPARγ mutations in colon 
cancer (358) were not observed in the 10 colon cancer cell lines and 58 clinical samples 
examined in this study. 
 Studies in this laboratory have characterized a series of 1,1-bis(3'-indolyl)-1-(p-
substitutedphenyl)methanes [methylene or C-substituted diindolylmethanes (DIMs)] that 
activate PPARγ-dependent transactivation and inhibit growth of MCF-7 breast cancer 
cells (359).  Compounds containing p-CF3 (DIM-C-pPhCF3), p-t-butyl (DIM-C-pPhtBu), 
and p-phenyl (DIM-C-pPhC6H5) were the most potent activators of PPARγ and 
inhibitors of cell growth.  Growth inhibition by C-substituted DIMs in MCF-7 cells was 
associated, in part, with proteasome-dependent downregulation of cyclin D1. 
 A recent study reported that several colon cancer cells expressed either wild-type 
or mutant PPARγ containing a point mutation at codon 422 (K422Q) (360).  HCT-15 
and other cells that express mutant PPARγ were resistant to the growth inhibitory and 
differentiation-inducing effects of rosiglitazone, whereas these responses were induced 
by rosiglitazone in cells (e.g. HT-29) expressing wild-type PPARγ.  Results of this study 
show that PPARγ-active C-substituted DIMs induce PPARγ-dependent transactivation 
and differentiation-induced genes/proteins in both rosiglitazone-responsive (HT-29) and 
-nonresponsive (HCT-15) colon cancer cell lines.  Caveolin 1 and caveolin 2 proteins 
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were induced by rosiglitazone only in HT-29 cells, whereas C-substituted DIMs induced 
these proteins in both HT-29 and HCT-15 cells.  The cell context-dependent growth 
inhibitory responses of rosiglitazone and PPARγ-active C-substituted DIMs correlated 
with induction of caveolins which exhibit tumor suppressor activity. 
Materials and Methods 
Cell lines and reagents 
 Human colon carcinoma cell lines RKO, DLD1, SW480 were provided by M.D. 
Anderson Cancer Center; HT-29 and HCT-15 were obtained from American Type 
Culture Collection (Manassas, VA). RKO, DLD1, SW480 and HT-29 cells were 
maintained in Dulbecco’s Modified Eagle’s Medium nutrient mixture F-12 Ham 
(DMEM:Ham’s F-12; Sigma, St. Louis, MO) with phenol red supplemented with 0.22% 
sodium bicarbonate, 0.011% sodium pyruvate and 5% fetal bovine serum (FBS) and 
10ml/L of 100X antibiotic antimycotic solution (Sigma). HCT-15 cells were maintained 
in RPMI-1640 medium (Sigma) supplemented with 0.22% sodium bicarbonate, 0.011% 
sodium pyruvate, 0.45% glucose, 0.24% HEPES, 10% FBS and 10ml/L of 100X 
Antibiotic Antimycotic solution (Sigma). Cells were maintained at 37°C in the presence 
of 5% CO2. Rosiglitazone was purchased from LKT Laboratories Inc. (St. Paul, MN). 
Antibodies for PPARγ (sc-7273), Sp1 (sc-59), bcl-2, bax, PARP, cyclin D1 (sc-718), p21 
(sc-756), p27 (sc-528) and caveolin 1 (sc-894) were purchased from Santa Cruz 
Biotechnology (Santa Cruz, CA).  Keratin-18 antibody was purchased from NeoMarkers 
(Fremont, CA). Caveolin 2 antibody was obtained from Transduction Laboratories 
(Lexington, KY). Reporter lysis buffer and luciferase reagent for luciferase studies were 
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purchased from Promega (Madison WI). β-Gal reagent was obtained from Tropix 
(Bedford, MA). Lipofectamine™ reagent and Plus™ reagent were supplied by 
Invitrogen (Carlsbad, CA). Western lightning™ chemiluminiscence reagent were from 
PerkinElmer Life Sciences (Boston, MA). The C-substituted DIMs were prepared in this 
laboratory by condensation of indole with p-substituted benzaldehydes, and compounds 
were > 95% pure by gas chromatography-mass spectrometry. 
Plasmids 
  The Gal4 reporter containing 5X Gal4 DBD (Gal4Luc) was kindly provided by 
Dr. Marty Mayo (University of North Carolina, Chapel Hill, NC). Gal4DBD-PPARγ 
construct (gPPARγ) was a gift of Dr. Jennifer L. Oberfield (Glaxo Wellcome Research 
and Development, Research Triangle Park, NC). The PPARγ-VP16 fusion plasmid (VP-
PPARγ) contained the DEF region of PPARγ (amino acids 183-505) fused to the pVP16 
expression vector and the GAL4-coactivator fusion plasmids pM-SRC1, pMSRC2, 
pMSRC3, pM-DRIP205and pM-CARM-1 were kindly provided by Dr. Shigeaki Kato 
(University of Tokyo, Tokyo, Japan). 
Transfection and luciferase assay 
 Colon cancer cells were plated in 12-well plates at 1 x 105 cells/well in DME-
F12 media supplemented with 2.5% charcoal-stripped FBS. After growth for 16 hr, 
various amounts of DNA, i.e. Gal4Luc (0.4 μg), b-gal 0.04 μg), VP-PPARγ (0.04 μg), 
pM SRC1 (0.04 μg), pMSRC2 (0.04 μg), pMSRC3 (0.04 μg), pMDRIP205 (0.04 μg) 
and pMCARM-1 (0.04 μg) were transfected by Lipofectamine or Lipofectamine Plus 
(Invitrogen) according to the manufacturer’s protocol. After 5 hr of transfection, the 
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transfection mix was replaced with complete media containing either vehicle (DMSO) or 
the indicated ligand for 20-22 hr. Cells were then lysed with 100 ml of 1 X reporter lysis 
buffer and 30 μl of cell extract were used for luciferase and β-Gal assays. Lumicount 
was used to quantitate luciferase and β-Gal activities, and the luciferase activities were 
normalized to β-Gal activity. 
Cell proliferation assay 
 Cells were plated at a density of 2 x 104/well in 12-well plates and replaced the 
next day with DMEM:Ham’s F-12 media containing 2.5% charcoal-stripped FBS  and 
either vehicle (DMSO) or the indicated ligand and concentration. Fresh media and 
compounds were added every 48 hr. Cells were counted at the indicated times using a 
Coulter Z1 cell counter. Each experiment was done in triplicate and results are expressed 
as means ± SE for each determination. 
Fluorescence-activated cell-sorting analysis 
 HT-29 and HCT-15 cells were synchronized in serum-free media for 3 days and 
then treated with either the vehicle (DMSO) or the indicated compounds for 24 hr. Cells 
were trypsinized, centrifuged, and resuspended in staining solution containing 50 μg/ml 
propidium iodide, 4 mM sodium citrate, 30 units/ml RNase, and 0.1% Triton X-100. 
After incubation at 37°C for 10 min, sodium chloride was added to give a final 
concentration of 0.15 M. Cells were analyzed on a FACS Calibur flow cytometer 
(Becton Dickinson Immunocytometry Systems, San Jose, CA), using CellQuest (Becton 
Dickinson) acquisition software. PI fluorescence was collected through a 585/42nm 
bandpass filter, and list mode data were acquired on a minimum of 20,000 single cells 
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defined by a dot plot of PI width versus PI area. Data analysis was performed in ModFit 
LT (Verity Software House, Topsham, ME) using PI width versus PI area to exclude cell 
aggregates. 
Western blot analysis 
 HT-29 and HCT-15 cells were seeded in DMEM:Ham’s F-12 media containing 
2.5% charcoal-stripped FBS for 24 hr and then treated with either the vehicle (DMSO) 
or the indicated compounds. For the apoptosis experiments, cells were treated for 72 hr 
with various compounds.  Western blot analysis of whole cell lysates was determined as 
previously described (359, 361).  Band intensities were evaluated by scanning laser 
densitometry (Sharp Electronics Corporation, Mahwah, NJ) using Zero-D Scanalytics 
software (Scanalytics Corporation, Billerica, MA).  
Statistical analysis 
 Statistical differences between different groups were determined by ANOVA and 
Scheffe's test for significance. The data are presented as mean ± standard deviation for at 
least 3 separate determinations for each treatment. 
Results 
Inhibition of colon cancer cell growth by rosiglitazone and PPARγ-active C-substituted 
DIMs 
 The effects of rosiglitazone, DIM-C-pPhCF3, DIM-C-pPhtBu and DIM-C-pPhC6-
H5 on the growth of HT-29, HCT-15, SW480 and RKO colon cancer cells are 
summarized in Figure 2.1 and Table 2.1.  The results obtained in HT-29 and HCT-15 
cells which express wild-type and mutant (K422Q) PPARγ (360) are illustrated in 
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Figures 2.1A and 2.1B.  Rosiglitazone significantly inhibited growth of HT-29 cells at 
concentrations of 1, 5 and 10 μM; however, the concentration required for 50%  
 
 
Table 2.1.  Percentage inhibition of SW480 and RKO colon cancer cell growth (6 days) 
by rosiglitazone and PPARγ-active C-substituted DIMs.a 
Treatment (μM) SW480 RKO 
Rosiglitazone   
 1 7.85 ± 0.92 0.39 ± 1.73 
 5 8.13 ± 1.34 2.79 ± 2.89 
 10 7.75 ± 2.21 2 ± 1.55 
   
DIM-C-pPhCF3   
 1 22.35 ± 3.87* 4.36 ± 0.18 
 5 104.83 ± 0.29* 101.65 ± 0.06* 
 10 104.93 ± 0.25* 101.71 ± 0.09* 
   
DIM-C-pPhtBu   
 1 1.43 ± 3.47 3.22 ± 1.70 
 5 65.52 ± 1.85* 41.04 ± 1.76* 
 10 102.03 ± 0.37* 103.82 ± 0.06* 
   
DIM-C-pPhC6H5   
 1 2.184 ± 2.44 6.34 ± 2.20 
 5 24.328 ± 1.67* 39.77 ± 2.33* 
 10 103.91 ± 0.08* 102.83 ± 0.052* 
a Cells were treated with different concentrations of the test compounds, and cell 
numbers were determined as described in the Materials and Methods, and the percent 
inhibition of cell growth was compared to DMSO (set at 100%).  Results are means ± 
SD for 3 replicate determinations for each treatment group, and significant (p < 0.05) 
inhibition ( * ) is indicated. 
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Fig. 2.1. Growth inhibition studies.  HT-29 [A] and HCT-15 [B] colon cancer cells were treated 
with 1 - 10 μM rosiglitazone, DIM-C-pPhCF3, DIM-C-pPhtBu and DIM-C-pPhC6H5 for 6 days, 
and cell numbers were determined using a Coulter Counter as described in the Materials and 
Methods.  Results are expressed as means ± SE for 3 separate determinations at each time point. 
 71
B HCT-15
DIM-C-pPhtBu ( #4)
0
0.5
1
1.5
2
2.5
0 2 4 6
Time (Days)
C
el
l n
um
be
r (
x 
10
6 )
DIM-C-pPhC6H5( #9)
0
0.5
1
1.5
2
2.5
0 2 4 6
Time (Days)
C
el
l n
um
be
r (
x 
10
6 )
Rosiglitazone 
0
0.5
1
1.5
2
2.5
0 2 4 6
Time (Days)
C
el
l N
um
be
r (
x 
10
6 )
DMSO
1 μM
5 μM
10 μM
DIM-C-pPhCF3 (# 1)
0
0.5
1
1.5
2
2.5
0 1 2 3 4 5 6
Time (Days)
C
el
l n
um
be
r (
x 
10
6 )
 
Fig. 2.1 Continued 
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Fig. 2.2. FACS analysis.  HT-29 [A] and HCT-15 [B] cells were growth arrested for 3 days and 
then treated for 24 hr with 10 μM rosiglitazone, DIM-C-pPhCF3 or DIM-C-pPhC6H5 and analyzed 
by FACS analysis as described in the Materials and Methods.  Results of a single experiment are 
presented and were also observed in two (HT-29) or three (HCT-15) separate studies. 
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inhibition of cell growth (IC50) was > 10 μM.  In contrast, 1 μM concentrations of DIM-
C-pPhCF3, DIM-C-pPhtBu and DIM-C-pPhC6H5 significantly (p < 0.05) inhibited 
growth of HT-29 cells, and IC50 values were < 5 μM for all three compounds.  
Rosiglitazone did not inhibit proliferation of HCT-15cells (360); the PPARγ-active C-
substituted DIMs all significantly inhibited growth at 5 or 10 μM concentrations, and 
IC50 values were < 10 μM.  The results in Table 2.1 show that rosiglitazone treatment (1 
- 10 μM) minimally affected growth of SW480 or RKO cells, whereas IC50 values for 
the PPARγ-active C-substituted DIMs varied from 1 - 5 or 5 - 10 μM with DIM-C-
pPhCF3 as the most potent compound in both cell lines. 
 HT-29 and HCT-15 cells were cultured in serum-free media for 3 days and then 
grown in 2.5% charcoal-stripped serum and treated with DMSO (solvent control), 10 
μM rosiglitazone, DIM-C-pPhCF3 or DIM-C-pPhC6H5.  Three days after treatment, the 
percentage distribution of cells in G0/G1, S and G2/M phases was determined by FACS 
analysis (Fig. 2.2).  The PPARγ agonists decreased the percentage of HT-29 cells in S 
phase and increased the percentage in G0/G1.  Rosiglitazone did not affect the percentage 
of HCT-15 cells in G0/G1, S or G2/M phase of the cell cycle, and this was consistent with 
the failure of this compound to inhibit proliferation of this cell line (Fig. 2.1B). 
Surprisingly, 10 μM DIM-C-pPhCF3 and DIM-C-pPhC6H5 also did not alter the 
percentage distribution of HCT-15 cells in G0/G1, S or G2/M phase, even though both 
compounds significantly inhibited growth of these cells (Fig. 2.1).  Previous studies with 
HCT-15 cells showed that the PPARγ agonists BRL 49653 did not inhibit growth of 
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these cells or block G0/G1 → S phase progression (362).   
PPARγ-dependent transactivation and coactivator interactions by rosiglitazone, DIM-C-
pPhCF3, DIM-C-pPhtBu and DIM-C-pPhC6H5 
 PPARγ is expressed in SW480, RKO, HT-29 and HCT-15 cells, and ligand-
dependent activation of PPARγ in HCT-15 and HT-29 colon cancer was determined in 
cells transfected with chimeric PPARγ-GAL4 and a GAL4 response element plasmid 
(pGAL4) containing 5 tandem GAL4 response elements linked to a luciferase reporter 
gene (Figs. 2.3A and 2.3B).  Rosiglitazone (1 - 10 μM) and 1 - 10 μM DIM-C-pPhCF3, 
DIM-C-pPhtBu and DIM-C-pPhC6H5 induced reporter gene activity in HCT-15 and HT-
29 cells, and similar results were observed in RKO and SW480 cells.  The magnitude of 
the induction responses were < 6-fold in the HCT-15 and HT-29 cells, and the relative 
potencies of the individual compounds were variable and dependent on cell context.  
DIM-C-pPhCH3 exhibited lower activity in the transactivation assays in the colon cancer 
cells as previously reported in breast cancer cell lines  (359).  Results in Figures 2.3C 
and 2.3D show that induction of luciferase activity by rosiglitazone and PPARγ-active 
C-substituted DIMs in HT-29 and HCT-15 cells transfected with PPARγ-GAL4/pGAL4 
was inhibited by GW9662, a PPARγ antagonist.  Results summarized in Figure 2.3E 
show that 7.5 μM GW9662 also significantly blocks the growth inhibitory effects of 2.5, 
5.0 or 7.5 μM DIM-C-pPhC6H5 in HCT-15 cells.  In contrast, GW9662 alone was 
growth inhibitory in HT-29 cells.  These data confirm the role of PPARγ in mediating 
inhibition of HCT-15 cell growth by DIM-C-pPhC6H5.   
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Figure 3. Ligand-induced activation of PPARγ, and effects of PPARγ antagonists.  [A] Ligand-
dependent activation of PPARγ-GAL4/pGAL4 in HT-29 cells.  Cells were transfected with 
PPARγ-GAL4/pGAL4, treated with 1, 5 or 10 μM of the PPARγ agonists, and luciferase activity 
was determined as described in the Materials and Methods.  Results of all transactivation studies 
in this Figure are presented as means ± SE for at least 3 separate determinations for each treatment 
group and significant (p < 0.05) induction compared to solvent (DMSO) control is indicated by an 
asterisk.  [B] Ligand-dependent activation of PPARγ-GAL4/pGAL4 in HCT-15 cells.  This 
experiment was carried out as described in Figure 3A.  Inhibition of transactivation in HT-29 [C] 
and HCT-15 [D] cells by GW9662.  Cells were transfected with PPARγ-GAL4/pGAL4, treated 
with 10 μM rosiglitazone or PPARγ-active C-substituted DIMs alone or in combination with 5 or 
10 μM GW9662, and luciferase activities were determined as described in Figure 3A.  Significant 
(p < 0.05) inhibition of induced transactivation by GW9662 is indicated (**).  [E]  Inhibition of 
HCT-15 cell growth by DIM-C-pPhC6H5:  effects of GW9662.  The effects of DIM-C-pPhC6H5 
alone and in combination with GW9662 on proliferation of HCT-15 cells were determined as 
described in the Materials and Methods and outlined in the caption for Figure 1.  Significant (p < 
trez/query.fcgi?cmd=Retrieve&amp;db=PubMed&amp;dopt=Citation&amp;list_uids=117147196
62 ( ** ) are indicated. 
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A previous report (363) showed that 15-deoxy-Δ12,14-prostaglandin J2 (PGJ2) but not 
TZDs induced transactivation in a mammalian two-hybrid assay in COS-1 cells 
transfected with VP-PPARγ and GAL4-coactivator chimeras (coactivators = SRC-1, 
SRC-2, SRC-3 and DRIP205/TBP/TRAP220).  Therefore, we investigated ligand-
dependent interactions of VP-PPARγ with chimeric GAL4-coactivator in colon cancer 
cells transfected with the pGAL4-luc reporter gene construct (Fig 2.4).  PPARγ-active C-
substituted DIMs and rosiglitazone induced transactivation in HT-29 cells transfected 
with VP-PPARγ and GAL4-PGC-1, and minimal interactions were observed using 
chimeric proteins containing SRC-1, SRC-2, SRC-3, DRIP205 or CARM-1.  DIM-C-
pPhCF3 also induced transactivation (< 2-fold) in cells transfected with GAL4-SRC-3 
and DIM-C-pPhC6H5 did not significantly induce activity in cells transfected with 
GAL4-PGC-1.  PPARγ-active C-substituted DIMs induced transactivation in HCT-15 
cells transfected with GAL4-PGC-1 and with one exception (DIM-C-pPhtBu/GAL4-
SRC2), minimal interactions with other coactivators were observed.  In SW480 and 
RKO colon cancer cells, a variable pattern of PPARγ-coactivator interactions were 
observed and the PPARγ-active C-substituted DIMs but not rosiglitazone induced 
interactions with PGC-1.    
Modulation of cell cycle proteins, differentiation markers and apoptosis by PPARγ 
agonists 
 The effects of rosiglitazone and PPARγ-active C-substituted DIMs on  
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Fig. 2.4. Ligand-induced PPARγ-coactivator interactions.  HT-29 [A] and HCT-15 [B] were 
transfected with VP-PPARγ, coactivator-GAL4/pGAL4, treated with 10 μM rosiglitazone, DIM-
C-pPhCF3 (#1), DIM-C-pPhtBu (#4) or DIM-C-pPhC6H5 (#9), and luciferase activity was 
determined as described in the Materials and Methods.  Results are expressed as means ± SE for 3 
replicate determinations for each treatment group, and significant (p < 0.05) induction is indicated 
by an asterisk. 
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Fig. 2.5. Modulation of cell cycle proteins.  HT-29 [A] or HCT-15 [B] cells were treated with 5.0 
or 7.5 μM rosiglitazone, DIM-C-pPhCF3 or DIM-C-pPhC6H5 for 24 hr, and whole cell lysates 
were analyzed by Western blot analysis as described in the Materials and Methods.  Cyclin D1, 
p21 and p27 protein levels were similar in all treatment groups in duplicate experiments after 
treatment for 24 hr. 
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cyclin D1, p21 and p27 protein expression were investigated in HT-29 and HCT-15 after 
treatment with DMSO (control) and 5 or 7.5 μM concentrations of these compounds for 
24 hr.  The results show that none of the treatments significantly affected levels of cyclin 
D1, p21 or p27 proteins (Fig. 2.5), and protein levels at other time points (6 and 12 hr) 
were also unchanged. 
 PPARγ agonists induce genes associated with differentiation in preadipocytes 
and cancer cell lines, and results in Figure 2.6 show that keratin 18 is constitutively 
expressed in both HT-29 and HCT-15 cells.  In the former cell line, 5 and 7.5 μM 
rosiglitazone, DIM-C-pPhCF3 and DIM-C-pPhC6H5 significantly induced keratin 18 
protein and a maximal 2-fold induction response was observed for 7.5 μM DIM-C-
pPhC6H5.  Rosiglitazone and PPARγ-active C-substituted DIMs also induced a 2.5- to 3-
fold increase in keratin 18 protein in HCT-15 cells showing that induction of this 
differentiation marker did not correlate with expression of wild-type or mutant PPARγ.  
A recent report showed that caveolins 1 and 2 were induced by TZDs in HT-29 cells 
(364).  Rosiglitazone, DIM-C-pPhCF3 and DIM-C-pPhC6H5 also significantly induced 
caveolins 1 and 2 in this cell line, and protein levels were increased by 5- to 9-fold after 
treatment for 72 hr.  Similar results were observed in HT-29 cells treated for only 48 hr 
with the PPARγ agonists.  In contrast, DIM-C-pPhCF3 and DIM-C-pPhC6H5, but not 
rosiglitazone, induced caveolins 1 and 2 in HCT-15 cells after treatment for 72 hr (Figs. 
2.7C and 2.7E).  Induction of caveolins 1 and 2 by DIM-C-pPhCF3 and DIM-C-pPhC6H5 
in HT-29 and HCT-15 cells was inhibited by cotreatment with the PPARγ agonist 
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Fig. 2.6. Expression of keratin 18.  HT-29 [A] and HCT-15 [B] cells were treated with 5.0 or 7.5 
μM rosiglitazone, DIM-C-pPhCF3 or DIM-C-pPhC6H5 for 3 days, and whole cell lysates were 
analyzed by Western blot analysis as described in the Materials and Methods.  Keratin 18 levels in 
each treatment group were quantitated relative to an Sp1 protein loading control, and results are 
expressed as means ± SE for 3 replicate determinations for each treatment group.  Significant (p < 
0.05) induction is indicated by an asterisk. 
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Fig. 2.7. Expression of caveolin 1 and caveolin 2.  HT-29 [A] and HCT-15 [B] cells were treated 
with 5.0 or 7.5 μM rosiglitazone, DIM-C-pPhCF3 or DIM-C-pPhC6H5 for 3 days, and whole cell 
lysates were analyzed by Western blot analysis as described in the Materials and Methods.  Using 
a similar approach, caveolin 2 protein levels were determined in HT-29 [C] and HCT-15 [D] cells. 
Results are expressed as means ± SE for 3 replicate determinations [A, B] or averages of two 
determinations [C, D], and significant (p < 0.05) induction (*) [A, B] was determined as outlined 
in Figure 6.  Inhibition of caveolin 1 induction in HT-29 [E] and HCT-15 [F] cells by GW9662. 
The experiment was carried out as described in Figures 7A and 7B; however, cells were also 
treated with the PPARγ agonists (7.5 μM) in combination with GW9662.  Comparable results 
were observed in duplicate experiments. 
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Fig. 2.8. Effects of PPARγ agonists on apoptosis.  HCT-15 [A] or HT-29 [B] cells were treated 
with DMSO, 10 μM DIM-C-pPhCF3 (1), DIM-C-pPhtBu (4), DIM-C-pPhC6H5 (9), or 
rosiglitazone for 72 hr or 10 μM MG132 for 20 hr, and whole cell lysates were analyzed by 
Western blot analysis for PARP112/85, bcl-2, bax or a non-specific (NS) (loading control) protein. 
Similar results were observed in duplicate analyses. 
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 GW9662; similar inhibition was observed for rosiglitazone in HT-29 cells (Figs. 2.7E 
and 2.7F).  Since caveolin 1 exhibits tumor suppressor and growth inhibitory activities, 
the results suggest that induction of caveolins may be important for the antiproliferative 
effects of PPARγ-active C-substituted DIMs and rosiglitazone in colon cancer cells (Fig. 
2.1).   
 PPARγ agonists also induce apoptosis in some cancer cell lines (254, 365, 366), 
and therefore this response was also investigated in HT-29 and HCT-15 cells.  PPARγ-
active compounds (10 μM) did not induce PARP cleavage (a marker of apoptosis) or 
alter levels of bax or bcl-2 protein expression in HCT-15 or HT-29 cells (Fig. 2.8).  In 
contrast, the proteasome inhibitor MG132 induced PARP cleavage in both cell lines but 
did not affect levels of bcl-2 or bax proteins.  Thus, differences in the observed 
antiproliferative activities of rosiglitazone and PPARγ C-substituted DIMs in HT-29 and 
HCT-15 cells (Fig. 2.1) was not due to apoptosis or modulation of cell cycle proteins but 
correlated with their cell context-dependent differential induction of caveolins 1 and 2, 
but not keratin 18. 
Discussion 
 PPARγ is overexpressed in multiple tumor types  (257) and studies in several 
laboratories have demonstrated that PGJ2 and TZDs inhibit growth of human cancer cell 
lines in vitro and also in xenograft models in vivo (359-361, 367, 368).  Two reports 
(368, 369) showed that treatment of Min mice, which express a mutated inactive form of 
the adenomatous polyposis coli (APC) tumor suppressor gene, with troglitazone or BRL-
49653 induced colon polyp formation.  These results contrast with xenograft studies 
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where PPARγ agonists inhibit colon tumor growth (367).  Moreover, a recent study 
reported that 100 or 200 ppm pioglitazone and bezafibrate in the diet of Apc-deficient 
mice reduced intestinal polyps and hyperlipidemia (370).  Another study used 
PPARγ+/-/Min mice and their crosses to show that inhibition of colon carcinogenesis in 
these mice by PPARγ agonists is Apc-dependent (371). 
 Recent studies in this laboratory showed the C-substituted DIMs inhibited 
growth and G0/G1 → S progression of MCF-7 breast cancer cells and activated PPARγ-
dependent transactivation (359).  The growth-inhibitory properties of rosiglitazone and 
three PPARγ-active C-substituted DIMs (DIM-C-pPhCF3, DIM-C-pPhtBu and DIM-C-
pPhC6H5) were also determined in HT-29, HCT-15, SW480 and RKO colon cancer cell 
lines.  At concentrations of 10 μM rosiglitazone significantly inhibited growth of HT-29 
cells (IC50 > 10 μM) but not the other cell lines, whereas the PPARγ-active C-substituted 
DIMs inhibited growth of all four colon cancer cell lines with IC50 values between 1 - 10 
μM.  The growth inhibitory effects of DIM-C-pPhC6H5 were inhibited by GW9662 in 
HCT-15 cells (Fig. 2.3E).  A recent report showed that troglitazone inhibited growth and 
induced differentiation genes in HCT-15 cells (372).  However, these responses were 
observed using 50 μM troglitazone, suggesting that activation of some mutant (K422Q) 
PPARγ-dependent responses in HCT-15 cells may be observed with higher 
concentrations of thiazolidinediones. 
 Rosiglitazone and the PPARγ-active C-substituted DIM activated PPARγ-
GAL4/pGAL4-luc in all four cell lines (Fig. 2.3) with variable potencies, and 
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transactivation was inhibited after cotreatment with the PPARγ antagonist GW9662.  
The pattern of coactivator-PPARγ interactions in HT-29 and HCT-15 cells paralleled, in 
part, their responsiveness to the growth inhibitory effects of rosiglitazone and the 
PPARγ-active C-substituted DIMs (Fig. 2.4).  Both structural classes of PPARγ agonists 
induced interactions between VP-PPARγ and GAL4-PGC-1 in HT-29 cells, whereas 
only the C-substituted DIMs induced the same interaction in HCT-15 cells (Fig. 2.4).  In 
contrast, the pattern of coactivator-PPARγ interactions in SW480 and RKO cells was 
more complex and minimal induction was observed for rosiglitazone in both cell lines.  
The differences in rosiglitazone-induced transactivation in the mammalian two-hybrid 
assay in HT-29 and HCT-15 were observed using VP-PPARγ (wild-type) in both cell 
lines.  This suggests that differences in PGC-1-PPARγ interactions in HT-29 and HCT-
15 cells are not due to expression of the PPARγ mutant (K422Q) in the latter cell line 
but related to differential expression in the two cell lines of other nuclear cofactors 
required for this response.  Although PPARγ-active C-substituted DIMs preferentially 
induce PPARγ-PGC-1 interactions in HT-28 and HCT-15 cells, this was not uniformly 
observed for all ligands in these cells (Fig. 2.4).  For example, DIM-C-pPhC6H5 inhibits 
HT-29 and HCT-15 cell growth (Fig. 2.1), induces caveolins 1/2 (Fig. 2.7), and both 
responses are inhibited by the PPARγ agonist GW9662 (Figs. 2.3E, 2.7E and 2.7F).  In 
contrast, 10 μM DIM-C-pPhC6H5 does not induce transactivation in the mammalian 
two-hybrid assay in HT-29 cells using GAL4-PGC-1 and VP-PPARγ (Fig. 2.4).  Current 
studies are investigating expression of PGC-1 and other coactivators and their role in 
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PPARγ-dependent transactivation and growth inhibition in HT-29 and HCT-15 cells. 
 We further investigated the role of wild-type vs. mutant (K422Q) PPARγ 
expression in mediating ligand-dependent responses in HT-29 and HCT-15 cells by 
examining their effects on proteins critical for cell cycle progression and differentiation.  
In HT-29 cells, treatment with rosiglitazone or PPARγ-active C-substituted DIMs 
inhibited G0/G1 → S phase progression (Fig. 2.2A).  These effects were not observed in 
HCT-15 cells (Fig. 2.2B) and may be due to the high percentage of cells in G0/G1 with or 
without treatment (> 74%).  Despite differences in FACS analysis, neither rosiglitazone 
or the PPARγ-active C-substituted DIMs significantly changed levels of the cell cycle 
regulatory proteins p27, p21 or cyclin D1 in HT-29 or HCT-15 cells (Fig. 2.5).  
Moreover, we did not observe PPARγ agonist-dependent induction of apoptosis in either 
cell line (e.g. Fig. 2.8) suggesting that the antiproliferative effects (Fig. 2.1) are not 
dependent on modulation of cell cycle proteins or induction of apoptosis in HT-29 or 
HCT-15 cells. 
 PPARγ agonists also induce genes/proteins associated with differentiation in 
colon cancer cells (360, 364, 370, 373, 374).  For example, troglitazone induced villin 
and intestinal alkaline phosphatase mRNA levels in several colon cancer cell lines (374), 
and TZDs and PGJ2 induced caveolin 1 and caveolin 2 protein expression in HT-29 cells 
(364).  Keratin 18 and 20 proteins and CEACAM6 mRNA levels were minimally 
expressed in HCT-15 cells but were not affected by treatment with rosiglitazone; 
however, after transfection of HCT-15 cells with wild-type PPARγ, rosiglitazone 
induced these responses (360).  A direct comparison of PPARγ agonist-induced 
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expression of differentiation markers in HCT-15 vs. HT-29 cells has not been previously 
reported.  The results in Figure 6 show that rosiglitazone, DIM-C-pPhCF3 and DIM-C-
pPhC6H5 significantly induced keratin 18 in both HT-29 and HCT-15 cells, indicating 
that keratin 18 protein induction was independent of PPARγ agonist structure and 
expression of wild-type or mutant (K422Q) PPARγ.  In contrast, induction of caveolin 1 
and caveolin 2 in HT-29 and HCT-15 was dependent on both ligand structure and cell 
context (Fig. 2.7).  Rosiglitazone induced caveolins 1 and 2 in HT-29 but not in HCT-15 
cells, whereas PPARγ-active C-substituted DIMs induced caveolins 1 and 2 in both HT-
29 and HCT-15 cells and these responses were inhibited after cotreatment with 
GW9662.  This pattern of induced caveolin expression parallels the growth inhibitory 
effects of rosiglitazone and PPARγ-active C-substituted DIMs in HT-29 and HCT-15 
cells (Fig. 2.1), suggesting that induced caveolin 1 and caveolin 2 expression may 
contribute to growth inhibition of colon cancer cells.  This observation is consistent with 
a report by Bender and coworkers  (375) showing that overexpression of caveolin 1 in 
HT-29 or DLD (HCT-15) cells significantly decreased their tumorigenicity in athymic 
nude mouse xenograft models. 
 In summary, this study demonstrates the PPARγ-active C-substituted DIMs 
induce PPARγ-dependent transactivation in colon cancer cells expressing wild-type 
(HT-29) or mutant (K422Q) (HCT-15) PPARγ.  Moreover, these compounds also inhibit 
growth of HT-29 and HCT-15 cells, whereas equivalent concentrations of rosiglitazone 
are active only in the former cell line.  The enhanced growth inhibitory activity of 
PPARγ-active C-substituted DIMs vs. rosiglitazone in HCT-15 cells correlated with the 
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induction of caveolins 1 and 2 by the former compounds and not by rosiglitazone (Fig. 
2.7).  Current studies are focused on the mechanisms of the growth inhibitory effects of 
this new class of PPARγ agonists in other colon cancer cell lines and the role of 
caveolins and other genes/proteins in mediating PPARγ-dependent antitumorigenic 
activities. 
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CHAPTER III 
INHIBITION OF BLADDER TUMOR GROWTH BY 1,1-BIS(3'-INDOLYL)-1-(p-
SUBSTITUTEDPHENYL)METHANES: A NEW CLASS OF PEROXISOME 
PROLIFERATOR-ACTIVATED RECEPTOR γ AGONISTS  
Introduction 
Metastatic UC of the bladder is typically treated with various combinations of 
systemic chemotherapy (376-379).  However, almost all patients with distant metastatic 
bladder cancer are dead within 1 to 2 years, despite treatment with the most effective 
regimens available (377, 378).  Since the mid-1980s, the standard treatment for 
metastatic UC has been a combination of methotrexate, vinblastine, adriamycin and 
cisplatin.  Recently, several novel combination regimes has been reported; however, 
there is no compelling evidence of enhanced patient survival with these treatments (380-
382).  An improved understanding of the biology of malignancy will provide novel 
therapeutic approaches. 
 One such strategy is targeted therapy which involves modulation of specific 
genes/pathways that are upregulated in cancer cells compared to normal tissues and can 
lead to decreased cancer cell survival and/or death.  The peroxisome proliferator-
activated receptor γ (PPARγ) is a ligand-activated receptor and a member of the nuclear 
receptor superfamily of transcription factors.  PPARγ, PPARα and PPARβ/δ are 
differentially expressed in normal tissues/organs and play diverse roles in metabolism, 
anti-inflammatory responses, and differentiation (355, 356, 383-385).  Synthetic PPARγ 
agonists such as the thiazolidinediones (TZDs) are now widely used for treatment of 
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insulin-resistant Type II diabetes.  PPARγ is highly expressed in tumor samples from 
different sites and, in one study, wild-type PPARγ mRNA was observed in multiple 
tumors and in 34 hematopoeitic cancer cell lines as well as several lung (385), colon 
(385), duodenal (376), prostate (380), breast (379), and glioblastoma (377) cell lines 
(257).  PPARγ has also been detected in bladder tumors and bladder cancer cell lines 
(386-389), and PPARγ is expressed in the epithelium but not surrounding smooth muscle 
or interstitium (387). 
 PPARγ is an excellent target for cancer chemotherapy not only due to its elevated 
expression in tumors but also for the induced responses which include decreased cell 
survival and G0/G1 to S phase progression, increased differentiation and apoptosis (254, 
360-366, 390-392).  Research in this laboratory has identified a new class of PPARγ 
agonists from a series of 1,1-bis(3'-indolyl)-1-(p-substitutedphenyl)methanes where the 
PPARγ-active compounds contain p-trifluromethyl (DIM-C-pPhCF3), p-t-butyl (DIM-C-
pPhtBu), and p-phenyl DIM-C-pPhC6H5) substituents (359, 391-395).  The PPARγ-
active methylene-substituted diindolylmethanes (C-DIMs) inhibit growth and/or induce 
apoptosis in breast, pancreatic and colon cancer cell lines and leukemia cells, and this 
study investigates their effects on bladder cancer cells in vitro and bladder tumors in 
vivo.  The PPARγ-active C-DIMs inhibit growth of KU7 bladder cancer cells and induce 
the tumor suppressor caveolin-1 but do not affect expression of cyclin D1, p21 or p27.  
In contrast, induction of p21 but not caveolin-1 was observed in 253JB-V33 cells.  C-
DIM compounds also inhibit growth of orthotopic and subcutaneous bladder tumors 
(KU7) in athymic nude mice, and this was accompanied by enhanced expression of 
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caveolin-1 in the tumors.  These data demonstrate that PPARγ-active C-DIMs exhibit 
antitumorigenic activity for bladder cancer, and current studies are evaluating these 
compounds for future clinical applications. 
Materials and Methods 
Cell lines, antibodies, plasmids and reagents 
KU7 and 253JB-V33 bladder cancer cell lines were obtained from American 
Type Culture Collection (Manassas, VA).  Cells were maintained in RPMI 1640 (Sigma-
Aldrich, St. Louis, MO) supplemented with 0.22% sodium bicarbonate, 0.011% sodium 
pyruvate, 0.45% glucose, 0.24% HEPES, 10% FBS, and 10 mL/L of 100x antibiotic 
antimycotic solution (Sigma-Aldrich).  Cells were maintained at 37°C in the presence of 
5% CO2.  Antibodies for cyclin D1 (sc-718), p27 (sc-528), phospho-Akt (sc-7985R), Akt 
(sc-8312), Sp1 (PEP2), and caveolin 1 (sc-894) were purchased from Santa Cruz 
Biotechnology (Santa Cruz, CA).  Monoclonal β-actin was purchased from Sigma-
Aldrich.  Reporter lysis buffer and luciferase reagent for luciferase studies were supplied 
by Promega (Madison, WI).  β-Galactosidase (β-Gal) reagent was obtained from Tropix 
(Bedford, MA) and Lipofectamine reagent was purchased from Invitrogen (Carlsbad, 
CA).  Western Lightning chemiluminescence reagent was from Perkin-Elmer Life 
Sciences (Boston, MA).  Rosiglitazone was purchased from LKT Laboratories, Inc. (St. 
Paul, MN).  The C-substituted DIMs were prepared in this laboratory as previously 
described (359, 393-395).  The Gal4 reporter containing 5x Gal4 response elements 
(pGal4) was kindly provided by Dr. Marty Mayo (University of North Carolina, Chapel 
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Hill, NC).  Gal4DBD-PPARγ construct was a gift of Dr. Jennifer L. Oberfield 
(GlaxoSmithKline Research and Development, Research Triangle Park, NC).   
Transfection and luciferase assay 
KU7 or 253JB-V33 cells (1 x 105 cells/well) were plated in 12-well plates in 
DMEM:Ham’s F-12 media supplemented with 2.5% charcoal-stripped FBS.  After 16 
hr, various amounts of DNA [i.e. pGal4 (0.4 μg), β-gal (0.04 μg), PPARγ-GAL4 (0.04 
μg)] were transfected by Lipofectamine (Invitrogen) according to the manufacturer’s 
protocol.  After 5 hr, the transfection mix was replaced with complete media containing 
either vehicle (DMSO) or the indicated ligand for 20 to 22 hr.  Cells were then lysed 
with 100 μL of 1x reporter lysis buffer, and cell extracts (30 μL) were used for luciferase 
and β-gal assays.  A Lumicount luminometer (PerkinElmer Life and Analytical 
Sciences) was used to quantitate luciferase and β-gal activities, and the luciferase 
activities were normalized to β-gal activity.  
Cell proliferation assay 
 The bladder cancer cells (2 x 104/well) were plated in 12-well plates and allowed 
to attach for 24 hr.  The medium was changed to DMEM:Ham’s F-12 media containing 
2.5% charcoal-stripped FBS and either vehicle (DMSO) or the indicated compounds 
were added.  Fresh media and compounds were added every 48 hr, and cells were then 
trypsinized and counted after 96 and 144 hr using a Coulter Z1 cell counter.  Each 
experiment was determined in triplicate, and results are expressed as means ± SE for 
each determination.  
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Western blot analysis 
The bladder cells cells were seeded in DMEM:Ham’s F-12 media containing 
2.5% charcoal-stripped FBS for 24 h and treated with either the vehicle (DMSO) or the 
compounds for different times as indicated.  Cells were collected by scraping in 150 μL 
high salt lysis buffer (50 mM HEPES, 0.5 M NaCl, 1.5mM MgCl2, 1 mM EGTA, 10% 
(v/v) glycerol, 1% (v/v) Triton-X-100 and 5 μL/ml of Protease Inhibitor Cocktail 
(Sigma).  The lysates were incubated on ice for 1 hr with intermittent vortexing followed 
by centrifugation at 40,000 g for 10 min at 4°C.  Samples were boiled for 3 min at 100°C 
prior to electrophoresis, protein concentrations were determined, and 60 μg protein 
applied per lane.  Samples were subjected to SDS-PAGE on 10% gel at 120 V for 3 to 4 
hr.  Proteins were transferred onto polyvinylidene membranes (PVDF; Bio-Rad, 
Hercules, CA) by semidry electroblotting in a buffer containing 25 mM Tris, 192 mM 
glycine and 20% methanol for 1.5 hr at 180 mA.  The membranes were blocked for 30 
min with 5% TBST-Blotto (10 mM Tris-HCl, 150 mM NaCl (pH 8.0), 0.05% Triton X-
100 and 5% non-fat dry milk) and incubated in fresh 5% TBST-Blotto with 1:1000 
primary antibody overnight with gentle shaking at 4°C.  After washing with TBST for 10 
min, the PVDF membrane was incubated with secondary antibody (1:5000) in 5% 
TBST-Blotto for 90 min.  The membrane was washed with TBST for 10 min and 
incubated with 10 ml of chemiluminiscence substrate (PerkinElmer Life Sciences) for 
1.0 min and exposed to Kodak X-OMAT AR autoradiography film (Eastman Kodak, 
Rochester, NY). 
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Animal experiments 
Male athymic BALB/c nude mice, 4-6 weeks old, were purchased from the 
Animal Production Area of the National Cancer Institute, Frederick Cancer Research 
Facility (Frederick, MD).  The mice were housed in laminar flow cabinets under specific 
pathogen-free conditions.  Animals were maintained in facilities approved by the 
American Association for Accreditation of Laboratory Animal Care and in accordance 
with current regulations and standards of the United States Department of Agriculture, 
Department of Health and Human Services, and NIH.  Mice were acclimatized for 2 
weeks and their use in these experiments was approved by the M. D. Anderson Cancer 
Center Institutional Animal Care and Use Committee.  We implanted the highly 
tumorigenic human cell carcinoma cell line, KU7 (1 million cells/injection), into the 
subcutis of athymic nude mice for the heterotopic xenograft experiment and into the 
bladder wall for the orthotpic xenograft experiment.  One week later, mice were treated 
(10 per treatment group) with placebo or DIM-C-pPhCF3 (60 mg/kg/dose on days 1, 3 
and 5).  Treatment was continued for 4 weeks, then the animals were sacrificed.  Tumor 
volumes were measured and tumor kinetics were established in the various groups.  
Apoptosis and proliferation were subsequently evaluated in tumor sections using 
immunohistochemical techniques. 
Immunohistochemistry 
For immunohistochemical (IHC) analysis, frozen tissue sections (8 μm thick) 
were fixed with cold acetone, chloroform/acetone, and acetone.  Tissue sections (5 μm 
thick) of formalin-fixed, paraffin-embedded specimens were deparaffinized in xylene 
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followed by treatment with a graded series of alcohol [100%, 95%, and 80% 
ethanol/double-distilled H2O (v/v)] and rehydrated in PBS (pH 7.5).  Antigen retrieval 
for paraffin-embedded tissues was performed with pepsin (Biomeda, Foster City, CA) 
for 15 min at 37°C.  Endogenous peroxidase was blocked by the use of 3% hydrogen 
peroxide in PBS for 10 min.  The samples were washed thrice with PBS and incubated 
for 20 min at room temperature with a protein blocking solution containing 5% normal 
horse serum and 1% normal goat serum in PBS (pH 7.5).  Excess blocking solution was 
drained, and the samples were incubated for 18 hr at 4°C with one of the following:  a 
1:100 dilution of mouse monoclonal anti-PCNA antibody (DAKO, Carpinteria, CA); or 
1:100 dilution of caveolin-1 antibody.  The samples were then rinsed four times with 
PBS and incubated for 60 min at room temperature with the appropriate dilution of the 
secondary antimouse IgG (Jackson ImmunoResearch Laboratory).  The slides were 
rinsed with PBS and incubated for 5 min with diaminobenzidine (Research Genetics). 
The sections were then washed with PBS (3X), counterstained with Gill’s hematoxylin 
(Biogenex Laboratories, San Ramon, CA), and again washed with PBS (3X).  The slides 
were mounted using a water and alcohol-based mounting medium (Universal mount, 
Research Genetics). 
TUNEL assay 
Frozen tissue sections fixed and treated as above were washed with PBS 
containing 0.1% Brij (v/v).  Terminal deoxynucleotidyl transferase (Tdt)-mediated nick 
end labeling (TUNEL) was performed using a commercial kit (Promega, Madison, WI) 
according to the manufacturer's instructions with the following modifications.  Samples 
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were fixed with 4% paraformaldehyde (methanol-free) for 10 min at room temperature, 
washed with PBS, and permeabilized by incubating with 0.2% Triton X-100 in PBS 
(v/v) for 15 min.  The samples were incubated with equilibration buffer (from the kit).  
Reaction buffer containing equilibration buffer (45 μL), nucleotide mix (5 μL), and Tdt 
(1 μL) was added to the sections and incubated in a humidified chamber for 1 hr at 37°C 
protected from light.  The reaction was terminated by immersing the samples in 2x SSC 
[30 mM NaCl, 3 mM sodium citrate (pH 7.2)] for 15 min followed by three washes to 
remove unincorporated fluorescein-dUTP.  Background reactivity was determined by 
processing the slides in the absence of Tdt (negative control).  Nuclei were stained with 
PI (1 μg/mL) for 10 min.  Fluorescent bleaching was minimized with an enhancing 
reagent (Prolong; Molecular Probes, Eugene, OR). Immunofluorescence microscopy was 
performed using a Zeiss Plan-Neofluar lens on an epifluorescence microscope equipped 
with narrow bandpass excitation filters mounted in a filter wheel (Ludl Electronic 
Products, Hawthorne, NY) to individually select for green, red, and blue fluorescence.  
Images were captured using a cooled CCD camera (Photometrics, Tucson, AZ).  DNA 
fragmentation was detected by localized green fluorescence within the nucleus of 
apoptotic cells. 
Quantification of cell proliferation and apoptosis in in vivo tissue samples 
Cell proliferation and apoptosis were determined by IHC of tissue sections with 
anti-PCNA antibodies and TUNEL assay.  The tissue was photographed using a cooled 
CCD Optotronics Tec 470 camera linked to a computer and digital printer.  The intensity 
of the immunostaining was quantified in five different areas of each sample by an image 
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analyzer using Optimas image analysis software program (Media Cybernetics) to obtain 
an average measurement.  The density of proliferative cells and  apoptotic cells was 
expressed as an average number of the five highest areas identified within a single x200 
field.  
Statistical analyses 
Statistical analysis was performed using SPSS (SPSS Inc., Chicago, IL) and 
Instat3 (San Diego, CA) software.  For in vitro data, analysis of variance was performed, 
and t-tests with the Bonferroni correction were used to evaluate for significant 
differences between the treated cells at each drug concentration and untreated control 
cells.  Tumor weights as well as expression intensities of TUNEL and PCNA counts 
were compared by unpaired Student's t-test.  For the primary end point of tumor size the 
sample size of 10 mice/treatment group were expected to have >90% power to detect a 
minimum difference of 24 mm3 in tumor size at a statistical significance level of 0.05%.  
Statistical significance for this study was set at two-sided p < 0.05. 
Results 
Decreased cell survival and activation of PPARγ 
 The effects of PPARγ-active C-DIMs and rosiglitazone, a widely used TZD on 
survival of KU7 and 253JB-V33 bladder cancer cell lines was investigated.  Results in 
Figure 3.1 illustrate the survival of KU7 cells after treatment with solvent (DMSO; set at 
100% survival), 1 - 10 μM rosiglitazone DIM-C-pPhCF3, DIM-C-pPhtBu and DIM-C-
pPhC6H5 for 48 hr.  Decreased survival of cells treated with rosiglitazone was not 
observed at the highest concentration (10 μM), whereas 1, 5 and 10 μM concentrations 
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of the PPARγ-active C-DIMs significantly decreased cell survival.  Moreover, 10 μM of 
the C-DIM compounds also induced cell death after treatment for 48 hr since the number 
of cells remaining was lower than the initial number of seeded cells (day 0).  We also 
examined KU7 cell survival after 96 and 144 hr and the results were similar to those 
observed after 48 hr; 10 μM rosiglitazone also decreased (10 - 25%) cell survival at the 
longer time points (Fig. 3.1).  We also examined the comparative effects of 
rosiglitazone, DIM-C-pPhCF3, DIM-C-pPhtBu and DIM-C-pPhC6H5 on 253JB-V33 cell 
survival, and the results after treatment for 48 hr are summarized in Figure 3.2.  
Rosiglitazone at the highest concentration exhibited minimal effects on cell survival, 
whereas 5 and 10 μM of the C-DIM compounds significantly decreased cell survival 
and, after 96 or 144 hr, both concentrations also induced cell death.  Based on their cell 
growth curves, the IC50 values for growth inhibition by the PPARγ-active C-DIMs 
ranged between 5- 10 and 1 - 5 μM in KU7 and 253JB-V33 cells, respectively, and the 
IC50 value for rosiglitazone was > 10 μM in both cell lines. 
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Fig. 3.1.  KU7 cell survival curves.  KU7 cells were treated with DMSO and different 
concentrations of [A] rosiglitazone, [B] DIM-C-pPhCF3, [C] DIM-C-pPhtBu, and [D] DIM-C-
pPhC6H5 for 48 hr, and the percent survival was determined as described in the Materials and 
Methods.  The number of cells in the DMSO treatment group was set at 100%.  Results are 
expressed as means ± SE for three replicate treatments for each concentration and significantly (p 
< 0.05) decreased cell survival is indicated by an asterisk.  Ten μM concentrations of the C-DIM 
compounds significantly (p < 0.05) induced cell death [i.e. the number of cells in the treatment 
groups were lower than the original number of seed cells (at time 0)]. 
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Fig. 3.2.  253JB-V33 survival curves.  253JB-V33 cells were treated with DMSO and 1, 5 or 10 
μM [A] rosiglitazone, [B] DIM-C-pPhCF3, [C] DIM-C-pPhtBu, and [D] DIM-C-pPhC6H5 for 48 
hr, and percent survival of cells in the treated groups [relative to DMSO (100%)] was determined 
as described in the Materials and Methods.  Results are expressed as means ± SE for three 
replicate determinations for each treatment group, and significantly (p < 0.05) decreased cell 
survival is indicated by an asterisk.  After 48 hr, cell death was observed for 10 μM concentrations 
of the C-DIMs and, after 144 hr, 5 μM concentrations also induced death. 
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 We also examined PPARγ activation in both cancer cell lines treated with DMSO, 
rosiglitazone or the C-DIMs and transfected with the GAL4-PPARγ/GAL4-luc 
constructs.  The results in KU7 cells show that rosiglitazone and the C-DIMs caused a 
concentration-dependent increase in transactivation (Fig. 3.3A).  These compounds also 
induced transactivation in 253JB-V33 cells (Fig. 3.3B) and the fold-induction was higher 
for rosiglitazone compared to the C-DIMs.  A concentration-dependent response was not 
observed for the latter compounds, and this may be due, in part, to their potent growth 
inhibitory effects at 5 and 10 μM concentrations in 253JB-V33 cells (Fig. 3.2). 
Effects of rosiglitazone and C-DIMs on cell cycle proteins and caveolin-1 
 In some cancer cell lines, PPARγ agonists modulate genes/proteins involved in 
G0/G1 to S cell cycle progression, and results in Figure 3.4A summarize the effects of 
rosiglitazone and C-DIMs on cyclin D1 (CD1), p27 and p21 expression in KU7 cells 
(Sp1 serves as a loading control).  CD1 and p27 levels were unaffected by the treatment, 
whereas increased expression of p21 protein was concentration-independent.  In 
contrast, the C-DIM compounds but not rosiglitazone induced p21 expression in 253JB-
V33 cells (Fig. 3.4B), whereas CD1 and p27 were unaffected by the treatments.  The 
upregulation of p21 expression in 253JB-V33 cells by the C-DIMs has previously been 
reported for the same compounds in Panc-28 cells (394) and is consistent with their 
growth-inhibitory effects (Fig. 3.2).  Previous studies in several colon cancer cell lines 
related the growth inhibitory effects of C-DIMs to the induction of caveolin-1 (393) 
which has been shown to inhibit growth of some colon cancer cells.  The effects of 
rosiglitazone and the PPARγ-active C-DIMs on caveolin-1 expression were further  
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Fig 3.3.  Activation of PPARγ-GAL4/pGAL4 by C-DIM compounds and rosiglitazone.  [A] KU7 
and [B] 253JB-V33 bladder cancer cells were transfected with PPARγ-GAL4/pGAL4, treated with 
DMSO or different concentrations of the test compounds, and luciferase determined as described 
in the Materials and Methods.  Results are expressed as means ± SE for at least three replicate 
determinations for each treatment group and significant (p < 0.05) induction is indicated by an 
asterisk. 
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Fig. 3.4.  Effects of C-DIM compounds on cell cycle protein expression.  [A] KU7 and [B] 253JB-
V33 cells were treated with DMSO or 5.0 and 7.5 μM of the PPARγ-active C-DIMs and 
rosiglitazone for 24 hr.  Whole cell lysates were analyzed in a Western blot assay as described in 
the Materials and Methods.  Sp1 protein serves as a loading control. 
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investigated in KU7 (Fig. 3.5A) and 253JB-V33 (Fig. 3.5B) cells.  The C-DIM 
compounds (but not rosiglitazone) induced approximately a 3- to 4-fold increase in 
caveolin-1 protein expression, and this was comparable to the response induced in colon 
cancer cells (393).  In contrast, constitutive caveolin-1 protein expression was relatively 
high in 253-JB-V33 cells and neither rosiglitazone or C-DIMs significantly enhanced 
levels of this protein.  The role of PPARγ in mediating induction of caveolin-1 was 
investigated in KU7 cells treated with 5 and 7.5 μM DIM-C-pPhCF3 alone or in 
combination with the PPARγ antagonist GW9662 (Fig. 3.5C).  The results show that 
induction of caveolin-1 by PPARγ-active C-DIMs was inhibited after cotreatment with 
GW9662, and these results are similar to those observed in colon cancer cells (393).  
There is also evidence that the PPARγ-active compounds including C-DIMs enhance 
phosphatidylinsositol-3-kinase (PI3-K) activity in colon cancer cell lines [(396) and 
unpublished observations], and the results in Figure 3.5C confirm that DIM-C-pPhCF3 
and DIM-C-pPhC6H5 also induced PI3-K-dependent phosphorylation of Akt.  The 
compounds did not affect Akt protein.  Thus, PPARγ-active C-DIMs decreased survival 
of KU7 and 253-JB-V33 cells and this correlated with increased expression of caveolin-
1 and p21, respectively, in these cell lines.  These results are another example of the 
cancer cell context-dependent differences in the growth inhibitory pathways induced by 
C-DIMs and other PPARγ agonists. 
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DIM-C-pPhtBu DIM-C-pPhC6H5
Fig. 3.5.  Induction of caveolin-1 by C-DIM compounds.  [A] KU7 and [B] 253JB-V33 cells were 
treated with DMSO or 5.0 and 7.5 μM PPARγ-active C-DIMs and rosiglitazone for 72 hr.  Whole 
cell lysates were analyzed for caveolin-1 in a Western blot assay as described in the Materials and 
Methods.  Sp1 protein served as loading control.  [C]  Effects of the PPARγ agonist GW9662. 
KU7 cells were treated with DIM-C-pPhCF3 or DIM-C-pPhC6H5 alone or in combination with 10 
μM GW9662 and analyzed in a Western blot assay for caveolin-1, Akt, phospho-Akt (pAkt) and 
β-actin (loading control) as described in the Materials and Methods. 
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Fig. 3.5 Continued 
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 Effects of PPARγ-active C-DIMs on bladder tumor growth in vivo 
 To confirm whether our in vitro data are comparable in an in vivo model for 
bladder cancer, the human UC cell line KU7 was implanted into the orthotopic bladders 
of athymic nude mice.  To establish tumor kinetics, another in vivo experiment was 
bladder cancer, the human UC cell line KU7 was implanted into the orthotopic bladders 
of athymic nude mice.  To establish tumor kinetics, another in vivo experiment was 
performed using subcutaneously implanted tumors.  No toxicity was seen in mice treated 
with DIM-C-pPhCF3 as demonstrated by weighing the mice.  Tumor growth was 
substantially inhibited with DIM-C-pPhCF3 compared with controls in both orthotopic 
and subcutaneous tumors (Fig. 3.6A).  In vivo, growth of orthotopic and subcutaneous 
tumors was significantly inhibited by DIM-C-pPhCF3 (32% and 60% growth inhibtion) 
when compared to control.  Mean tumor weights of mice in control and DIM-C-pPhCF3-
treated groups were 265 mg and 191 mg in the orthotopic model compared with 997 mg 
and 398 mg in the s.c.model, respectively.  DIM-C-pPhCF3 significantly inhibited cell 
proliferation in both orthotopic and subcutaneous bladder tumors by 26% and 55%, 
respectively (Fig. 3.6B).  However, tumors obtained from mice in the treatment group 
displayed low levels of apoptosis that were not appreciably different from those in 
controls.  Furthermore, DIM-pPhCF3 significantly induced expression of caveolin in 
both orthotopic and subcutaneous bladder tumors by 30% and 25%, respectively (Fig. 
3.7) and these in vivo results complement in vitro studies (Fig. 3.5) which showed 
upregulation of caveolin-1 protein expression. 
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Fig. 3.6.  DIM-C-pPhCF3 inhibits bladder tumor growth.  Inhibition of [A] orthotopic and [B] 
subcutaneous bladder tumor growth.  KU7 cells (1?106 cells/injection) were administered to 
athymic nude mice via subcutaneous (sc) injection or by direct injection into the bladder wall as 
described in the Materials and Methods.  Mice were administered DIM-C-pPhCF3 (60 mg/kg) 
three times each week (days 1, 3 and 5) for 4 weeks.  Tumor weights at the end of the treatment 
are summarized in [A] and tumor volumes in the subcutaneous group are given in [B].  [C] 
Proliferation index and apoptosis were determined as described in the Materials and Methods. 
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Fig. 3.7.  Induction of caveolin-1 in bladder tumors by DIM-C-pPhCF3.  The caveolin-1 index [A] 
and immunostaining [B] of bladder tumors for caveolin-1 expression was determined as described 
in the Materials and Methods. 
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Discussion 
 The potential anticarcinogenic activities of different structural classes of PPARγ 
agonists have been investigated in various cancer cell lines in vitro and in vivo models 
(254, 359, 362-366, 391-395).  PPARγ agonists induce genes and activities linked to 
differentiation, growth inhibition, and apoptosis; however, the induced responses are 
highly variable and dependent on ligand structure and cell context.  Moreover, there is 
evidence that the effects induced by these compounds may be PPARγ-dependent or -
independent.  For example, the PPARγ agonists troglitazone and 15-deoxyΔ12,14-
prostaglandin J2 (PGJ2) induce the NSAID-activated gene (NAG-1) in HCT-116 colon 
cancer cells by receptor-independent and -dependent pathways, respectively (397).  
PPARγ-active C-DIMs induce p21 expression in Panc-28 but not other pancreatic cell 
lines, and this response was PPARγ-dependent.  Rosiglitazone induced caveolin-1 in 
HT-29 colon cancer cells expressing wild-type PPARγ but not in HCT-15 cells which 
express a mutant (K422Q) form of this receptor (393).  In contrast, PPARγ-active C-
DIMs induce caveolin and other genes associated with differentiation in colon cancer 
cells expressing either wild-type or mutant PPARγ (393).  A recent study showed that 2-
cyano-3,12-diooxoolean-1,9-dien-oic acid (CDDO) and related PPARγ agonists also 
induced caveolin-1 in colon cancer cells and this was inhibited by PPARγ antagonists, 
whereas higher concentrations of CDDO induced apoptosis and this response was 
receptor independent (396). 
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 Bladder cancer cells also overexpress PPARγ (386-389).  One study showed that 
although PGJ2 and TZDs both decreased cell survival, there were significant differences 
in the responsiveness of bladder cancer cells to these compounds (389).  For example, 
the IC50 value for growth inhibition by troglitazone and pioglitazone was > 50 μM in 
253J bladder cancer cells; IC50 values in T24, RT4 and IT-1 cells were ≤ 30, 15 and 10 
μM, respectively (389).  Both PPARγ-active C-DIMs and rosiglitazone activated PPARγ 
(Fig. 3.3), and the C-DIMs decreased cell survival (Figs. 3.1 and 3.2) in KU7 and 
253JB-V33 cells.  KU7 cells were less responsive than 253JB-V33 cells to the growth 
inhibitory effects of ≤ 10 μM C-DIMs, whereas ≤ 10 μM rosiglitazone was relatively 
ineffective in both cell lines.  Thus, as previously reported in colon cancer cells (393), 
PPARγ-active C-DIMs were more potent than rosiglitazone as inhibitors of bladder 
cancer cell growth. 
 The modulation of cell cycle genes (p21) associated with G0/G1 to S phase 
progress, and the induction of caveolin-1 have been linked to PPARγ-dependent 
inhibition of Panc-28 pancreatic and HT-29/HCT-15 colon cancer cell growth after 
treatment with C-DIMs (393, 394).  Differences in activation of specific PPARγ-
dependent "growth inhibitory" genes by C-DIMs in these cell lines was also observed 
253JB-V33 and KU7 cells in which C-DIMs induced p21 and caveolin-1, respectively 
(Figs. 3.4 and 3.5).  The reason for cell context-dependent regulation of p21 and 
caveolin-1 by C-DIM compounds is unknown; however, based on results of ongoing 
studies with colon cancer cells, the fold-induction of caveolin-1 is inversely related to 
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constitutive levels of this protein.  Thus, high basal expression of caveolin-1 in 253JB-
V33 cells (Fig. 3.5) may preclude further induction of this protein. 
 We further investigated the in vivo anticarcinogenic activity of DIM-C-pPhC6H5 
and DIM-C-pPhCF3 by implanting the highly tumorigenic KU7 cell line into the 
orthotopic bladder of athymic nude mice and also in a subcutaneous implant model using 
the same cell line.  Both PPARγ agonists inhibited tumor growth in the orthotopic and 
subcutaneous implant models in athymic nude mice.  DIM-C-pPhCF3 significantly 
inhibited tumor growth in both models, whereas initial in vivo studies with DIM-C-
pPhC6H5 were not completed due, in part, to formulation problems.  We also 
demonstrated that for DIM-C-pPhCF3 there was a significantly increased expression of 
caveolin-1 in the orthotopic (30%) and subcutaneous (25%) bladder cancer models, and 
these in vivo responses (Fig. 3.7) correlated with induced expression of caveolin-1 in 
KU7 cancer cells (Fig. 3.5A).  Thus, PPARγ-active C-DIMs inhibit growth of bladder 
cancer cells in vitro and bladder tumors in both an orthotopic and subcutaneous in vivo 
mouse models.  We also observed the somewhat paradoxical induction of PI3-K activity 
by PPARγ-active C-DIMs in KU7 cells (Fig. 3.5), and a previous study also showed that 
the triterpenoid PPARγ agonist CDDO also induced this kinase pathway in SW-480 
colon cancer cells (396).  Although PI3-K has been linked to cell survival pathways, 
increased PI3-K-dependent activity and caveolin-1 expression sensitizes HeLa and 293 
cells to the cytotoxicity of arsenite and hydrogen peroxide (398) and L929 cells to tumor 
necrosis factor α-induced cell death (399).  Thus, activation of PI3-K and induction of 
caveolin-1 expression may be an important element in the antitumorigenic activity of 
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PPARγ-active C-DIMs.  Current studies are investigating other receptor-dependent and -
independent pathways responsible for the anticancer activities of these compounds, and 
their application in the treatment of bladder and other cancers. 
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CHAPTER IV 
 
1,1-BIS(3'-INDOLYL)-1-(p-SUBSTITUTEDPHENYL)METHANES ARE 
PEROXISOME PROLIFERATOR-ACTIVATED RECEPTOR γ AGONISTS BUT 
DECREASE HCT-116 COLON CANCER CELL SURVIVAL THROUGH 
RECEPTOR-INDEPENDENT ACTIVATION OF EARLY GROWTH 
RESPONSE-1 AND NAG-1* 
Introduction 
NSAID-activated gene-1 (NAG-1) is a transforming growth factor β (TGFβ)-like 
secreted protein and was initially characterized as a p53-regulated gene (400, 401).  
Overexpression of NAG-1 in breast cancer cells resulted in growth arrest and apoptosis, 
and similar results were also observed in colon cancer cells (401, 402).  Baek, Eling and 
their coworkers have extensively investigated the induction of NAG-1 by several 
different structural classes of drugs and chemoprotective phytochemicals in HCT-116 
colon and other cancer cell lines (303, 402-413).  Chemicals that induce NAG-1 
expression in cancer cell lines generally inhibit growth and/or induce apoptosis in these 
cells, and these effects are due, in part, to induction of NAG-1 protein.  In addition to 
NSAIDs, other agents that induce NAG-1 include phorbol esters, cyclooxygenase
__________________ 
*Reprinted with permission from “1,1-Bis(3'-indolyl)-1-(p-substitutedphenyl)methanes 
are peroxisome proliferator-activated receptor {gamma} agonists but decrease HCT-116 
colon cancer cell survival through receptor-independent activation of early growth 
response-1 and nonsteroidal anti-inflammatory drug-activated gene-1” by Chintharlapalli 
S, Papineni S, Baek SJ, Liu S, Safe S. Mol Pharmacol 2005;68:1782-1792. Copyright 
2005 by American Society for Pharmacology and Experimental Therapeutics. All rights 
reserved. 
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inhibitors, genistein, plant polyphenolics, diallyl disulfide, retinoids, indole-3-carbinol 
(I3C), diindolylmethane (DIM), and peroxisome proliferator-activated receptor γ 
(PPARγ) agonists (303, 402-413). 
 Several mechanisms of NAG-1 induction have been described and these are 
dependent not only on the structure or class of inducing agents but also on cell context.  
For example, diallyl disulfide and genistein are antitumorigenic components of garlic 
and soy, and their induction of NAG-1 in HCT-116 cells is p53-dependent (405, 407).  
In contrast, induction of NAG-1 by indole-3-carbinol and diindolylmethane (DIM), two 
anticarcinogenic components in cruciferous vegetables, is p53-independent in the same 
cell line (414).  Two PPARγ agonists, 15-deoxy-Δ12,14-prostaglandin J2 (PGJ2) and 
troglitazone, also induce NAG-1 expression in HCT-116 cells, and the PPARγ 
antagonist 2-chloro-5-nitrobenzanilide (GW9662) inhibits the induction response by 
PGJ2 but not troglitazone (303).  It was also shown that the PPARγ-independent 
activation of NAG-1 by troglitazone is due to induction of early growth response gene 
(Egr-1) which in turn activates NAG-1 (303, 397). 
 Recent studies in this laboratory have identified 1,1-bis-(3'-indolyl)-1-(p-
substitutedphenyl)methanes [methylene-substituted DIMs (C-DIMs)] as PPARγ 
agonists, and the most active compounds contain p-trifluoromethyl (DIM-C-pPhCF3), p-
t-butyl (DIM-C-pPhtBu), and phenyl (DIM-C-pPhC6H5) (359, 393-395).  These PPARγ 
agonists decrease survival and induce apoptosis in breast, leukemia, pancreatic and colon 
cancer cells.  In the latter two cell lines, growth inhibition is associated with receptor-
dependent activation of p21 (394) and the tumor suppressor gene caveolin-1 (393).  
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There is also evidence that decreased cancer cell survival induced by these compounds is 
also receptor-independent (359, 395).  The PPARγ-active methylene-substituted 
diindolylmethanes (C-DIMs) also decrease cell survival and induce apoptosis in HCT-
116 cells but do not induce caveolin-1, as previously reported in HT-29 and HCT-15 
colon cancer cells (393).  In contrast, these compounds induce NAG-1 in HCT-116 cells 
and this response is not inhibited by PPARγ antagonists.  Like troglitazone, the PPARγ-
active C-DIMs also induce Egr-1 which in turn interacts with proximal (GC-rich) Egr-1 
motifs in the NAG-1 gene promoter.  However, in contrast to troglitazone, the C-DIM 
compounds induce Egr-1 through a phosphatidylinositol-3-kinase (PI3K)-dependent 
pathway which in turn activates serum response elements in the Egr-1 promoter.  This 
represents a novel pathway for induction of Egr-1 and NAG-1, and these responses 
contribute to the induction of growth inhibition and apoptosis by the PPARγ-active C-
DIMs in colon cancer cells.  Moreover, these results also distinguish the mode of action 
of these C-DIM analogs from that of troglitazone and DIM and identify an important 
PPARγ-independent mode of action. 
Materials and Methods 
Cell lines 
HCT-116 (human colon carcinoma cell line) and LNCap (human prostate cancer 
cell line) were obtained from American Type Culture Collection (Manassas, VA).  HCT-
116 and LnCap cells were maintained in RPMI 1640 (Sigma-Aldrich, St. Louis, MO) 
supplemented with 0.22% sodium bicarbonate, 0.011% sodium pyruvate, 0.45% glucose, 
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0.24% HEPES, 10% FBS, and 10 mL/L of 100x antibiotic antimycotic solution (Sigma-
Aldrich).  Cells were maintained at 37°C in the presence of 5% CO2.  
Antibodies and reagents 
Antibodies for poly(ADP-ribose) polymerase (sc-8007), cyclin D1 (sc-718), p27 
(sc-528), phospho-Akt (sc-7985R), Akt (sc-8312) p53 (sc-126) and caveolin 1 (sc-894) 
were purchased from Santa Cruz Biotechnology (Santa Cruz, CA), NAG-1 from Upstate 
Biotechnology (Lake Placid, NY), and Egr-1 from Cell Signaling Technology, Inc. 
(Beverly, MA).  Monoclonal β-actin antibody was purchased from Sigma-Aldrich.  
Reporter lysis buffer and luciferase reagent for luciferase studies were supplied by 
Promega (Madison, WI).  β-Galactosidase (β-Gal) reagent was obtained from Tropix 
(Bedford, MA) and Lipofectamine reagent was purchased from Invitrogen (Carlsbad, 
CA).  Western Lightning chemiluminescence reagent was from Perkin-Elmer Life 
Sciences (Boston, MA).  Rosiglitazone was purchased from LKT Laboratories, Inc. (St. 
Paul, MN).  The C-substituted DIMs were prepared in this laboratory as previously 
described (359, 393) and the Egr-1 constructs were kindly provided by Mr. C.-C. Chen 
and Mrs. W.-R. Lee (Texas A&M University). 
Plasmids 
The Gal4 reporter containing 5x Gal4 response elements (pGal4) was kindly 
provided by Dr. Marty Mayo (University of North Carolina, Chapel Hill, NC).  
Gal4DBD-PPARγ construct (gPPARγ) was a gift of Dr. Jennifer L. Oberfield 
(GlaxoSmithKline Research and Development, Research Triangle Park, NC).  PPRE-luc 
construct contains three tandem PPREs with a minimal TATA sequence in pGL2 (359, 
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393).  pNAG-1A - pNAG-1D, pNAG-1Dm1, pNAG-1Dm2 and pNAG-1Dm3 were 
generated previously (397, 403).  pEGR-1A - pEGR-1E constructs containing Egr-1 
promoter inserts have also previously been described (415). 
Transfection and luciferase assay 
HCT-116 cells (1 x 105 cells/well) were plated in 12-well plates in 
DMEM:Ham’s F-12 media supplemented with 2.5% charcoal-stripped FBS.  After 16 
hr, various amounts of DNA [i.e. Gal4Luc (0.4 μg), β-gal (0.04 μg), PPRE-Luc (0.04 
μg)] and 0.25 μg of the NAG-1/EGR-1 constructs were transfected by Lipofectamine 
(Invitrogen) according to the manufacturer’s protocol.  Five hours after transfection, the 
transfection mix was replaced with complete media containing either vehicle (DMSO) or 
the indicated ligand for 20 to 22 hr.  Cells were then lysed with 100 μL of 1x reporter 
lysis buffer, and 30 μL of cell extract were used for luciferase and β-gal assays.  A 
Lumicount luminometer (PerkinElmer Life and Analytical Sciences) was used to 
quantitate luciferase and β-gal activities, and the luciferase activities were normalized to 
β-gal activity. 
Cell proliferation assay 
HCT-116 cells (2 x 104/well) were plated in 12-well plates.  After cell attachment 
for 24 hr, the medium was changed to DMEM:Ham’s F-12 media containing 2.5% 
charcoal-stripped FBS and either vehicle (DMSO) or the indicated compound.  Fresh 
media and compounds were added every 48 hr, and the cells were then trypsinized and 
counted at the indicated times using a Coulter Z1 cell counter.  Each experiment was 
done in triplicate, and results are expressed as means ± SE for each determination.  
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Western blot analysis 
HCT-116 cells were seeded in DMEM:Ham’s F-12 media containing 2.5% 
charcoal-stripped FBS for 24 h and then treated with either the vehicle (DMSO) or the 
compounds for different times as indicated.  Cells were collected by scraping in 150 μL 
high salt lysis buffer (50 mM HEPES, 0.5 M NaCl, 1.5mM MgCl2, 1 mM EGTA, 10% 
(v/v) glycerol, 1% (v/v) Triton-X-100 and 5 μL/ml of Protease Inhibitor Cocktail 
(Sigma).  The lysates were incubated on ice for 1 hr with intermittent vortexing followed 
by centrifugation at 40,000 g for 10 min at 4°C.  Before electrophoresis, the samples 
were boiled for 3 min at 100°C, the amounts of protein was determined and 60 μg 
protein applied per lane.  Samples were subjected to SDS-PAGE on 10% gel at 120 V 
for 3 to 4 hr.  Proteins were transferred onto polyvinylidene membranes (PVDF; Bio-
Rad, Hercules, CA) by semidry electroblotting in a buffer containing 25 mM Tris, 192 
mM glycine and 20% methanol for 1.5 hr at 180 mA.  The membranes were blocked for 
30 min with 5% TBST-Blotto (10 mM Tris-HCl, 150 mM NaCl (pH 8.0), 0.05% Triton 
X-100 and 5% non-fat dry milk) and incubated in fresh 5% TBST-Blotto with 1:1000 
(for caveolin 1, p27 and cyclin D1), 1:250 (for PARP), 1:500 (for NAG-1 and Egr-1), 
1:5000 (for β-actin) primary antibody overnight with gentle shaking at 4°C.  After 
washing with TBST for 10 min, the PVDF membrane was incubated with secondary 
antibody (1:5000) in 5% TBST-Blotto for 90 min.  The membrane was washed with 
TBST for 10 min and incubated with 10 ml of chemiluminiscence substrate 
(PerkinElmer Life Sciences) for 1.0 min and exposed to Kodak X-OMAT AR 
autoradiography film (Eastman Kodak, Rochester, NY). 
 124
Chromatin immunoprecipitation (ChIP) assay 
HCT-116 cells (2x107) were treated with Me2SO (time 0), or DIM-C-pPhC6H5 
(20 μM) for 1 or 2 hr.  Cells were then fixed with 1.5% formaldehyde, and the cross-
linking reaction was stopped by addition of 0.125 M glycine.  After washing twice with 
phosphate-buffered saline, cells were scraped and pelleted.  Collected cells were 
hypotonically lysed, and nuclei were collected.  Nuclei were then sonicated to desired 
chromatin length (~500 bp).  The chromatin was pre-cleared twice by addition of protein 
A-conjugated beads (PIERCE), and then incubated at 4°C for 1 hr with gentle agitation.  
The beads were pelleted, and the pre-cleared chromatin supernatants were 
immunoprecipitated with antibodies specific to IgG, Sp1, Sp3, Sp4 (Santa Cruz 
Biotechnology), and Egr-1 (Cell Signaling Technology) at 4°C overnight.  Protein-
antibody complexes were collected by addition of protein A-conjugated beads at room 
temperature for 1 hr.  Beads were extensively washed; the protein-DNA crosslinks were 
eluted and reversed.  DNA was purified by phenol extraction/ethanol precipitation 
followed by PCR amplification.  The NAG-1 primers are: 5’ - TAC TGA GGC CCA 
GAA ATG TG - 3’ (forward),  and 5’ - GAG CTG GGA CTG ACC AGA  TG - 3’ 
(reverse).  These primers amplify a 211-bp region of the human NAG-1 promoter 
containing two Sp1/Egr-1 binding sites.  The positive control primers are: 5’ - TAC 
TAG CGG TTT TAC GGG CG - 3’ (forward), and 5’ - TCG AAC AGG AGG AGC 
AGA GAG CGA - 3’ (reverse),  which amplify a 167-bp region of human 
glyceraldehydes-3-phosphate dehydrogenase (GAPDH) gene. The negative control 
primers are: 5’ - ATG GTT GCC ACT GGG GAT CT -  3’ (forward), and 5’ - TGC 
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CAA AGC CTA GGG GAA GA - 3’ (reverse), which amplify a 174-bp region of human 
CNAP1 exon.  PCR products were resolved on a 2% agarose gel in the presence of 1:10 
000 SYBR gold (Molecular Probes, Eugene, OR). 
Statistical analysis 
Statistical significance was determined by analysis of variance and Scheffe's test, 
and the levels of probability are noted.  The results are expressed as means ± SE for at 
least three separate (replicate) experiments for each treatment. 
Results 
 Studies in this laboratory have characterized selected C-DIMs as PPARγ agonists 
that inhibit growth of colon and other cancer cell lines through receptor-dependent and -
independent pathways (359, 393-395).  Results illustrated in Figure 4.1 show that three 
PPARγ-active C-DIM compounds, namely DIM-C-pPhCF3, DIM-C-pPhtBu and DIM-
C-pPhC6H5, decreased HCT-116 colon cancer cell survival at concentrations of 1 - 10 
μM after treatment for 48 or 96 hr.  Treatment for 96 hr resulted in cell death using 10 
μM concentrations (i.e. cell numbers were lower than the initial number of seeded cells).  
In contrast, 10 μM rosiglitazone decreased cell survival but did not induce cell death, 
which is observed only at higher concentrations of this compound.  Previous studies in 
colon cancer cells show that PPARγ-active C-DIMs induced transactivation in cells 
transfected with PPRE-luc or GAL4-PPRγ/pGAL4-luc constructs (393).  In HCT-116 
cells, PPARγ-active C-DIMs induced a concentration-dependent increase in 
transactivation in cells transfected with PPRE-luc, and 10 μM rosiglitazone also 
increased activity but with lower fold-inducibility (Fig. 4.2A).  The same compounds 
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also induced transactivation in HCT-116 cells transfected with GAL4-PPARγ/GAL4-luc 
constructs and treated with 5 and 10 μM of the C-DIMs, and cotreatment with the 
PPARγ antagonist GW9662 significantly inhibited this response (Fig. 4.2B).  These 
results confirm that PPARγ-active C-DIMs induce receptor-dependent transactivation in 
HCT-116 cells, and this complements results of recent studies that show similar response 
in HT-29 and HCT-15 colon cancer cell lines (393). Treatment of HCT-116 cells for 24 
hr with 2.5, 5.0 and 7.5 μM DIM-C-pPhCF3, DIM-C-pPhtBu or DIM-C-pPhC6H5 did 
not affect expression of cyclin D1 or p27 proteins (Fig. 4.3A).  PPARγ agonists 
frequently affect expression of these proteins in other cancer cell lines (255, 361, 390, 
391, 394, 416, 417); however, the results (Fig. 4.3A) are comparable to those observed 
for the same compounds in HT-29 and HCT-15 cells (393).  The growth inhibitory 
effects of these compounds in HT-29 and HCT-15 cells are associated with receptor-
dependent activation of the tumor suppressor gene caveolin-1 (393) which inhibits colon 
cancer cell growth.  However, in HCT-116 cells, treatment with 5, 10 or 15 μM DIM-C-
pPhCF3 or DIM-C-pPhC6H5 for 72 hr did not affect caveolin-1 protein expression (Fig. 
4.3B).  Moreover, unlike HT-29 and HCT-15 cells, relatively high levels of caveolin-1 
were detected in solvent (DMSO)-treated HCT-116 cells.  Other PPARγ agonists such as 
PGJ2 and troglitazone, induce the TGFβ-like protein NAG-1 in HCT-116 cells (397, 
407), and therefore induction of NAG-1 protein and apoptosis by PPARγ-active C-DIMs 
was investigated in HCT-116 cells treated with relatively high concentrations (10 - 20 
μM) over 24 hr.  The results (Fig. 4.3C) show that NAG-1 protein expression was not  
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Fig. 4.1.  PPARγ-active C-DIMs decrease HCT-116 cancer cell survival.  HCT-116 cells were 
treated for 48 [A] or 96 [B] hr with DMSO or different concentrations of C-DIMs, and cell 
numbers as a percentage of DMSO-treated cells were determined as described in the Materials and 
Methods.  Results are expressed as means ± SE for three separate determinations for each 
treatment group and a significant (p < 0.05) decreased in cell survival is indicated with an asterisk.
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Fig. 4.2.  Activation of PPARγ-dependent transactivation.  HCT-116 cells were transfected with 
PPRE3-luc [A] or PPARγ-GAL4/pGAL4 [B], treated with DMSO, different concentrations of C-
DIMs or rosiglitazone alone or in combination with GW9662, and luciferase activity was 
determined as described in the Materials and Methods.  Results are expressed as means ± SE for 
replicate determinations for each treatment group, and significant (p < 0.05) induction (*) or 
inhibition after cotreatment with GW9662 (**) are indicated. 
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Fig. 4.3.  Modulation of cell cycle proteins, caveolin-1, PARP cleavage, and NAG-1 by PPARγ-
active C-DIMs.  HCT-116 cells were treated with DMSO or different concentrations of C-DIMs 
and analyzed for cyclin D1 (CD1)/p27 [A], caveolin-1 [B], PARP cleavage/NAG-1 and CD1 [C], 
and NAG-1 [D] by Western blot analysis as outlined in the Materials and Methods.  Treatment 
times were varied and similar results were observed in duplicate experiments for [A] - [D]. 
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detectable in solvent-treated cells; however, treatment with 10 - 20 μM DIM-C-pPhCF3, 
DIM-C-pPhtBu or DIM-C-pPhC6H5 induced NAG-1 protein expression.  We also 
observed induction of NAG-1 by C-DIMs in LNCaP cells as previously described for 
other NAG-1 inducers (408).  The induction of NAG-1 in HCT-116 cells was 
accompanied by activation of apoptosis as indicated by PARP cleavage.  In contrast, p27 
expression was unaffected by this treatment and cyclin D1 was downregulated only at 
the highest dose level.  The coordinate induction of NAG-1 and apoptosis in HCT-116 
cells by PPARγ-active C-DIMs after treatment for 24 hr is consistent with the effects of 
these compounds on decreased cell survival (Fig. 4.1).  However, the induction of NAG-
1 by PPARγ-active C-DIMs was not strictly a high dose effect since treatment of HCT-
116 cells with 2.5, 5.0 and 7.5 μM DIM-C-pPhCF3 and DIM-C-pPhC6H5 for 72 hr show 
that NAG-1 protein was induced at concentrations as low as 2.5 μM (Fig. 4.3D). 
 The concentration-dependent effects of DIM-C-pPhCF3 and DIM-C-pPhC6H5 on 
induction of NAG-1 and other proteins that are often induced along with NAG-1 were 
determined in HCT-116 cells after treatment for 24 hr (Fig. 4.4A).  NAG-1 protein levels 
were elevated at concentrations as low as 7.5 μM.  After 24 hr, maximal induction was 
observed at concentrations ≤ 15 μM and this was accompanied by PARP cleavage.  
Induction of NAG-1 by some compounds is accompanied by increased expression of 
p53 protein (405, 407) or ATF3 (411, 414), and the PPARγ-active C-DIMs induced the 
latter protein but not p53.  Although other PPARγ agonists induce NAG-1, the role of 
the receptor in mediating these responses is structure dependent since studies with 
PPARγ antagonists showed that induction of NAG-1 by PGJ2 and troglitazone was  
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Fig. 4.4.  Induction of NAG-1 and related proteins by C-DIMs and the role of PPARγ.  [A] 
Induction of NAG-1 and related proteins by C-DIMs.  HCT-116 cells were treated with DMSO or 
7.5 - 20 μM C-DIMs for 24 hr and proteins were analyzed by Western immunoblot analysis as 
described in the Materials and Methods.  [B]/[C]  Role of PPARγ in activation of NAG-1/PARP 
cleavage by C-DIMs.  HCT-116 cells were treated for 24 hr with DMSO, 10 or 15 μM C-DIMs 
alone or in combination with 10 μM GW9662 and whole cell lysates were analyzed by Western 
immunoblot analysis as described in the Materials and  Methods.  [D]  Role of PPARγ in 
mediating C-DIM-induced cell survival.  Cell survival data (after 96 hr) were obtained as 
described in Figure1, and the effects of C-DIMs alone or in combination with GW9662 were 
determined.  No significant (p < 0.05) effects on cell survival were observed in cells treated with 
D-DIMs plus GW9662.  Experiments illustrated in [B] - [D] were also determined using the 
PPARγ antagonist T007 and similar results were obtained. 
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PPARγ-dependent and -independent, respectively (303).  Treatment of HCT-116 cells 
with DIM-C-pPhCF3 (Fig. 4.4B) or DIM-C-pPhC6H5 (Fig. 4.4C) alone or in 
combination with the PPARγ antagonist GW9662 shows that induction of NAG-1 or 
apoptosis by the C-DIM compounds is not inhibited by GW9662.  We have also 
repeated the same experiment with another PPARγ antagonist, 2-chloro-5-nitro-N-4-
pyridinyl-benzamide (T007) and observed no inhibition of the C-DIM-mediated 
induction of NAG-1 or PARP cleavage.  In addition, GW9662 did not affect decreased 
HCT-116 cell survival after treatment with the C-DIM compounds for 96 hr (Fig. 4.4D).  
Apoptosis (PARP cleavage) was induced by PPARγ-active C-DIMs at concentrations as 
low as 10 μM (after 24 hr); this was more pronounced after 48 hr  and correlated with 
the cell survival results (Fig. 4.1).  Thus, like troglitazone, the PPARγ-active C-DIMs 
induce NAG-1 and apoptosis in HCT-116 cells via a PPARγ-independent pathway. 
 Previous reports have linked the anticarcinogenic activity of troglitazone to 
induction of both NAG-1 and Egr-1 and enhanced Egr-1 expression has been linked to 
upregulation of NAG-1 in HCT-116 cells (303, 397, 411).  The results in Figure 4.5A 
show that both DIM-C-pPhCF3 and DIM-C-pPhC6H5 induce Egr-1 and NAG-1 proteins 
in HCT-116 cells; however, the temporal expression of both proteins is different.  Egr-1 
is maximally induced within 2 hr after treatment and levels then decline 4 to 24 hr after 
treatment.  In contrast, induction of NAG-1 protein increases over the 24 hr treatment 
period and the highest levels are observed after 24 hr.  The temporal sequence of C-
DIM-induced NAG-1 and Egr-1 expression is comparable to that observed for 
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troglitazone in HCT-116 cells except that the time-course for induction of both proteins 
is somewhat delayed (397).  
    
Fig. 4.5.  Induction of Egr-1 protein/reported gene activity by C-DIMs.  [A]  Time course 
induction of NAG-1 and Egr-1.  HCT-116 cells were treated with DMSO or 15 μM C-DIMs for 
up to 24 hr, and whole cell lysates were analyzed for Egr-1, NAG-1 and β-actin (control) by 
Western immunoblot analysis as described in the Materials and Methods.  Activation of EGR-1A 
[B], EGR-1B [C], EGR-1C [D], EGR-1D [E], and EGR-1E [F] by C-DIMs.  HCT-116 cells were 
transfected with the various constructs treated with DMSO or C-DIMs and luciferase activity 
determined as described in the Materials and Methods.  Results are expressed as means ± SE for 
three replicate determinations for each treatment group, and significant (p < 0.05) induction is 
indicated by an asterisk. 
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We also investigated the effects of the PPARγ-active C-DIMs on transactivation in cells 
transfected with constructs containing -600 to +12 (pEGR-1A), -460 to +12 (pEGR-1B), 
and -164 to +12 (pEGR-1C) Egr-1 promoter inserts (Figs. 4.5B – 4.5D).  All three 
compounds induced transactivation in cells transfected with pEGR-1A and pEGR-1B 
but not pEGR-1C, suggesting that SRE2-4 motifs within the -460 to -164 region of the 
promoter were required for activation of Egr-1.  Further deletion of the 3' region of the 
promoter was investigated in cells transfected with pEGR-1D (-480 to -285) and pEGR-
1E (-480 to -376).  The C-DIM compound induced transactivation only in cells 
transfected with pEGR-1D and not pEGR-1E demonstrating that the minimal region of 
the Egr-1 promoter required for transactivation (-376 to -285) contained SRE3 and 
SRE2. 
 The potential role of Egr-1 in mediating induction of NAG-1 was further 
investigated in HCT-116 cells transfected with a series of constructs containing the 
-3500 to +41 (pNAG-1A), -1086 to +41 (pNAG-1B), -474 to +41 (pNAG-1C), and -133 
to +41 (pNAG1D) NAG-1 promoter inserts (Figs. 4.6A – 4.6D).  The results show that 
the C-DIM compounds induce transactivation in HCT-116 cells transfected with all four 
constructs.  Previous studies show that the -73 to -44 region of the NAG-1 gene 
promoter contains two GC-rich Sp1 binding sites that overlap two Egr-1 sites (303, 402, 
403).  Therefore, cells were transfected with pNAG-1D or constructs containing a single 
Egr-1 site mutation (pNAG-1Dm1 and pNAG-1Dm2) or both sites mutated (pNAG-
1Dm3).  The results (Fig. 4.6E) show that C-DIM-induced transactivation was decreased 
in cells transfected with pNAG-1Dm1 and pNAG-1Dm2 and no significant induction 
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Fig. 4.6.  Activation of NAG-1 promoter constructs by C-DIMs and Egr-1.  HCT-116 cells were 
transfected with pNAG-1A [A], pNAG-1B [B], pNAG-1C [C], pNAG-1D [D], or pNAG-1D 
mutants [E], treated with DMSO or C-DIMs, and luciferase activity determined as described in the 
Materials and Methods.  Results in [A] - [E] are expressed as means ± SE for three replicate 
determinations for each treatment group, and significant (p < 0.05) induction is indicated by an 
asterisk. 
 140
DIM-C-pPhCF3 DIM-C-pPhC6H5DIM-C-pPhtBu
pNAG-1C
0
1
2
3
4
5
DMSO 15 20 25 10 15 20 15 20 25
Fo
ld
 In
du
ct
io
n
*
*
*
*
*
*
*
*
LUC
+41-474
C
DIM-C-pPhCF3 DIM-C-pPhC6H5DIM-C-pPhtBu
pNAG-1D
0
1
2
3
4
DMSO 15 20 25 10 15 20 15 20 25
Fo
ld
 In
du
ct
io
n
*
*
*
*
*
*
*
*
LUC
+41-133
D
*
0 1 2 3
Fold Induction
DIM-C-pPhCF3 
DIM-C-pPhC6H5
DMSO
DIM-C-pPhtBu
**
*
*
**
**
**
**
**
**
**
**
LUCpNAG-1D
wt wt
LUCpNAG-1Dm1
mu wt
LUCpNAG-1Dm2
muwt
LUCpNAG-1Dm3
mumu
E
Fig. 4.6 Continued 
 141
was observed in cells transfected with pNAG-1Dm3.  Thus, mutation of the Egr-1 sites 
resulted in loss of inducibility of the NAG-1 constructs.  Moreover, in cells transfected 
with pNAG-1D, cotransfection with Egr-1 expression plasmid also induces 
transactivation (Fig. 4.7A).  These results are consistent with a mechanism of NAG-1 
induction by C-DIMs which involves initial activation of Egr-1 which in turn activates 
the NAG-1 promoter through proximal Egr-1 motifs.  We also investigated interactions 
of Egr-1 with the NAG-1 promoter in a ChIP assay with PCR primers that target the 
proximal region of the NAG-1 promoter that contain the Egr-1 motifs.  HCT-116 cells 
were treated with DMSO or 20 μM DIM-C-pPhC6H5 for 1 or 2 hr; cells were then 
crosslinked with formaldehyde and the ChIP assay procedure was used to determine 
interactions of Sp proteins and Egr-1 with the NAG-1 promoter (Fig. 4.7B).  The results 
show binding of Sp1, Sp3 and Sp4 proteins to the NAG-1 promoter and the band 
intensities are increased after treatment with DIM-C-pPhC6H5.  Similar results were 
observed for Egr-1 suggesting that induction of Egr-1 protein (Fig. 4.5) facilitates 
recruitment of Egr-1 and Sp proteins to the NAG-1 promoter.  As a control experiment 
for the ChIP assay, the binding of TFIIB to the GAPDH promoter, but not exon 1 of the 
CNAP1 gene, is illustrated in Figure 4.7C as previously described (394). 
 Egr-1 is an immediate early gene that is activated by multiple factors in different 
cell lines, including UV light, ER stress, hormones, phorbol esters, and troglitazone 
(303, 397, 412, 418-423), and many of the responses involve activation of kinases.  
Moreover, troglitazone activates Egr-1 and NAG-1 in HCT-116 cells through activation 
of the mitogen-activated protein kinase (MAPK) pathway (303, 397).  The role of  
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Fig. 4.7.  Activation of NAG-1 by Egr-1.  [A]  Activation of NAG-1 promoter constructs by Egr-1 
expression plasmid.  HCT-116 cells were transfected with pNAG-1D and different amounts of 
Egr-1 expression plasmid (or empty vector to maintain a constant amount of transfected DNA), 
and luciferase activity determined as described in the Materials and Methods.  Results are 
expressed as means ± SE for three replicate determinations for each group, and significant (p < 
0.05) induction compared to empty vector is indicated by an asterisk.  [B]  ChIP assay.  HCT-116 
cells were treated with DMSO or 20 μM DIM-C-pPhC6H5, and interactions of various proteins 
with the NAG-1 promoter were determined in a ChIP assay as described in the Materials and 
Methods.  [C]  Control binding of TFIIB.  The control ChIP assay illustrates binding of TFIIB to 
the GAPDH promoter but not to exon 1 of the CNAP1 gene (negative control). 
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Fig. 4.8.  C-DIM compounds activate PI3-K in HCT-116 cells.  Effects of kinase inhibitors on 
induction of NAG-1 [A] or Egr-1 [B] by C-DIMs.  HCT-116 cells were treated with DMSO, C-
DIMs alone or in combination with 20 μM PD98059 or 20 μM LY294002 for 24 [A] or 2 [B] hr, 
and whole cell lysates were analyzed by Western immunoblot analysis as described in the 
Materials and Methods.  Similar results were observed using DIM-C-pPhCF3 or DIM-C-pPhtBu. 
[C]  Inhibition of pEGR-1D activation by LY294002.  HCT-116 cells were transfected with 
pEGR-1D, treated with 10 or 15 μM C-DIM compounds alone or in combination with 20 μM 
LY294002 and luciferase activity determined as described in the Materials and Methods.  Results 
are expressed as means ± SE (triplicate).  Significant (p < 0.05) induction by C-DIMs and 
inhibition by LY294002 are indicated by (*) and (**), respectively.  [D]  Activation of Akt 
phosphorylation by C-DIMs.  HCT-116 cells were treated with the C-DIM compounds for 
different periods of time, and whole cell lysates were analyzed by Western blot analysis for 
phospho-Akt and Akt as described in the Materials and Methods.  Results shown in the bar graph 
are means of two duplicate determinations. 
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kinases in activation of NAG-1 by C-DIM compounds was therefore investigated in 
HCT-116 cells treated with 15 μM DIM-C-pPhC6H5 for 24 hr in the presence or absence 
of PD98059 or LY294002 which inhibit MAPK and PI3-K-dependent phosphorylation, 
respectively.  The results showed that induction of NAG-1 protein by DIM-C-pPhC6H5 
was inhibited by LY294002 but not PD98059 (Fig. 4.8A); similar inhibitory responses 
were also observed for induction of Egr-1 (Fig. 4.8B).  Interestingly, PD98059 alone 
also induced Egr-1 (Fig. 4.8B) but not NAG-1 (Fig 4.8A), suggesting that Egr-1 alone is 
not sufficient for activation of NAG-1.  The inhibitory effects of LY294002 suggest that 
the C-DIM compounds induce PI3-K.  Moreover, in cells transfected with pEGR-1D, 
induction of luciferase activity by the C-DIM compounds was inhibited by cotreatment 
with LY294002 (Fig. 4.8C).  The results in Figure 4.8D show the time-dependent 
induction of Akt phosphorylation by DIM-C-pPhC6H5 and a similar induction response 
was observed for DIM-C-pPhCF3 and DIM-C-pPhtBu.  Activation of PI3-K was time-
dependent since induction of Akt phosphorylation was not observed after treatment for 2 
hr.  These results demonstrate that PPARγ-active C-DIMs coordinately induce Egr-1 and 
NAG-1 through a novel pathway which involves initial PI3-K-dependent activation of 
Egr-1 through SRE3 and SRE2 motifs on the Egr-1 promoter. 
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Discussion 
 PPARγ-active C-DIMs and other PPARγ agonists inhibit growth and induce 
apoptosis in several different cell lines, and these responses are both receptor-dependent 
and -independent (254, 359, 361, 390, 391, 393-395, 416-418).  For example, studies in 
this laboratory have demonstrated that induction of p21 in Panc-28 cells and 
upregulation of caveolin-1 in HT-29 and HCT-15 cells is PPARγ-dependent and 
inhibited by PPARγ antagonists or by PPARγ knockdown with small inhibitory RNAs 
(393, 394).  In contrast, induction of apoptosis and downregulation of cyclin D1 in breast 
cancer cells was PPARγ-independent (359).  The interplay between receptor-dependent 
and -independent pathways has also been reported for the potent triterpenoid-derived 
PPARγ agonist 2-cyano-3,12-dioxooleana-1,9-dien-28-oic acid and related compounds 
in HCT-15, HT-29 and SW-480 colon cancer cells (396).  At lower growth-inhibitory 
concentrations, CDDO induced caveolin-1, and this response was inhibited in cells 
cotreated with the PPARγ antagonist T007.  In contrast, at higher concentrations, 
caveolin-1 expression was decreased and apoptosis was induced and this latter response 
was receptor-independent and not inhibited by T007.  The type of differential 
concentration-dependent induction of PPARγ-dependent and -independent responses has 
also been observed for PPARγ-active C-DIM compounds in SW-480 cells. 
 In this study, we have investigated the effects of PPARγ-active C-DIMs in HCT-
116 cells and, as previously reported in HCT-15 and HT-29 cells (393), these 
compounds decrease HCT-116 cell survival (Fig. 4.1), activate PPARγ-dependent 
transactivation (Fig. 4.2), and p21, p27 and cyclin D1 levels were unchanged except for 
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downregulation of cyclin D1 at high concentrations (Fig. 4.3).  In contrast to 
observations in HT-29 and HCT-15 cells (393), the PPARγ-active compounds did not 
induce caveolin-1 in HCT-116 cells (Fig. 4.3), and this may be due, in part, to the 
relatively high constitutive expression of caveolin-1 in this cell line.  Thus, the growth 
inhibitory responses of C-DIMs in HCT-116 cells must be related to activation of other 
pathways.  Previous studies in HCT-116 cells have reported that several different 
structural classes of growth inhibitory/antitumorigenic compounds, including the PPARγ 
agonists PGJ2 and troglitazone, and DIM induced NAG-1 expression and this protein 
exhibits both growth inhibitory and pro-apoptotic activity (303, 397, 402-414).  Our 
results show that PPARγ-active C-DIMs also induce NAG-1 protein expression in HCT-
116 cells (Figs. 4.3 and 4.4), and this is consistent with their growth inhibitory (Fig. 4.1) 
and apoptotic (Figs. 4.3 and 4.4) effects in HCT-116 cells.  It was also shown that 
induction of NAG-1 and apoptosis in HCT-116 cells by DIM-C-pPhCF3 and DIM-C-
pPhC6H5 was not inhibited by the PPARγ antagonists GW9662 or T007 and the PPARγ 
antagonists also did not affect C-DIM-induced growth inhibition (Fig. 4.4).  Thus, 
induction of NAG-1 by PPARγ-active C-DIMs and troglitazone was receptor-
independent, and this was in contrast to induction of NAG-1 by PGJ2 since this response 
was inhibited by a PPARγ antagonist (303). 
 Induction of NAG-1 by troglitazone was linked to activation of the tumor 
suppressor gene Egr-1 which in turn directly activates NAG-1 promoter constructs.  The 
C-DIM compounds also rapidly activate Egr-1 protein expression in HCT-116 cells and 
maximal induction was observed within 2 hr after treatment, whereas NAG-1 protein 
 149
expression is increased with time over 24 hr (Fig. 4.5A).  In contrast, DIM induced 
NAG-1 but did not affect Egr-1 expression in HCT-116 cells (414), and this clearly 
differentiated between diarylmethane (DIM) from the triarylmethane (C-DIM) 
compounds.  Constructs containing Egr-1 promoter inserts (Figs. 4.5B – 4.5E) are also 
activated by the C-DIM compounds, and the minimal promoter region required for 
transactivation contains SRE3 and SRE2 which have previously been identified as 
critical cis-elements required for activation of Egr-1 (415).  Moreover, these compounds 
also activate NAG-1 promoter constructs (Fig. 4.6) and deletion/mutation analysis of the 
NAG-1 promoter indicates that mutation of the proximal Egr-1 sites resulted in loss of 
C-DIM-induced transactivation (Fig. 4.6E).  These results, coupled with the observed 
interactions of Egr-1 with the NAG-1 promoter in a ChIP assay (Fig. 4.7), clearly link 
the induction of NAG-1 by C-DIMs to the rapid induction of Egr-1 which subsequently 
activates NAG-1 expression in HCT-116 cells. 
 Thus, the induction of NAG-1 by PPARγ-active C-DIMs and troglitazone in 
HCT-116 cells is receptor-independent and also involves Egr-1 induction.  However, 
induction of NAG-1 protein and reporter gene activity by troglitazone was inhibited by 
the MAPK inhibitor PD98059 suggesting that this response may be due, in part, to 
induction of Egr-1 through activation of kinases by troglitazone (303).  Kinase-
dependent activation of NAG-1 by C-DIMs was further investigated by determining the 
effects of PI3-K and MAPK inhibitors on induction of NAG-1 and Egr-1 proteins and 
reporter gene activity (pEGR-1D) in HCT-116 cells (Figs. 4.8A – 4.8C).  The results 
show that PI3-K, and not MAPK inhibitors, block induction of NAG-1 and Egr-1 
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proteins and induction of transactivation in cells transfected with pEGR-1D, and this was 
consistent with the identification of kinase-responsive SRE3 and SRE2 as critical cis-
elements in the Egr-1 promoter that are required for C-DIM-dependent activation of the 
Egr-1 constructs (Fig. 4.5).  Kinase-mediated activation of Egr-1 is highly variable and 
dependent on cell context (415, 418-424); however, it is apparent from this study that 
activation of Egr-1 by C-DIMs is PI3-K-dependent, whereas troglitazone activation of 
Egr-1/NAG-1 was linked to a MAPK pathway (303).  In this study, 20 μM LY294002 
alone did not affect NAG-1 or Egr-1 protein expression, but inhibited induction of these 
proteins by PPARγ-active C-DIMs (Fig. 4.8), and induction of Egr-1-derived promoter 
constructs by DIM-C-pPhtBu was also inhibited by LY294002.  In contrast, a recent 
study reported that higher concentrations of LY294002 (50 μM) induced NAG-1 protein 
expression and this was linked to activation of GSK-3β through dephosphorylation of 
this protein (412).  Thus, PI3-K plays a pivotal role in activation of Egr-1 (and NAG-1) 
by the C-DIM compounds, whereas inactivation of PI3-K after treatment with high 
concentrations of LY294002 results in GSK-3β-dependent activation of NAG-1 (412). 
 In summary, our results show that PPARγ-active C-DIMs induce both NAG-1 
and Egr-1 in HCT-116 cells through receptor-independent pathways.  NAG-1 
upregulation is linked to prior PI3-K-dependent induction of Egr-1 which directly 
activates NAG-1 through interaction with Egr-1 cis-elements in the NAG-1 promoter.  It 
is also possible that the decreased HCT-116 cell survival and apoptosis observed after 
treatment with the C-DIM compounds is due, in part, to activation of other Egr-1-
dependent genes which mediate the apoptotic and growth inhibitory effects (425).  The 
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induction of PI3-K by the C-DIM compounds (Fig. 4.8D) is somewhat paradoxical since 
this kinase is linked to cell survival pathways.  However, recent studies have 
demonstrated that activation of PI3-K can sensitize caveolin-1-expressing HeLa and 293 
cells to the cytotoxicity of arsenite and hydrogen peroxide (398).  Moreover, caveolin-1 
and PI3-K also sensitize L929 cells to tumor necrosis factor-α-induced cell death, and it 
was postulated that this may be due to Akt-dependent inactivation of forkhead 
transcription factors (399).  Although the C-DIM compounds do not induce caveolin-1 in 
HCT-116 cells, the high endogenous expression of caveolin-1 in these cells (Fig. 4.3B) 
coupled with the induction of PI3-K may also contribute to the decreased HCT-116 cell 
survival and apoptosis after treatment with the C-DIMs.  Thus, like other PPARγ 
agonists, the C-DIM compounds activate receptor-independent responses that contribute 
to their effectiveness as a new class of drugs with potential clinical applications for 
cancer chemotherapy. 
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CHAPTER V 
1,1-BIS(3'-INDOLYL)-1-(p-SUBSTITUTEDPHENYL)METHANES INHIBIT 
COLON CANCER CELL AND TUMOR GROWTH THROUGH PEROXISOME 
PROLIFERATOR-ACTIVATED RECEPTOR γ-DEPENDENT AND -
INDEPENDENT PATHWAYS  
Introduction 
Peroxisome proliferator-activated receptor γ (PPARγ) is a member of the nuclear 
receptor superfamily of ligand-activated transcription factors (354-356, 383-385).  
Although the endogenous ligand for PPARγ has not been determined, several 
endogenous molecules such as 15-deoxy-Δ12,14-prostaglandin J2 (PGJ2), other 
prostaglandin-derived compounds, fatty acids, and flavonoids activate PPARγ.  It has 
recently been reported that nitrolinoleic acid, a stress-induced fatty acid oxidation 
product may be an endogenous PPARγ agonist (426).  Several different structural classes 
of PPARγ agonists have been synthesized and these include thiazolidinediones (TZDs), 
2-cyano-3,12-dioxoolean-1,9-dien-28-oic acid (CDDO) and related triterpenoids, 3-
benzyl and acyl-substituted indoles, substituted chromane carboxylic acids and 
phosphonophosphates (427-432).  Among the synthetic PPARγ agonists, the TZDs are 
now being extensively used as insulin-sensitizing agents for treatment of type II diabetes 
(354, 356).  PPARγ is highly expressed in many tumor samples and cancer cells lines 
derived from hematopoietic and non-hematopoietic tumors (257), and several studies 
show that PPARγ agonists inhibit growth and/or induce apoptosis in multiple cancer cell 
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lines and in in vivo tumor models (254, 255, 303, 359-362, 365-367, 370, 372-374, 391, 
393, 397, 416, 433-435).   
 Research in this laboratory has identified a new structural class of 3,3'-
diindolylmethane  (DIM) analogs.  Several methylene-substituted DIMs (C-DIMs) 
including 1,1-bis(3'-indolyl)-1-(p-substitutedphenyl)-methanes containing 
trifluoromethyl (DIM-C-pPhCF3), t-butyl (DIM-C-pPhtBu), and phenyl (DIM-C-
pPhC6H5) substituents activate PPARγ in several cancer cell lines including colon cancer 
cells (359, 393-395).  The effects of these compounds depend on cell context and this is 
commonly observed for other PPARγ agonists.  The PPARγ-active C-DIMs inhibit 
growth and/or induce apoptosis in cancer cells; in HT-29 and HCT-15 colon cancer 
cells, these compounds induce caveolin-1, whereas p21 is induced in Panc28 pancreatic 
cancer cells and both responses are inhibited by PPARγ antagonists (393, 394).  In 
contrast, induction of cyclin D1 downregulation and apoptosis in breast cancer cells 
(359) and induction of nonsteroidal anti-inflammatory drug (NSAID) activated gene-1 
(NAG-1) are PPARγ-independent (436, 437). 
 In this study, we show that PPARγ-active C-DIMs inhibit growth of SW480 
colon cancer cells and this is associated with PPARγ-dependent induction of caveolin-1 
and receptor-independent activation of both NAG-1 and PARP cleavage.  Moreover, in 
athymic nude mice bearing SW480 cell xenografts, DIM-C-pPhC6H5 (20 and 40 
mg/kg/d) inhibits tumor growth and immunostaining of tumors shows both 
overexpression of caspase-3 and NAG-1 in the treated groups.  These data demonstrate 
that PPARγ-active C-DIMs inhibit colon cancer cell/tumor growth and confirm that 
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PPARγ agonists are an important class of compounds for potential applications in the 
treatment of colon cancer. 
Materials and Methods 
Cell lines, plasmids, chemicals and reagents 
The SW480 human colon cancer cell line was provided by Dr. S. Hamilton (M.D 
Anderson Cancer Center, Houston, TX).  SW480 cells were maintained in Dulbecco’s 
Modified Eagle’s Medium nutrient mixture F-12 Ham (DMEM:Ham’s F-12; Sigma, St. 
Louis, MO) with phenol red supplemented with 0.22% sodium bicarbonate, 0.011% 
sodium pyruvate and 5% fetal bovine serum (FBS) and 10 ml/L of 100X antibiotic 
antimycotic solution (Sigma).  The Gal4 reporter containing 5X Gal4 DBD (Gal4Luc) 
was kindly provided by Dr. Marty Mayo (University of North Carolina, Chapel Hill, 
NC).  Gal4DBD-PPARγ construct (GAL4-PPARγ) was a gift of Dr. Jennifer L. 
Oberfield (Glaxo Wellcome Research and Development, Research Triangle Park, NC) 
and chimeric pM-PPARγ coactivator-1 (PGC1) was a gift of Dr. Bruce M. Spiegelman 
(Harvard University, Boston, MA).  The PPARγ2-VP16 fusion plasmid (VP-PPARγ) 
contained the DEF region of PPARγ (amino acids 183–505) fused to the pVP16 
expression vector and the GAL4-coactivator fusion plasmids pM-SRC1, pMAIBI, 
pMTIFII, pM-DRIP205, pMTRAP220 and pM-CARM-1 were kindly provided by Dr. 
Shigeaki Kato (University of Tokyo, Tokyo, Japan).  Rosiglitazone was purchased from 
LKT Laboratories, Inc. (St. Paul, MN).  Horseradish peroxidase substrate for Western 
blot analysis was purchased from NEN Life Science Products (Boston, MA).  Cell lysis 
buffer and luciferase reagent were purchased from Promega (Madison, WI), and β-
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galactosidase (β-gal) reagent was from Tropix (Bedford, MA).  Antibodies for cyclin D1 
(sc-718), p27 (sc-528), phospho-Akt (sc-7985R), Akt (sc-8312), Bcl2 (sc-7382), Bax 
(sc20067), caveolin 1 (sc-894), and PARP (sc-8007) were purchased from Santa Cruz 
Biotechnology (Santa Cruz, CA).  NAG-1 antibodies were obtained from Upstate 
Biotechnology (Lake Placid, NY); monoclonal anti-β-actin was purchased from Sigma 
(St. Louis, MO).  
Cell proliferation assay 
Cells were plated at a density of 2 x 104/well in 12-well plates and replaced the 
next day with DMEM:Ham’s F-12 media containing 2.5% charcoal-stripped FBS and 
either vehicle (DMSO) or the indicated ligand and concentration.  Fresh media and 
compounds were added every 48 hr.  Cells were counted at the indicated times using a 
Coulter Z1 cell counter.  Each experiment was carried out in triplicate and results are 
expressed as means ± SE for each determination. 
Transfection and luciferase assay 
SW480 cells were plated in 12-well plates at 1 x 105 cells/well in DME-F12 
media supplemented with 2.5% charcoal-stripped FBS.  After growth for 16 hr, various 
amounts of DNA, i.e. Gal4Luc (0.4 μg), b-gal 0.04 μg), VP-PPARγ (0.04 μg), pM SRC1 
(0.04 μg), pMTIFII (0.04 μg), pMAIBI (0.04 μg), pMDRIP205 (0.04 μg), and 
pMCARM-1 (0.04 μg) were transfected by lipofectamine (Invitrogen) according to the 
manufacturer’s protocol.  Briefly, 2 μL of lipofectamine was mixed with 50 μL of 
serum-free medium.  Appropriate concentrations of plasmid DNA were mixed with 50 
μL of serum-free medium.  The lipofectamine solution was then mixed with the DNA 
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solution and the mixture was allowed to incubate at room temperature for 45 min to form 
the DNA/lipofectamine complex.  In the mean time, cells grown in the presence DME-
F12 media supplemented with 2.5% charcoal-stripped FBS were washed with serum free 
DME-F12 media and then 400 μL of serum free media was added.  Following 45 min 
incubation, the lipofectamine/DNA complex was carefully dropped over the cells and 
incubated for 5 - 6 hr at 37°C.  Five hr after transfection, the transfection mix was 
replaced with complete media containing either vehicle (DMSO) or the indicated ligand 
for 20 to 22 hr.  Cells were then lysed with 100 μL of 1X reporter lysis buffer, and 30 
μL of cell extract were used for luciferase and β-gal assays.  A Lumicount luminometer 
(PerkinElmer Life and Analytical Sciences) was used to quantitate luciferase and β-gal 
activities, and the luciferase activities were normalized to β-gal activity.  
Western blot analysis 
SW480 cells were seeded in DMEM:Ham’s F-12 media containing 2.5% 
charcoal-stripped FBS for 24 hr and then treated with either the vehicle (DMSO) or the 
indicated compounds.  Whole cell lysates were obtained using high salt buffer [50 mM 
HEPES, 500 mM NaCl, 1.5 mM MgCl2, 1 mM EGTA, 10% glycerol, 1% Triton X-100 
(pH 7.5), and 5 μL/ml of Protease Inhibitor Cocktail (Sigma-Aldrich)].  Protein samples 
were incubated at 100°C for 2 - 3 min, separated on 10% SDS-PAGE at 120 V for 3 - 4 
hr in 1X running buffer [25 mM Tris-base, 192 mM glycine, and 0.1% SDS (pH 8.3)], 
and transferred to polyvinylidene difluoride membrane (PVDF, Bio-Rad, Hercules, CA) 
at 0.1 V for 16 hr at 4°C in 1X transfer buffer (48 mM Tris-HCl, 39 mM glycine, and 
0.025% SDS).  The PVDF membrane was blocked in 5% TBST-Blotto [10 mM Tris-
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HCl, 150 mM NaCl (pH 8.0), 0.05% Triton X-100, and 5% non-fat dry milk] with gentle 
shaking for 30 min and incubated in fresh 5% TBST-Blotto with 1:1000 (for CD1, p27, 
Bcl2, Bax and caveolin 1), 1:500 (for PARP and NAG-1) and 1: 5000 (for β-actin) 
primary antibody overnight with gentle shaking at 4°C.  After washing with TBST for 10 
min, the PVDF membrane was incubated with secondary antibody (1:5000) in 5% 
TBST-Blotto for 90 min.  The membrane was washed with TBST for 10 min and 
incubated with 10 ml of chemiluminiscence substrate (PerkinElmer Life Sciences) for 
1.0 min and exposed to Kodak X-OMAT AR autoradiography film (Eastman Kodak, 
Rochester, NY).  
Xenograft experiment 
Male athymic BALB/c nude mice (aged 4 - 6 weeks) were purchased from 
Harlan (Indianapolis, IN).  Mice were housed and maintained in laminar flow cabinets 
under specific pathogen-free conditions.  SW480 cells were concentrated to 2 x 106 per 
200 μL and injected s.c. into the left flank of each mouse using a 30-gauge needle.  Six 
days after cell inoculation, animals were divided into three equal groups of 10 mice 
each.  The first group received 70 μL of vehicle (corn oil) by oral gavage and the second 
and third groups of animals received 20 and 40 mg/kg/day doses of DIM-C-pPhC6H5 in 
vehicle, every second day. The mice were weighed, and tumor areas were also measured 
every other day.  Final body and tumor weights were determined at the end of the dosing 
regimen, and selected tissues were further examined by routine H & E staining and 
immunohistochemical analysis.  
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Immunohistochemistry 
Tissue sections (4-5 μm thick) mounted on poly-L-lysine-coated slide were 
deparaffinized by standard methods.  Endogenous peroxidase was blocked by the use of 
3% hydrogen peroxide in PBS for 10 min.  Antigen retrieval for NAG-1 staining was 
performed for 7.5 min in 10 mm sodium citrate buffer (pH 6) heated at 95°C in a 
steamer, followed by cooling for 15 min.  The slides were washed with PBS and 
incubated for 30 min at room temperature with a protein blocking solution (Biostain 
Rabbit IgG system, Biomeda, Foster City, CA).  Excess blocking solution was drained, 
and the samples were incubated overnight at 4°C with one of the following:  a 1:100 
dilution of activated caspase-3 antibody; or 1:100 dilution of NAG-1 antibody.  Sections 
were then incubated with biotinylated secondary antibody followed by steptavidin 
(Biostain Rabbit IgG system, Biomeda, Foster City, CA).  The color was developed by 
exposing the peroxidase to diaminobenzidine reagent (Vector Laboratories, Burlingame, 
CA), which forms a brown reaction product.  The sections were then counterstained with 
Gill’s hematoxylin.  Activated caspase-3 and NAG-1 expression were identified by the 
brown colored cytoplasmic staining.  
Assesment of apoptotic cells 
Four slides per group were stained and apoptotic cells were identified by the dark brown 
cytoplasmic staining.  Ten microscopic fields in each slide were counted for cytoplasmic 
staining and averaged.  
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Results 
Inhibition of cell proliferation and activation of PPARγ 
 Previous studies in colon and pancreatic cancer cells showed that PPARγ-active 
C-DIMs inhibit cell growth (394, 395) and results in Figure 5.1 also show the DIM-C-
pPhCF3, DIM-C-pPhtBu and DIM-C-pPhC6H5 inhibit SW480 cancer cell proliferation.   
IC50 values varied between 1 - 10 μM and the relative order of potency was DIM-C-
pPhCF3 > DIM-C-pPhtBu > DIM-C-pPhC6H5.  In contrast, 1 - 10 μM rosiglitazone did 
not significantly affect growth of SW480 cells.  Activation of PPARγ was also 
investigated in SW480 cells transfected with chimeric PPARγ-Gal4 and a Gal4 response 
element reporter plasmid containing five tandem Gal4 response elements linked to a 
luciferase reporter gene. 
 The results showed that DIM-C-pPhCF3, DIM-C-pPhtBu and DIM-C-pPhC6H5 
significantly induced transactivation with a maximal 17-fold increase observed for 10 
μM DIM-C-pPhCF3, whereas a < 4-fold induction of luciferase activity was observed for 
rosiglitazone (Fig. 5.2A).  We also investigated ligand-induced interactions of PPARγ 
with a panel of coactivators in a mammalian two-hybrid assay in SW480 cells (Fig. 
5.2B).  The results show that the PPARγ-active C-DIMs induce interactions between 
PPARγ and PGC-1 and similar results were obtained for the compounds in previous 
studies in HCT-15 cells, whereas in HT-29 cells, PGC-1 - PPARγ interactions were 
induced by DIM-C-pPhCF3 and DIM-C-pPhtBu, but not DIM-C-pPhC6H5 (393).  In 
contrast to results obtained in HT-29/HCT-15 cells, the PPARγ-active C-DIMs also 
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Fig. 5.1.  Cell proliferation assays.  SW480 cells were treated with DIM-C-pPhCF3 [A], DIM-C-
pPhtBu [B], DIM-C-pPhC6H5 [C] or rosiglitazone [D], and cell numbers were determined after 2, 
4 and 6 days as described in the Materials and Methods.  Significant (p < 0.05) inhibition of cell 
proliferation was observed for the C-DIMs (≥ 5 μM) and results are expressed as means ± SE for 
three replicate determinations for each treatment group. 
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Fig. 5.1 Continued 
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Fig. 5.2.  C-DIMs activate PPARγ.  [A]  Transactivation.  SW480 cells were transfected with 
PPARγ/Gal4/pGal4, treated with DMSO or different concentrations of compounds, and luciferase 
activity determined as described in the Materials and Methods.  [B]  Mammalian two-hybrid 
assay.  SW480 cells were transfected with GAL4 chimeras, VP-PPARγ (LBD) and pGAL4-luc, 
treated with various compounds, and luciferase activity determined as described in the Materials 
and Methods.  Results [A / B] are expressed as means ± SE for three replicate determinations for 
each treatment group and significant (p < 0.05) induction is indicated by asterisks. 
 
 163
SW480
0
1
2
3
4
5
D R 1 4 9 D R 1 4 9 D R 1 4 9 D R 1 4 9 D R 1 4 9 D R 1 4 9 D R 1 4 9
SRC-1 PGC-1 TRAP220 SMRT CARML TIFII AIBI
Fo
ld
 In
du
ct
io
n
*
*
*
*
*
*
*
**
* *
* * * *
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significantly induced interactions of PPARγ with SRC-1, SRC-2 and the corepressor 
SMRT and this pattern of ligand-induced PPARγ-coactivator/corepressor interactions 
clearly differentiated between the effects of these compounds in SW480 and other colon 
cancer cells.  In addition, rosiglitazone was inactive in the mammalian two hybrid assay 
in SW480 cells and this assay distinguished between the activities of this compound and 
the PPARγ-active C-DIMs. 
Effects of PPARγ-active C-DIMs on expression of proteins associated with cell 
proliferation and cell death 
 The effects of two prototypical PPARγ-active C-DIMs on expression of various 
cell cycle proteins and apoptosis (PARP cleavage) was investigated in SW480 cells 
treated with 5 - 10 μM Dim-C-pPhCF3, DIM-C-pPhC6H5 or rosiglitazone for 24 hr (Fig. 
5.3A).  The PPARγ-active C-DIMs enhanced p27 expression and downregulated cyclin 
D1 protein only at the highest concentration and this was also accompanied by PARP 
cleavage.  Previous studies with different structural classes of PPARγ agonists have 
reported induction of p27 in colon and other cancer cell lines, and we have also observed 
cyclin D1 downregulation and PARP cleavage in other cancer cell lines treated with C-
DIM compounds (359, 393-395, 436, 437).  There were minimal compound-induced 
changes in bax levels and decreased expression of bcl-2 at the 10 μM concentrations of 
DIM-C-pPhCF3 and DIM-C-pPhC6H5, whereas up to 10 μM rosiglitazone did not affect 
expression of apoptotic or cell cycle proteins.  The growth inhibitory effects of 
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Fig. 5.3.  Cell cycle proteins, caveolin-1 expression and Akt phosphorylation.  [A]  Cell cycle 
proteins.  SW480 cells were treated with different concentrations of compounds for 24 hr, and 
whole cell lysates were analyzed by Western blot analysis as described in the Materials and 
Methods.  Induction of caveolin-1 [B / C], Akt phosphorylation [D], and inhibition by GW9662 [C 
/ D].  SW480 cells were treated with different concentrations of compounds alone or in 
combination, and whole cell lysates were analyzed by Western blot analysis as indicated in the 
Materials and Methods.  β-Actin was used as a loading control for these experiments and levels of 
bax and p21 proteins [A] were unchanged in all treatment groups. 
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PPARγ-active C-DIMs in HT-29 and HCT-15 cells have been linked, in part, to 
induction of caveolin-1  (393) and the results in Figure 5.3B show that at doses as low as 
2.5 μM, there was induction of caveolin-1 in SW480 cells.  This is a response that was 
not observed until 48 hr after treatment and only minimal apoptosis was induced in the 
7.5 μM DIM-C-pPhCF3 treatment group, suggesting that caveolin-1 was primarily 
associated with growth inhibitory responses observed at lower concentrations (≤ 7.5 
μM).  Induction of caveolin-1 by 5 μM DIM-C-pPhCF3 and DIM-C-pPhC6H5 was 
inhibited after cotreatment with the PPARγ antagonist GW9662 (Fig. 5.3C), 
demonstrating that this response was PPARγ-dependent, and this was previously 
observed in HT-29 and HCT-15 cells (393).  We also recently reported that PPARγ-
dependent induction of caveolin-1 was observed in SW480 cells treated with CDDO and 
related compounds (396) and this was accompanied by induction of PI3-K-dependent 
phosphorylation of Akt.  The results in Figure 5.3D also show that 5 μM DIM-C-pPhCF3 
and DIM-C-pPhC6H5 also induce Akt phosphorylation and in SW480 cells cotreated 
with GW9662, there was a dose-dependent decrease in Akt phosphorylation.  Thus, the 
PPARγ-active C-DIMs coordinately induced caveolin-1 and phospho-Akt in SW480 
cells and it has been reported that combined activation of caveolin-1 and PI3-K enhances 
the effects of agents that decrease cancer cell survival (364, 438). 
 The role of PPARγ in mediating DIM-C-pPhCF3- and DIM-C-pPhC6H5-induced 
apoptosis was investigated in SW480 cells cotreated with C-DIMs and the PPARγ 
antagonist GW9662 (Fig. 5.4A).  The results show that GW9662 did not affect induced 
 168
PARP cleavage, suggesting that this response was PPARγ-independent and similar 
results were observed for cyclin D1 downregulation.  Interestingly, we also observed 
that at higher concentrations (> 7.5 μM) of C-DIMs that induce apoptosis in SW480 
cells (Fig. 5.4A), there is a loss of caveolin-1 induction by these same compounds (Fig. 
5.4B).  The reason for this concentration-dependent switch between PPARγ-dependent 
and -independent responses is unknown; however, we have also observed similar 
responses for CDDO and related compounds.  Recent studies in this laboratory show that 
PPARγ-active C-DIMs induced cell death through activation of endoplasmic reticulum 
(ER) stress in pancreatic cancer cells (437) or through induction of NAG-1 in HCT116 
colon cancer cells (436).  Results in Figure 5.4C show that induction of apoptosis in 
SW480 cells treated with DIM-C-pPhCF3 or DIM-C-pPhC6H5 for 24 hr is not 
accompanied by induction of the stress protein GRP78.   
 NAG-1 is a transforming growth factor β (TGFβ)-like peptide which is induced 
by C-DIMs and many other growth inhibitory agents including rosiglitazone in selected 
cell lines including HCT-116 colon cancer cells.  Preliminary studies did not detect 
induction of NAG-1 by C-DIMs in SW480 cells (437); however, repetition of this 
experiment with a different antibody showed that within 24 hr after treatment with DIM-
C-pPhCF3 or DIM-C-pPhC6H5, there was induction of NAG-1 protein (Fig. 5.5A).  
Moreover, in SW480 cells cotreated with PPARγ-active C-DIMs (5 - 10 μM) plus the 
PPARγ agonist GW9662 (10 μM), the antagonist did not block induction of NAG-1 
(Fig. 5.5B), suggesting that this response was PPARγ-independent as previously 
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A
Fig. 5.4.  Effects of higher concentrations of C-DIMs on PARP cleavage [A], caveolin-1 [B], 
GRP78 [C] expression.  SW480 cells were treated with different compounds (alone or combined) 
for 24 [A and C] or 72 [B] hr, and whole cell lysates were assayed by Western blot analysis as 
described in the Materials and Methods.  β-Actin served as a loading control for all experiments. 
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β-actin
SW 480A
Fig. 5.5.  Induction of NAG-1 by C-DIM compounds.  SW480 cells were treated for 24 hr with 
DIM-C-pPhCF3 or DIM-C-pPhC6H5 alone [A] or in combination with GW9662 [B] or for 96 hr 
[C].  Whole cell lysates were analyzed for NAG-1 expression by Western blot analysis as 
described in the Materials and Methods.  β-Actin was used as a loading control for these 
experiments. 
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reported in HCT-116 cells (437). We also observed induction of NAG-1 after treatment 
with C-DIMs for 96 hr (Fig. 5.5C) and at both the 24 and 96 hr time points, effective 
doses were in the 7.5 - 10 μM range. 
 The in vivo antitumorigenic activity of PPARγ-active C-DIMs was further 
investigated in male athymic nude mice bearing SW480 cell xenografts.  After palpable 
tumors were first observed (< 15 mm2), animals were treated with corn oil (70 
μL/mouse) or DIM-C-pPhC6H5 (20 or 40 mg/kg) in corn oil by oral gavage every second 
day for 21 days and tumor areas were determined.  The results (Fig. 5.6A) show that 
tumor areas were significantly decreased after treatment with DIM-C-pPhC6H5 
compared to the corn oil (control) group and after sacrifice, tumor weights were also 
decreased in both treatment groups (Fig. 5.6B).  We also investigated the effects of 
DIM-C-pPhC6H5 (40 mg/kg/d) on expression of the apoptotic gene caspase 3 (Figs. 5.6C 
and 5.6D) and NAG-1 in tumors by immunohistochemical analysis.  DIM-C-pPhC6H5 
significantly induced active caspase 3 expression compared to control (corn oil) tumors 
(Fig. 5.6C).  NAG-1 was not detected in tumors from control animals, whereas massive 
expression (brown staining) of NAG-1 was detected in tumors from DIM-C-pPhC6H5-
treated mice (Fig. 5.6D), suggesting an important role for this protein in the 
antitumorigenic activity of this C-DIM compound.  These data complement the in vitro 
studies and demonstrate that PPARγ-active C-DIMs inhibit colon cancer cell/tumor 
growth and these compounds are being developed for future clinical applications. 
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Fig. 5.6.  In vivo antitumorigenic activity of DIM-C-pPhC6H5.  Tumor areas [A] and weights [B]. 
When palpable tumors were first observed (15 mm2), athymic nude mice bearing SW480 colon 
cancer cell xenografts were administered corn oil (control) or DIM-C-pPhC6H5 (20 or 40 mg/kg/d) 
in corn oil by oral gavage, and tumor areas and weights were determined as described in the 
Materials and Methods.  Results are expressed as means ± SE for 10 animals for each treatment 
group, and a significant (p < 0.05) decrease in tumor areas and weights in the treatment groups 
compared to the corn oil (control) group is indicated by an asterisk.  [C]  Active caspase 3 
expression.  Active caspase 3 expression was quantitated by immunohistochemical analysis of 
caspase 3 in tumor sections from control and treated (DIM-C-pPhC6H5, 40 mg/kg/d) mice as 
described in the Materials and Methods.  Arrows indicate positive caspase 3 staining.  [D] 
Immunohistochemical analysis of NAG-1.  Tumors from control or DIM-C-pPhC6H5-treated mice 
were analyzed for NAG-1 expression by immunohistochemistry as described in the Materials and 
Methods.  There were no significant differences in animal weight gain, organ weights or 
histopathology in any of the treatment groups. 
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Discussion 
 Several studies report that PPARγ agonists inhibit growth of colon cancer cells; 
however, their induced responses and mechanisms of action are dependent on multiple 
factors including ligand structure, cell context and wild-type or variant PPARγ  
expression.  For example, troglitazone (a TZD), PGJ2 and PPARγ-active C-DIMs induce 
the TGFβ-like peptide NAG-1 in HCT-116 cells and GW9662 inhibits the effects of 
PGJ2 but had no effect on troglitazone or the PPARγ-active C-DIMs (303, 436).  
Although troglitazone, DIM-C-pPhCF3, DIM-C-pPhtBu and DIM-C-pPhC6H5 induce 
NAG-1 through prior activation of early growth response gene (303, 436), the former 
response is dependent on activation of mitogen-activated protein kinase, whereas the C-
DIMs activate Egr-1 and NAG-1 through induction of PI3-K.  Dubois and coworkers 
(360, 362, 373) have reported that the effects of rosiglitazone on cell proliferation and 
differentiation in several colon cancer cell lines were dependent on their expression of 
wild-type or mutant K422Q PPARγ where rosiglitazone responsiveness was observed 
only in cells (e.g. HT-29) expressing wild-type receptor (362). 
 PPARγ-active C-DIMs inhibit growth of HT-29 and HCT-15 colon cancer cell 
lines expressing wild-type and mutant PPARγ, respectively, and these compounds also 
induce caveolin-1 in both cell lines (393).  The results in Figures 5.1 and 5.2 
demonstrate that the C-DIM compounds but not rosiglitazone inhibit SW480 cancer cell 
growth and induced PPARγ-dependent transactivation.  These data are similar to those 
previously reported in rosiglitazone-nonresponsive HCT-15 cells, suggesting that 
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SW480 cells may also express mutant PPARγ which is not responsive to the growth 
inhibitory effects of rosiglitazone. 
 The short-term effects of DIM-C-pPhCF3 and DIM-C-pPhC6H5 on cell cycle 
protein expression and apoptosis in SW480 (Fig. 5.4) vs. HT-29/HCT-15 cells (393) 
were different.  Growth inhibitory concentrations (5.0 and 7.5 μM) did not affect p21  or 
cyclin D1 expression in SW480, HT-29 or HCT-15 cells, whereas p27 protein levels 
were slightly elevated in SW480 cells after treatment with 7.5 μM DIM-C-pPhCF3 and 
10 μM DIM-C-pPhCF3 and DIM-C-pPhC6H5.  Another major difference observed in this 
study with SW480 cells was the induction of apoptosis and downregulation of cyclin D1 
after treatment with 10 μM DIM-C-pPhCF3 and DIM-C-pPhC6H5 for 24 hr, whereas 
these responses were not observed in HT-29 or HCT-15 cells (393). 
 Despite the cell context-dependent differences in the effects of PPARγ-active C-
DIMs in colon cancer cells, the results in Figure 5.3 demonstrate that PPARγ-active C-
DIMs induce caveolin-1 expression in SW480 cells after prolonged treatment (3 d) with 
concentrations as low as 2.5 μM.  This response in SW480 cells was inhibited by 
GW9662 and similar results were observed for PPARγ-active C-DIMs and also for 
CDDO and related compounds in colon cancer cells (393, 396).  In this study, we also 
observed PPARγ-dependent upregulation of phospho-Akt in SW480 cells and similar 
results have been observed for CDDO and related compounds in the same cell line  
(396).  The induction of caveolin-1 at the lower doses (< 7.5 μM) of DIM-C-pPhCF3 and 
DIM-C-pPhC6H5 is consistent with the growth inhibitory effects of these compounds 
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since caveolin-1 expression has been linked to inhibition of colon cancer cell/tumor 
proliferation in both in vitro and in vivo models (398, 399).  The observation that DIM-
C-pPhCF3 and DIM-C-pPhC6H5 induce PI3-K dependent phosphorylation of Akt, which 
is normally a cell survival pathway, was also consistent with the observed growth 
inhibitory effects of these compounds.  PI3-K and caveolin-1 coexpression sensitizes 
HeLa and 293 cells to the cytotoxicity of arsenite and hydrogen peroxide (438) and 
sensitizes L929 cells to tumor necrosis factor α-induced cell death (364). 
 Several studies show that PPARγ agonists induce both receptor-dependent and 
independent responses (303, 359, 391, 393-397, 436, 437) and in this study these 
pathways are separable at different concentrations of C-DIMs.  At low concentrations (> 
7.5 μM), DIM-C-pPhCF3 and DIM-C-pPhC6H5 induce receptor-dependent upregulation 
of caveolin-1 (Fig. 5.3), whereas at higher concentrations (> 7.5 μM), these same 
compounds induce apoptosis which was not inhibited by GW9662, a PPARγ antagonist 
(Fig. 5.4A).  Similar results were observed for CDDO and related compounds in SW480 
cells (396).  Interestingly, there appears to be a narrow concentration range for the 
switch between receptor-dependent and receptor-independent responses.  Moreover, 
induction of PPARγ-dependent caveolin-1 expression by ≥ 7.5 μM DIM-C-pPhCF3 or 
DIM-C-pPhC6H5 is lost in cells treated with 10 μM concentrations of these same 
compounds (Fig. 5.4B) where extensive apoptosis is observed.  In other cell lines, we 
have recently shown that C-DIMs induce ER stress  which leads to activation of DR5 
and the extrinsic pathway for apoptosis (436); however, this response was not observed 
in SW480 cells (Fig. 5.4C).  In contrast, both DIM-C-pPhC6H5 and DIM-C-pPhCF3 
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induced NAG-1 expression at concentrations (≥ 7.5 μM) similar to those required for 
induction of apoptosis (PARP cleavage) and both responses were PPARγ-independent.  
Moreover, previous studies have demonstrated that NAG-1 induces apoptosis and 
activation of caspases in cancer cell lines (402, 439), suggesting that PPARγ-
independent induction of apoptosis in SW480 cells by C-DIM compounds is due to 
upregulation of NAG-1 expression.  These in vitro responses are also duplicated in the 
athymic nude mouse xenograft studies where DIM-C-pPhC6H5 not only inhibits tumor 
growth but induces caspase 3 and NAG-1 expression in the tumors (Fig. 5.6) 
 In summary, our results show that PPARγ-active C-DIMs inhibit SW480 cell 
proliferation and inhibit colon tumor growth in an athymic nude mouse xenograft model 
(Fig. 5.6).  The effectiveness of C-DIMs as anticancer agents is enhanced by their 
activation of both receptor-dependent and -independent pathways and this dual 
mechanism of action is shared by other classes of PPARγ agonists.  Ongoing studies in 
this laboratory are focused on development of new and more potent C-DIM analogs for 
treatment of colon cancer and on determining the receptor-independent mechanisms of 
action of C-DIMs and related PPARγ agonists. 
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CHAPTER VI 
 
ACTIVATION OF NUR77 BY SELECTED 1,1-BIS(3'-INDOLYL)-1-(p-
SUBSTITUTEDPHENYL)METHANES INDUCES APOPTOSIS THROUGH 
NUCLEAR PATHWAYS* 
Introduction 
The nuclear receptor superfamily of eukaryotic transcription factors encompasses 
steroid hormone and other nuclear receptors for which ligands have been identified and 
orphan receptors with no known ligands (440-446).  Nuclear receptors share common 
structural features which include an N-terminal A/B domain, containing activation 
function-1 (AF-1), and a C-terminal E domain, which contains AF-2 and the ligand 
binding domain (LBD).  Nuclear receptors also have a DNA binding domain [DBD, 
(C)], a variable hinge (D), and C-terminal F regions.  Ligand activation of class 1 steroid 
hormone receptors induces homo- or heterodimer formation which interact with 
consensus or nonconsensus palindromic response elements.  In contrast, class 2 receptors 
form heterodimers with the retinoic X receptor (RXR) as a common partner, whereas 
class 3 and 4 orphan receptors act as homodimers or monomers and bind to direct 
response element repeats or single sites, respectively.  The DBDs of nuclear receptors all  
__________________ 
*Reprinted with permission from “Activation of Nur77 by selected 1,1-bis(3'-indolyl)-1-
(p-substituted phenyl)methanes induces apoptosis through nuclear pathways” by 
Chintharlapalli S, Burghardt R, Papineni S, Ramaiah S, Yoon K, Safe S. J Biol Chem 
2005;280:24903-24914. Copyright 2005 by American Society for Biochemistry and 
Molecular-Biology.
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contain two zinc finger motifs that interact with similar half-site motifs; however, these 
interactions vary with the number of half-sites (1 or 2), their orientation, and spacing.  
Differences in nuclear receptor action are also determined by their other domains which 
dictate differences in ligand binding, receptor dimerization and interaction with other 
nuclear cofactors. 
 Most orphan receptors were initially cloned and identified as members of the 
nuclear receptor family based on their domain structure and endogenous or exogenous 
ligands have subsequently been identified for many of these proteins  (444-446).  The 
nerve growth factor I-B (NGFI-B) family of orphan receptors were initially 
characterized as immediate early genes induced by nerve growth factor in PC12 cells 
and the three members of this family include NGFI-Bα (Nur77), NGFI-Bβ (Nurr1), 
NGFI-Bγ (Nor1) (447-449).   
 Nur77 plays an important role in thymocyte-negative selection and in T-cell 
receptor (TCR)-mediated apoptosis in thymocytes (327, 450), and overexpression of 
Nur77 in transgenic mice resulted in high levels of apoptosis in thymocytes (451, 452).  
In cancer cells, several mechanisms for Nur77-mediated apoptosis have been described 
and differences between studies may be due to the apoptosis-inducing agent or cell line 
(453-459).  For example, the retinoid 6-[3-(1-adamantyl)-4-hydroxyphenyl]-2-
naphthalene carboxylic acid (CD437) and 12-O-tetradecanoylphorbol-13-acetate (TPA) 
induce translocation of Nur77 from the nucleus to the mitochondria where Nur77 binds 
Bcl-2 to form a pro-apoptotic complex (453, 454).  In contrast, it has been suggested that 
TPA-induced Nur77 in LNCaP prostate cancer cells activates transcription of E2F1 
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which is also pro-apoptotic (459).  These studies are examples of ligand-independent 
pathways where Nur77 expression is induced and/or Nur77 protein undergoes 
intracellular translocation since ligands for this receptor have hitherto not been reported. 
This paper shows that 1,1-bis(3'-indolyl)-1-(p-substitutedphenyl)methanes containing 
trifluoromethyl, hydrogen and methoxy substituents induce Nur77-dependent 
transactivation in Panc-28 pancreatic and other cancer cell lines.  Nur77 agonists also 
induce typical cellular signatures of apoptosis including PARP cleavage and induction of 
TRAIL, and both ligand-dependent transactivation and induction of apoptosis were 
associated with the action of nuclear Nur77.  This study shows for the first time that 
ligand-dependent activation of the orphan receptor Nur77 induces apoptosis in cancer 
cells, suggesting that Nur77 agonists represent a new class of anticancer drugs. 
Materials and Methods 
Cell lines and reagents 
Panc-28, Panc-1, MiaPaCa-2, LNCaP, MCF-7, HT-29 and HCT-15 cancer cell 
lines were obtained from the American Type Culture Collection (Manassas, VA).  RKO, 
DLD-1 and SW-480 colon cancer cells were provided by Dr. S. Hamilton, and KU7 and 
253-JB-V-33 bladder cells were provided by Dr. A. Kamat (M.D. Anderson Cancer 
Center, Houston, TX).  The C-substituted DIMs were synthesized in this laboratory as 
previously described (359).  Antibodies for PARP (sc8007), Sp1 (sc-59) and TRAIL 
(sc7877) were purchased from Santa Cruz Biotechnology (Santa Cruz, CA) and Nur77 
(IMG-528) from Imgenex (San Diego, CA).  The GAL 4 reporter containing five GAL4 
response elements (pGAL4) was provided by Dr. Marty Mayo (University of North 
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Carolina, Chapel Hill, NC).  The GAL4-Nur77 (full length) and GAL4-Nur77 (E/F) 
chimeras were provided by Dr. Jae W. Lee (Baylor College of Medicine, Houston, TX) 
and Dr. T. Perlmann (Ludwig Institute for Cancer Research, Stockholm, Sweden) 
respectively, and Dr. Lee also provided the Nur77 response element-luciferase (NurRE-
Luc) reporter construct.  The GAL-4-coactivator fusion plasmids pM-SRC1, pMSRC2, 
pMSRC3, pM-DRIP205 and pMCARM-1 were kindly provided by Dr. Shigeaki Kato 
(University of Tokyo, Tokyo, Japan).  For RNA interference assays, we used a non-
specific scrambled (iScr) oligonucleotide as described (460).  The small inhibitory RNA 
for Nur77 (iNur77) was identical to the reported oligonucleotide (454) and these were 
purchased from Dharmacon Research (Lafayette, CO).  Leptomycin B (LMB) was 
obtained from Sigma (St Louis, MO) and caspase inhibitors were purchased from BD 
Pharminogen (San Diego, CA).  The following oligonucleotides were prepared by IDT 
(Coralville, IA) and were used in gel mobility shift assays; NBRE:5’-GAT CCT CGT 
GCG AAA AGG TCA AGC GCT A-3’; NurRE:5’- GAT CCT AGT GAT ATT TAC 
CTC CAA ATG CCA GGA-3’. 
Transfection assays 
 Transfection assays were essentially carried out as previously described using 
Lipofectamine Plus reagent (Invitrogen, Carlsbad, CA) and luciferase activities were 
normalized to β-galactosidase activity.  For RNA interference studies, cells were 
transfected with small inhibitor RNAs for 36 hr to ensure protein knockdown prior to the 
standard transfection and treatment protocols (359, 460).  Results are expressed as 
means ± SE for at least three replicate determinations for each treatment group. 
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Mammalian two-hybrid assay 
Panc-28  cells were plated in 12-well plates at 1 x 105 cells/well in DME-F12 
media supplemented with 2.5% charcoal-stripped FBS.  After growth for 16 hr, various 
amounts of DNA, i.e. Gal4Luc (0.4 μg), β-gal (0.04 μg), VP-Nur77(E/F) (0.04 μg), pM 
SRC1 (0.04 μg), pMSRC2 (0.04 μg), pMSRC3 (0.04 μg), pMDRIP205 (0.04 μg) and 
pMCARM-1 (0.04 μg) were transfected by Lipofectamine (Invitrogen) according to the 
manufacturer’s protocol.  After 5 hr of transfection, the transfection mix was replaced 
with complete media containing either vehicle (DMSO) or the indicated ligand for 20-22 
hr.  Cells were then lysed with 100 ml of 1X reporter lysis buffer, and 30 μl of cell 
extract were used for luciferase and β-Gal assays.  Lumicount was used to quantitate 
luciferase and β-Gal activities, and the luciferase activities were normalized to β-Gal 
activity. 
Cell growth and apoptosis assays 
The different cancer cell lines were cultured under standardized conditions.  Panc-28 
cells were grown in DMEM:Ham's F-12 media containing 2.5% charcoal stripped fetal 
bovine serum, and cells were treated with DMSO and different concentrations of test 
compounds as indicated.  For longer term cell survival studies, the media was changed 
every second day, and values were presented for a 4 day experiment.  For all other 
assays, cytosolic, nuclear fractions, or whole cell lysates were obtained at various time 
points, analyzed by Western blot analysis, and bands were quantitated as previously 
described (359, 460).  Immunocytochemical analysis was determined using Nur77 
antibodies as previously reported (460). 
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Gel shift assay 
Cells were seeded in DME/F12 medium supplemented with 2.5% charcoal-
stripped serum and treated with 10 μM DIM-C-pPhOCH3 for 30 min.  Nuclear extracts 
were obtained using NE-PER nuclear and cytoplasmic extraction reagents (Pierce 
Chemical Co.).  Oligonucleotides were synthesized, purified, and annealed, and 5 pmol 
of specific oligonucleotides were 32P-labeled at the 5'-end using T4 polynucleotide kinase 
and [32γP]ATP.  Nuclear extracts were incubated in HEPES with ZnCl2 and 1 µg poly 
deoxyinosine-deoxycytidine for 5 min; 100-fold excess of unlabeled wild-type or mutant 
oligonucleotides were added for competition experiments and incubated for 5 min.  The 
mixture was incubated with labeled DNA probe for 15 min on ice.  The reaction mixture 
was loaded onto a 5% polyacrylamide gel and ran at 150 V for 2 hr.  The gel was dried 
and protein DNA complexes were visualized by autoradiography using a Molecular 
Dynamics, Inc. Storm 860 instrument (Molecular Dynamics Inc., Sunnyvale CA). 
Annexin-V staining 
Detection of phosphatidylserine on the outside of the cell membrane, a unique 
and early marker for apoptosis, was performed using a commercial kit (Vybrant 
Apoptosis Assay Kit #2; Molecular Probes, Eugene, OR).  Panc-28 cells were cultured as 
described above, and treated with 10 μM DIM-C-pPhOCH3 or camptothecin for 6, 12 
and 24 hrs.  Binding of annexin V-Alexa-488 conjugate and propidium iodide (PI) was 
performed according to the manufacturer's instructions.  After binding and washing, cells 
were observed under phase contrast and epifluorescent illumination using a 495-nm 
excitation filter and a 520-nm absorption filter for annexin V-Alexa 488 and a 546-nm 
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excitation filter and a 590-nm absorption filter for PI.  Healthy cells were unstained by 
either dye; cells in early stages of apoptosis were stained only by annexin V, while dead 
cells were stained by annexin V and PI.  The assay was repeated on three separate Panc-
28 cell preparations. 
Quantitative real-time PCR 
cDNA was prepared from the Panc-28 cell line using a combination of 
oligodeoxythymidylic acid (Oligo d(T)16), and dNTP mix (Applied Biosystems) and 
Superscript II (Invitrogen).  Each PCR was carried out in triplicate in a 20-µl volume 
using Sybr Green Mastermix (Applied Biosystems) for 15 min at 95°C for initial 
denaturing, followed by 40 cycles of 95°C for 30 s and 60°C for 1 min in the ABI Prism 
7700 Sequence Detection System.  The ABI Dissociation Curves software was used 
following a brief thermal protocol (95°C 15 s and 60°C 20 s, followed by a slow ramp to 
95°C) to control for multiple species in each PCR amplification.  Values for each gene 
were normalized to expression levels of TBP.  The sequences of the primers used for 
RT-PCR were as follows: TRAIL forward, 5'-CGT GTA CTT TAC CAA CGA GCT 
GA-3', reverse, 5'-ACG GAG TTG CCA CTT GAC TTG-3'; and TBP forward, 5'-TGC 
ACA GGA GCC AAG AGT GAA-3', reverse, 5'-CAC ATC ACA GCT CCC CAC CA-
3'. 
Xenograft experiment 
Male athymic nude mice (BALB/c, ages 8-12 weeks) were purchased from 
Harlan (Indianapolis, IN). The mice were housed and maintained in laminar flow 
cabinets under specific pathogen-free conditions. Panc-28 cells were harvested from 
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subconfluent cultures by trypsinization and washed. Panc-28 cells (2 x 106) were 
injected subcutaneously into each mouse on both flanks using a 30-gauge needle. The 
tumors were allowed to grow for 11 days until tumors were palpable. Mice were then 
randomized into two groups of seven mice per group and dosed by oral gavage with 
either corn oil or DIM-C-pPhOCH3 every second day. The volume of corn oil was 75 µl, 
and the dose of DIM-C-pPhOCH3 was 25 mg/kg/day. The mice were weighed, and 
tumor areas were also measured every other day. Final body and tumor weights were 
determined at the end of the dosing regiment, and selected tissues were further examined 
by routine H & E staining and immunohistochemical analysis for apoptosis using the 
TUNEL assay. 
Results 
Nur77 expression and structure-dependent activation by C-substituted DIMs 
 Studies in this laboratory have been investigating the anticarcinogenic activities 
of a series of ring-substituted 3,3'-diindolylmethanes (DIMs) and methylene (C)-
substituted DIMs, and many of these compounds were active in vivo and in cell culture 
assays (359, 393, 461, 462).  Some members of a series of C-substituted DIMs activated 
peroxisome proliferator-activated receptor γ (PPARγ) but not PPARα, retinoic acid 
receptor (RAR), retinoic X receptor (RXR), estrogen receptor α, or the aryl hydrocarbon 
receptor (AhR).  Previous studies have linked Nur77 to decreased cell survival and 
activation of cell death pathways by apoptosis-inducing agents in some cancer cell lines 
(453-459), and we therefore investigated  expression of Nur77 in cancer cell lines and 
the effects of a series of eleven C-substituted DIMs on Nur77 activation/translocation.  
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Figure 6.1A summarizes Western blot analysis of Nur77 in whole cell lysates from 12 
different cancer cell lines derived from pancreatic, prostate, breast, colon and bladder 
tumors.  Only the 253 JB-V-33 bladder cancer cell line exhibited relatively low 
expression of Nur77, and the antibodies and electrophoretic conditions gave two 
immunostained bands as previously reported in other studies.  Western blot analysis of 
the other NGFI-B proteins showed variable expression of Nurr1, and Nor1 was not 
detectable in these cancer cell lines.  Similar results were also obtained in Jurkat T-cell 
leukemia cells.  Structure-dependent activation of Nur77 by a series of eleven C-
substituted DIMs was investigated in Panc-28 cells transfected with a GAL4-Nur77 (full 
length) chimera and a reporter construct containing five GAL4 response elements linked 
to a luciferase reporter gene (pGAL4).  The results (Fig. 6.1B) showed that three 
compounds containing p-trifluoromethyl (DIM-C-pPhCF3) and methoxy (DIM-C-
pPhOCH3) substituents or the unsubstituted phenyl group (DIM-C-Ph) activated 
luciferase activity.  Similar results were also obtained in Panc-28 cells transfected with a 
construct containing a Nur response element (NurRE) (Fig. 6.1C), and these same 
compounds also activated GAL4-Nur77/pGAL4 and NurRE in MiaPaCa-1 pancreatic, 
HCT-15 colon, and MCF-7 breast cancer cells.  The structure-dependent activation of 
Nur77 was also investigated using DIM-C-pPhOCH3 as a model and the position of the 
methoxyl group was changed to the meta (DIM-C-mPhOCH3) and ortho (DIM-C-
oPhOCH3) positions (Fig. 6.1D).  Only the para- substituted compound was active.  We 
also investigated N-methyl and 2-methyl indole ring-substituted analogs of DIM-C-
pPhOCH3, DIM-C-Ph, and DIM-C-pPhCF3) and these compounds did not activate
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Fig. 6.1. Nur77 expression and activation in cancer cell lines.  [A]  Nur77 protein expression. 
Whole cell lysates from 12 different cancer cell lines were analyzed for Nur77, Nurr1 and Nor1 by 
Western blot analysis as described in the Materials and Methods.  Nor1 protein was not detected in 
these cell lines.  Activation of Gal4-Nur77 [B] and NuRE [C]  Panc-28 cells were treated with 10 
or 20 μM of the various compounds, transfected with GAL4-Nur77/pGAL4 or NuRE, and 
luciferase activity determined as described in the Materials and Methods.  [D]  Nur77 activation 
by isomeric DIM-C-PhOCH3 compounds.  Panc-28 cells were treated with 10 or 20 μM of the 
DIM-C-PhOCH3 isomers, transfected with GAL4-Nur77/pGAL4 and luciferase activity 
determined as described in the Materials and Methods.  Results are expressed as means ± SE for at 
least 3 separate determinations for each treatment group and significant (p < 0.05) induction is 
indicated by an asterisk. 
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Nur77.  These results demonstrate that activation of Nur77 by C-DIMs was structure-
dependent and sensitive to substitution on the phenyl and indole rings.  Thus, at least 
three C-substituted DIMs activate Nur77; one of these compounds (DIM-C-pPhCF3) 
also activates PPARγ (359, 393), whereas DIM-C-pPhOCH3 and DIM-C-Ph are PPARγ-
inactive (359).  DIM-C-pPhOH was inactive in both transactivation assays and, at higher 
concentrations, decreased activity lower than observed in solvent (DMSO) control. 
Characterization and interactions of C-DIMs that activate and inhibit Nur77-mediated 
transactivation 
 The role of the LBD or E/F region in ligand-induced transactivation of Nur77 
was investigated in Panc-28 cells transfected with pGAL4 and a chimeric GAL4-
Nur77(E/F) construct containing only the E/F domain of Nur77.  Treatment of Panc-28 
cells with different concentrations (5 - 15 μM) of DIM-C-pPhCF3, DIM-C-pPhOCH3 
and DIM-C-Ph induced luciferase activity, whereas no response was observed in cells 
treated with Nur77-inactive DIM-C-pPhOH (Fig. 6.2A).  These results are the first to 
identify a series of compounds that directly activate Nur77(LBD)-dependent 
transactivation in Panc-28 or any other cancer cell line.  The role of Nur77 in mediating 
transactivation was further investigated in Panc-28 cells treated with 10 or 20 μM DIM-
C-pPhOCH3 or DIM-C-Ph and transfected with pNurRE, a non-specific "scrambled" 
small inhibitory RNA (iScr), or small inhibitory RNA for Nur77 (iNur77).  The results 
(Fig. 6.2B) showed decreased Nur77 protein in whole cell lysates and a 90-100% 
decrease in ligand-induced transactivation over the different concentrations of 
compounds, thus confirming the role of Nur77 in mediating this response.  As noted  
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Fig. 6.2. Activation of Nur77. [A] Activation of GAL4-Nur77(E/F)/pGAL4.  The effects of the 
various compounds was essentially determined as described in Figure 1; however, a truncated 
GAL4 chimera expressing only the E/F domain of Nur77 was used in this experiment.  [B] 
Effects of iNur77 on transactivation.  Cells were treated with DIM-C-pPhOCH3 or DIM-C-Ph, 
transfected with NuRE and iNur77 or iScr (non-specific), and luciferase activity determined as 
described.  Similar results were obtained for DIM-C-pPhCF3.  Nur77 antagonist activity of DIM-
C-pPhOH [C], DIM-C-mPhOH [D], and DIM-C-oPhOH [E].  Cells were transfected with GAL4-
Nur77/pGAL4 and different concentrations of the DIM-C-PhOH isomers and the Nur77 agonists, 
and luciferase activity determined as described in the Materials and Methods.  Significant (p < 
0.05) inhibition of transactivation is indicated (**).  Results are expressed as means ± SE for at 
least 3 separate determinations for each treatment group and significant (p < 0.05) induction (*) or 
inhibition by iNur77 or DIM-C-pPhOH (**) is indicated. 
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above, one compound which contained a p-hydroxy substituent (DIM-C-pPhOH) did not 
induce activity (Fig. 6.1B) and DIM-C-pPhOH was further investigated as a potential 
Nur77 antagonist.  Panc-28 cells were transfected with GAL4-Nur77/pGAL4 and 
cotreated with DIM-C-pPhOH and Nur77 agonists DIM-C-pPhCF3, DIM-C-pPhOCH3, 
and DIM-C-pH (Fig. 6.2C).  The results show that DIM-C-pPhOH antagonizes 
activation of Nur77 by all three C-DIM compounds.  The structural specificity of Nur77 
antagonists was further investigated using meta-hydroxy (DIM-C-mPhOH) and ortho-
hydroxy (DIM-C-oPhOH) analogs.  DIM-C-mPhOH (10 or 20 μM) did not inhibit DIM-
C-pPhOCH3- or DIM-C-Ph-induced transactivation (Fig. 6.2D).  DIM-C-oPhOH also 
did not exhibit Nur77 antagonist activity (Fig. 6.2E); however, high doses (20 μM) of 
both Nur77 agonists and DIM-C-oPhOH were toxic.  Thus, activation of Nur77 by C-
DIMs was E/F domain-dependent and Nur77 activation was inhibited by DIM-C-
pPhOH; moreover, both activation and inhibition of Nur77-mediated transactivation was 
dependent on the structure of the C-DIM compounds. 
Nur77 DNA-binding and C-DIM-induced Nur77-coactivator interactions 
 Incubation of nuclear extracts from Panc-28 cells treated with DMSO or DIM-C-
pPhOCH3 with 32P-labeled NBRE and NurRE (lanes 1, 2, and 5, 6, respectively) gave 
retarded bands in EMSA assays (Fig. 6.3A).  Retarded band intensities were decreased 
after incubation with 100-fold excess NurRE (lane 3) or NBRE (lane 7) but not by 
mutant NurRE (lane 4) or mutant NBRE (lane 8) oligonucleotides.  These results show 
that nuclear extracts containing Nur77 bind NurRE and NBRE as dimers and monomers, 
respectively, and this corresponds to their migration in the EMSA assay.  Results 
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obtained for nuclear extracts from solvent-treated cells show that formation of the 
retarded bands is ligand-independent and the retarded band pattern corresponds to 
previous studies using nuclear extracts from cells or in vitro translated Nur77 (463, 464).  
Extracts from cells treated with Nur77-active C-substituted DIMs gave retarded band 
intensities similar to that observed for solvent-treated extracts suggesting minimal 
ligand-dependent loss of nuclear Nur77 in these cells. 
 Ligand-dependent activation of nuclear receptors is dependent on interaction of 
the bound receptor with coactivators (465-467) and Figures 6.3B – 6.3D summarize 
results of a mammalian two-hybrid assay in Panc-28 cells transfected with VP-Nur77 
(ligand binding domain) and GAL4-coactivator chimeras.  Ligand-induced Nur77-
coactivator interactions were determined using a construct (pGAL4) containing 5 GAL4 
response elements.  Coactivators used in this study include SRC-1, SRC-2 (TIFII), SRC-
3 (AIB1), PGC-1, TRAP220 and CARM-1.  A GAL4-repressor (SMRT) chimera was 
also included in the assay.  All three ligands induced transactivation in cells transfected 
with GAL4-SRC-1, GAL4-PGC-1 and GAL4-TRAP220 chimeras.  DIM-C-pPhOCH3 
induced transactivation in cells transfected with GAL4-SRC-3 and GAL4-CARM-1 was 
slightly activated by DIM-C-pPhOCH3 and DIM-C-pPhCF3.  The results demonstrate 
that although there were some ligand-dependent differences in transactivation observed 
for GAL4-SRC-3 and GAL4-CARM-1; however, the most significant interactions 
between VP-Nur77 and GAL4 chimeras expressing SRC-1, PGC-1 and TRAP220 were 
induced by all three compounds. 
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A
Fig. 6.3. DNA binding of Nur77 and ligand-induced coactivator-Nur77 interactions.  [A]  Gel 
mobility shift assay.  Cells were treated with DMSO or Nur77 agonists for 0.5 hr, nuclear extracts 
were incubated with 32P-labeled NurRE and NBRE, and formation of retarded bands was 
determined in a gel mobility shift assay as described in the Materials and Methods.  Arrows denote 
the specifically bound bands.  GAL4-coactivator interactions with VP-Nur77(E/F) in Panc-28 
cells treated with DIM-C-pPhCF3 [B], DIM-C-pPhOCH3 [C], and DIM-C-Ph [D].  Cells were 
transfected with the pGAL4, VP-Nur77(E/F) and GAL4-coactivator/repressor (chimera) 
constructs, treated with the Nur77 agonists, and luciferase activity determined as described in the 
Materials and Methods.  Significant (p < 0.05) induction of luciferase activity is indicated (*) and 
results are expressed as means ± SE for three separate determinations for each treatment group. 
 198
0
20
40
60
80
100
120
140
160
D
M
SO 1
0 20 10 20 10 20 10 20 10 20 10 20 10 20
SRC3 SRC1 PGC1 TRAP220 CARM-1 SRC2 SMRT
DIM-C-pPhCF3 (μM) 
Fo
ld
 In
du
ct
io
n
*
*
*
*
*
*
*
*
B
0
5
10
15
20
25
30
35
40
D
M
SO 1
0 20 10 20 10 20 10 20 10 20 10 20 10 20
SRC3 SRC1 PGC1 TRAP220 CARM-1 SRC2 SMRT
DIM-C-pPhOCH3 (μM)
Fo
ld
 In
du
ct
io
n
*
*
*
* *
*
*
*
C
Fig. 6.3 Continued 
 199
0
10
20
30
40
50
60
70
D
M
SO 1
0 20 10 20 10 20 10 20 10 20 10 20 10 20
SRC3 SRC1 PGC1 TRAP220 CARM-1 SRC2 SMRT
DIM-C-pPh (μM)
FO
LD
 IN
D
U
C
TI
O
N
*
*
*
*
*
*
D
Fig. 6.3 Continued 
 200
Effects of Nur77-active C-DIMs on cell survival and apoptosis and role of nuclear 
Nur77 
 In several cancer cell lines transfected with Nur77-GFP constructs, treatment 
with apoptosis and differentiation-inducing agents results in rapid translocation of Nur77 
into the cytosol/mitochondria (453-458).  Similar results have been observed in BGC-
823 human gastric cancer cells where endogenous Nur77 is nuclear and TPA induced 
Nur77 translocation into the cytosol and this was accompanied by apoptosis but not by 
Nur77-dependent transactivation (455).  Results summarized in Figure 6.4A show 
immunostaining of Nur77 in the nucleus of Panc-28 cells treated with DMSO and 
Nur77-active DIM-C-pPhCF3, DIM-C-pPhOCH3 and DIM-C-Ph for 6 hr, and 
comparable results were obtained in Panc-28, MiaPaCa and LNCaP cells after treatment 
for 6 or 12 hr.  In all cases, Nur77 remained in the nucleus, and cells exhibited a 
compacted nuclear staining pattern typically observed in cells activated for cell death 
pathways. In a separate experiment, Panc-28 cells were treated with 10 or 20 μM DIM-
C-pPhCF3, DIM-C-pPhOCH3 and DIM-C-Ph or 10 μM DIM-C-pPhOH for 12 hr, and 
Nur77 protein levels were determined by Western blot analysis of cytosolic and nuclear 
extracts (Fig. 6.4B).  These results also confirm that Nur77, in the presence or absence of 
C-substituted DIM agonists, is a nuclear protein and ligand-induced Nur77 translocation 
from the nucleus is not observed.  Sp1 is a nuclear protein and was used as a control to 
ensure efficient separation of the two extracts and Sp1 was identified only in the nuclear 
fraction (Fig. 6.4B).   
 Nur77 agonists significantly decreased survival of Panc-28 cells (Fig. 6.5A), and  
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Fig. 6.4. Nuclear localization of Nur77.  [A]  Immunostaining.  Panc-28 cells were treated with 
DMSO or 10 μM Nur77 agonists for 6 hr, and cells were immunostained for Nur77 as described in 
the Materials and Methods.  Nur77 staining was not observed in cells treated with non-specific 
IgG.  [B]  Nuclear localization in subcellular fractions.  Panc-28 cells were treated with the various 
compounds for 12 hr and Nur77 protein expression in cytosolic and nuclear extracts were 
determined by Western blot analysis.  Sp1 protein and a non-specific (NS) band serve as loading 
controls, and Sp1, a nuclear protein, also serves as a control for separation of nuclear and cytosolic 
extracts.   
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Fig. 6.5. Nur77 agonists decrease cell survival and induce apoptosis.  [A]  Cell survival.  Panc-28 
cells determined as described in the Materials and Methods.  Results are expressed as means ± SE 
for 3 separate determinations for each treatment group, and a significant (p < 0.050 decrease in 
cell survival is indicated by an asterisk (*).  DIM-C-pPhOH inhibited cell growth only after 
treatment for 96 or 144 hr; however, this compound did not induce cell death at any time point. 
[B]  Effects of Nur77 agonists on PARP cleavage in Panc-28.  Cells were treated with the different 
compounds alone or with LMB and PARP cleavage was determined by Western blot analysis of 
whole cell lysates as described in the Materials and Methods.  Bax and bcl-2 (not shown) protein 
levels were not affected by treatment and NS (non-specific) protein served as a loading control. 
[C]  Annexin staining.  Panc-28 cells were treated with camptothecin (positive control) or DIM-C-
pPhOCH3 for 6 hr, and annexin staining was determined as described in the Materials and 
Methods.  Approximately 30 - 40% of cells treated with DIM-C-pPhOCH3 exhibited annexin 
staining.  Induction of apoptosis in LNCaP, MiaPaCa-1 and MCF-7 cells [D] or Panc-28 cells [E] 
treated with Nur77 agonists alone or in combination with LMB, respectively.  Cells were treated 
essentially as described [A] and PARP cleavage determined by Western blot analysis as described 
in the Materials and Methods. 
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IC50 values for DIM-C-pPhCF3, DIM-C-pPhOCH3 and DIM-C-Ph were between 1 - 5 
μM, whereas DIM-C-pPhOH did not affect cell survival.  At longer time points (4 and 6 
days), DIM-C-pPhOH slightly inhibited cell proliferation; however, induction of cell 
death was not observed for this compound at concentrations as high as 20 μM. 
Decreased cell survival is also observed for agents that induce apoptosis and/or Nur77 
nuclear to cytosolic translocation in cancer cells (453-458).  Results illustrated in Figure 
6.5B show that treatment of Panc-28 cells with Nur77 agonists induced cleavage of 
PARP, whereas the Nur77-inactive DIM-C-pPhOH did not induce this response.  PARP 
cleavage is associated with activation of cell death pathways; however, this was not 
accompanied by changes in levels of bax (Fig. 6.5B) or bcl-2 proteins.  Moreover, 
treatment of Panc-28 cells with 10 and 20 μM DIM-C-pPhOCH3 for 8 and 12 hr showed 
a time- and dose-dependent increase of annexin V-stained cells using a green-fluorescent 
Alexa Fluor 488 probe (Fig. 6.5C).  The effects of camptothecin (positive control for 
apoptosis) and DIM-C-pPhOCH3 were comparable.  After treatment with DIM-C-
pPhOCH3 for 6 hr, annexin V-stained cells were significantly increased, plasma 
membrane blebbing was observed, and there was minimal PI staining.  However, after 
12 hr, PI staining was increased.  Induction of PARP cleavage by Nur77 agonists was 
also observed in other pancreatic (MiaPaCa-2), prostate (LNCaP) and breast (MCF-7) 
cancer cell lines (Fig. 6.5D).  Induction of PARP cleavage by the Nur77-active 
compounds in Panc-28 cells was not accompanied by changes in Nur77 expression (Fig. 
6.4B), and this was in contrast to TPA which activates nuclear pathways by inducing 
Nur77 expression (459).  Using a protocol comparable to that outlined in Figure 6.5B, 
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Fig. 6.6. Induction of TRAIL and PARP cleavage in Panc-28 cells is dependent on Nur77.  [A] 
Induction of TRAIL.  Cells were treated with Nur77 agonists and levels of TRAIL protein in 
whole cell lysates were determined by Western blot analysis as described in the Materials and 
Methods.  Results are expressed as means ± SE for 3 separate determinations and significant (p < 
0.05) induction is indicated.  [B]  Induction of TRAIL mRNA.  Panc-28 cells were treated with 10 
or 20 μM DIM-C-pPhOCH3 or DIM-C-Ph for 12 hr, and TRAIL mRNA levels were determined 
by RT-PCR as described in the Materials and Methods.  Results are expressed as means ± SE for 3 
separate determinations for each treatment group as significant (p < 0.05) is indicated by an 
asterisk.  [C]  Effects of caspase inhibitors.  Cells were treated and analyzed essentially as 
described  in [A]; however cells were also cotreated with caspase 8 and pancaspase inhibitors  Z-
IETD or Z-VAD-FMK, respectively.  Both inhibitors partially decreased PARP cleavage. [D] 
Effects of iNur77 on TRAIL expression and PARP cleavage.  Panc-28 cells were treated with 
DMSO or 10 μM DIM-C-pPhOCH3 for 24 hr, transfected with iNur77 or iScr (non-specific), and 
whole cell lysates were analyzed by Western blot analysis as described in the materials and 
methods.  Results are expressed as means ± SE for 3 separate determinations for each treatment 
group and significant (p < 0.05) induction (*) or inhibition by iNur77 (**) is indicated.  [E] 
Inhibition of induced PARP cleavage and TRAIL by DIM-C-pPhOH.  Panc-28 cells were treated 
with 10 μM DIM-C-pPhOCH3 or DIM-C-Ph alone or in the presence of 20 μM DIM-C-pPhOH, 
and PARP cleavage and TRAIL protein expression were determined by Western blot analysis as 
described in the Materials and Methods. 
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the induction of PARP cleavage by the Nur77 agonists in Panc-28 cells was not affected 
by the nuclear export inhibitor leptomycin B (LMB) (1 ng/ml) (Fig. 6.5E).  LMB alone 
slightly induced PARP cleavage and, for some cells cotreated with LMB plus Nur77 
agonists, there was enhanced PARP cleavage.  In contrast, previous studies showed that  
LMB inhibits apoptosis in cells treated with apoptosis-inducing agents that activate 
nuclear-cytosol/mitochondrial translocation of Nur77 (453, 454).  These results 
demonstrate that activation of nuclear Nur77 by C-substituted DIMs induces apoptosis in 
Panc-28 and other cancer cell lines; however, evidence for activation of the intrinsic 
apoptotic pathways was not observed. 
Nur77-active C-DIMs induce TRAIL 
 In thymocytes, there is evidence that Nur77-induced apoptosis is linked to 
transcriptional activation (468), and microarray studies in thymocytes undergoing 
Nur77-dependent apoptosis identified several apoptosis-related genes including fasL and 
TRAIL (469).  Results in Figure 6.6A show that Nur77 agonists that induce PARP 
cleavage also induce TRAIL (but not fasL) protein expression in Panc-28 cells, 
suggesting that this response may be a direct or indirect downstream target of Nur77 
agonists in cancer cells.  The Nur77-inactive DIM-C-pPhOH did not induce TRAIL.  In 
addition, DIM-C-pPhOCH3 or DIM-C-Ph induced TRAIL mRNA levels in Panc-28 cells 
(Fig. 6.6B).  Since TRAIL activates the extrinsic apoptosis pathway and activation of 
caspase 8, we also investigated the effect of a caspase 8 inhibitor (Z-IETD-FMK) and 
the pan-caspase inhibitor (Z-VAD-FMK) on induction of PARP cleavage by Nur77 
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agonists (Fig. 6.6C).  The results show that both inhibitors blocked (60 - 90%) induction 
of PARP cleavage by Nurr7 agonists. 
 The role of Nur77 in mediating induction of TRAIL and PARP cleavage by 
DIM-C-pPhOCH3 was further investigated in Panc-28 cells transfected with non-specific 
RNA (iScr) and iNur77 (Fig. 6.6D).  Levels of Nur77, PARP cleavage, and TRAIL 
proteins were determined by Western blot analysis of whole cell extracts and the results 
showed that iNurr significantly decreased levels of all three proteins.  In addition, 
cotreatment of Panc-28 cells with DIM-C-pPhOH3 or DIM-C-Ph and the Nur77 
antagonist DIM-C-pPhOH (Fig. 6.6E) showed that the latter compound also inhibited 
induction of PARP cleavage and TRAIL protein expression induced by Nur77 agonists.  
These results demonstrate that Nur77 agonists induce apoptosis pathways in cancer cells 
through transcriptional (nuclear) mechanisms, and at least one of the induced proteins 
(TRAIL) activates an extrinsic apoptotic pathway.  In summary, selected C-substituted 
DIMs have now been identified as ligands for the orphan receptor Nur77 and activation 
of this receptor is associated with decreased cancer cell survival, induction of TRAIL 
and apoptosis.  
Inhibition of tumor growth in athymic nude mice bearing Panc-28 cell xenografts 
Approximately 11 days after injection of Panc-28 cells, palpable tumors were 
detected and the mice were administered corn oil (control) or DIM-C-pPhOCH3 (in corn 
oil) at a dose of 25 mg/kg/day, which was given by oral gavage. The animals were 
treated every second day, and tumor areas were determined over the duration of the 
experiment. The results (Fig. 6.7A) showed that DIM-C-pPhOCH3 significantly  
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Fig. 6.7. Inhibition of tumor growth by DIM-C-pPhOCH3. Tumor areas (A) and weights (B). Male 
athymic nude mice bearing Panc-28 cell xenografts were treated every second day with corn oil 
and DIM-C-pPhOCH3 in corn oil as described under "Materials and Methods." The overall dose of 
DIM-C-pPhOCH3 was 25 mg/kg/day. Significant (p < 0.05) inhibition of tumor areas and weights 
is indicated by an asterisk. H&E stainings of muscle and brain tissue from control and treated 
animals were similar, and tumors from control and treated animals exhibited apoptosis (data not 
shown). 
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inhibited tumor growth (area), and this was also complemented by a parallel decrease in 
tumor weights (Fig. 6.7B). Analysis of tumors from control and treated animals (TUNEL 
assay) indicated similar levels of apoptosis. Animal weight gain and organ weights were 
comparable in both treatment groups, and there were no apparent signs of toxicity in the 
DIM-C-pPhOCH3-treated mice compared with the corn oil controls. The mouse brain 
and muscle express relatively high levels of Nur77 (470), and examination of brain 
regions by H&E staining did not indicate any differences between the control (corn oil) 
and DIM-C-pPhOCH3-treated animals.  
Discussion 
 Nur77 is widely expressed in multiple tissues and has been identified as a critical 
mediator of T-cell receptor-dependent apoptosis in T-lymphocytes and T-hybridoma 
cells (471, 472).  Expression of dominant negative or antisense Nur77 blocked T-cell 
receptor-mediated apoptosis in T-hybridoma cells and extensive apoptosis of thymocytes 
was observed in transgenic mice overexpressing full length Nur77 (451, 452).  
Activation of cell death in macrophages is associated with increased expression of 
Nur77 and decreased cell death was observed in Nur77-deficient macrophages (473).  A 
recent study (474) show that cadmium acetate induced apoptosis in WI-38 human lung 
fibroblasts and A549 human lung carcinoma cells and this was also accompanied by 
induction of Nur77.  Moreover, transfection with dominant-negative Nur77 protected the 
cells against cadmium-induced apoptosis. 
 Ongoing studies in the laboratory with a series of C-substituted DIMs indicate 
that these compounds inhibit growth or induce cell death of multiple cancer cell lines, 
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and some of these analogs including DIM-C-pPhCF3 activate PPARγ (359, 393).  
However, several PPARγ-inactive C-substituted DIMs also decreased cell survival of 
several cancer cell lines (e.g. Fig. 6.5A) and inhibited carcinogen-induced mammary 
tumor growth in female Sprague-Dawley rats.  Nur77 was considered as a possible target 
for C-DIM compounds based on results of several studies with retinoids, apoptosis and 
differentiation-inducing agents that also inhibit cell growth and activate extranuclear 
Nur77 (453-458).  Initial studies confirmed Nur77 protein expression in 12 prostate, 
colon, bladder, pancreatic and breast cancer cell lines (Fig. 6.1A).  Results of screening a 
panel of structurally-diverse C-substituted DIMs shows that DIM-C-pPhCF3 and two 
PPARγ-inactive analogs, DIM-C-pPhOCH3 and DIM-C-Ph, activate Nur77-dependent 
transactivation in Panc-28 and other cancer cell lines transfected with GAL4-Nur77 (full 
length) or NuRE (Figs. 6.1B and 6.1C).  Moreover, ligand-induced transcriptional 
activation is observed with GAL4-Nur77(E/F) chimeras (Fig. 6.2C) in which only the 
ligand binding domain of Nur77 is expressed.  The role of Nur77 in mediating ligand-
dependent transactivation was confirmed in studies showing that these responses were 
inhibited by either iNur77 (small inhibitory RNA) (Fig. 2B) or DIM-C-pPhOH which 
exhibited Nur77 antagonist activity (Fig. 6.2C).  Previous studies on the crystal structure 
of the mouse Nurr1 LBD (475) and the Drosophila Nurr1 homolog DHR38 (476) show 
that the ligand binding pocket (LBP) is occupied by bulky hydrophobic amino acid side-
chains.  Moreover, due to the high sequence homology among NGFI-B family proteins, 
it has been suggested that Nur77, Nurr1 and Nor-1 may represent a class of orphan 
receptors that function independently of ligand binding (477).  In contrast, this study 
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shows that selected C-DIM compounds uniquely induce nuclear Nur77-mediated 
transactivation; this induction response is observed through the E/F domain of Nur77 
(Fig. 6.1C) and can be inhibited by DIM-C-pPhOH, a Nur77 antagonist (Figs. 6.2 and 
6.5).  Moreover, both activation of Nur77 and Nur77 antagonist activities by C-DIMs 
were highly structure-dependent (Figs. 6.1 and 6.2).  These results suggest that the active 
C-DIM compounds interact with the E/F domain of Nur77 and induce conformational 
changes, resulting in binding to the LBP or other sites within the C-terminal region of 
Nur77.  Currently, we are examining critical ligand interaction sites within the E/F 
domain of Nur77 by deletion/mutation analysis and by crystallization of the Nur77 LBD 
in the presence or absence of the C-DIM ligands. 
 Several studies have reported activation of Nur77-dependent transactivation in 
different cell lines and these responses primarily involve the AF-1 domain of Nur77 and 
activation by kinases (464, 478, 479).  For example, induction of Nur77-dependent 
transactivation was observed for the coactivator ASC-2 in CV-1 and HeLa cells; 
however, this effect was dependent on calcium/calmodulin-dependent protein kinase IV 
and did not involve direct ASC-2-Nur77 interactions (478).  Transactivation mediated by 
Nur77 homodimers is enhanced by protein kinase A and SRC1-3 in CV-1 and AtT-20 
cells and these responses were AF-1-dependent (464).  Another report also confirmed 
that Nur77 transactivation in C2C12 and COS-1 cells was enhanced by SRCs and other 
coactivators, and involved direct interactions of coactivators with the A/B (and not E/F) 
domain of Nur77 (479).  These observations were consistent with the crystal structure of 
Nurr1 which lacks the "classical binding site for coactivators" (475).  However, ligand-
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dependent activation of Nur77 E/F domain observed in this study (Fig. 6.1C) should also 
be accompanied by interactions with some nuclear receptor coactivators/coregulators.  
Initial studies sowed that in the absence of ligand, VP-Nur77(E/F) did not interact with 
GAL-4-coactivators (PGF-1, CARM-1, SRC1-3, TRAP 220) or GALR-SMRT chimeras; 
however, DIM-C-pPhCF3, DIM-C-pPhOCH3 and DIM-C-Ph induced interactions 
between several common nuclear receptor coactivators (PGC-1, SRC-1 and TRAP220) 
and the LBD (E/F) of Nur77 in mammalian two-hybrid assays (Figs. 6.3B – 6.3D).  
These results are consistent with other studies on activation of nuclear receptors by 
ligands and their interactions with specific coactivators through binding receptor E/F 
domains.  For example, our recent studies with PPARγ-active C-substituted DIMs in 
colon cancer cells show that ligand-induced PPARγ(E/F domain)-coactivator 
interactions in mammalian two-hybrid assays primarily involved PGC-1 (393), whereas 
C-DIM-induced Nur77-coactivator interactions in Panc-28 cells involve multiple 
coactivators.  Although the crystal structure of unliganded Nurr1 shows that this receptor 
does not contain a classical coactivator interaction site in the E/F domain (helix 12), 
novel coactivator interactions surfaces have recently been identified between helices 11 
and 12 in Nurr1 (480).  This region is similar in human Nur77 and current studies are 
investigating C-DIM-induced interaction surfaces between the E/F domain of Nur77 and 
coactivators.  In summary, the transactivation and coactivator-Nur77 interactions 
induced by DIM-C-pPhCF3, DIM-C-pPhOCH3 and DIM-C-Ph are consistent with 
results obtained for other ligand-activated nuclear receptors suggesting that selected C-
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substituted DIMs are a novel class of compounds that induce E/F domain-dependent 
activation of Nur77. 
 Treatment of Panc-28 cells with Nur77-active C-substituted DIMs agonists 
decreased cell survival (Fig. 6.4A) and induced nuclear condensation within 48 and 24 
hr, respectively and this is typically observed in cells undergoing cell death.  We 
therefore further examined Nur77-mediated induction of PARP cleavage which is a 
well-characterized downstream marker of activated cell death pathways.  PARP cleavage 
was induced in Panc-28 cells treated with Nur77 agonists (Fig. 6.5B), and similar results 
were observed in other pancreatic, prostate and breast cancer cell lines (Fig. 6.5D).  
Annexin V staining was also observed in Panc-28 cells treated with Nur77-active C-
DIMs (Fig. 6.5C) and these data further confirm induction of apoptosis in these cancer 
cell lines.  Previous studies report that induction of cell death pathways by apoptosis-
inducing agents in some cancer cell lines is accompanied by translocation of Nur77 from 
the nucleus to the cytosol/mitochondria, and this has been linked to cytochrome c release 
and direct interaction of Nur77 with bcl-2 (453-458).  In contrast, we observed that 
treatment of Panc-28 cells with Nur77-active C-DIMs resulted only in formation of a 
nuclear complex (Figs. 6.4A and 6.4B).  Moreover, inhibition of nuclear export of Nur77 
by LMB did not affect PARP cleavage induced by Nur77-active C-DIMs (Fig. 6.5E) 
suggesting that this response is mediated through nuclear Nur77.  This nuclear pathway 
for induction of apoptosis is in contrast to the effects observed for TPA and CD437 
which induce nuclear export of Nur77 in cancer cell lines and inhibition of Nur77 
nuclear export by LMB inhibits induction of apoptosis (453, 454).  These results clearly 
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distinguish between the induction of cell death pathways in cancer cells through ligand-
dependent activation of nuclear Nur77 (this study) and through induction of Nur77 
nuclear translocation (453-458).   
 Overexpression of Nur77 in thymocytes induces expression of several genes 
associated with apoptosis (469), and at least one of the genes, TRAIL (protein and 
mRNA), is also induced by Nur77 agonists in Panc-28 cells (Figs. 6.6A and 6.6B).  
RNA interference assays with iNur77 (Fig. 6.6D) and inhibition studies with the Nur77 
antagonist DIM-C-pPhOH (Fig. 6.6E) demonstrate that induction of TRAIL and PARP 
cleavage by DIM-C-pPhOCH3 and DIM-C-Ph are Nur77-dependent.  Thus, the nuclear 
action of Nur77 agonists in cancer cell lines is comparable to the transcriptionally-
dependent pathway observed in T-cells overexpressing Nur77 (469). TRAIL typically 
activates caspase 8 and the extrinsic pathways of apoptosis and the caspase 8 inhibitor Z-
IETD-FMK significantly blocks (>60%) induction of PARP cleavage by Nur77 agonists 
(Fig. 6.5C).  The pancaspase inhibitor Z-VAD-FMK blocked >90% of induced PARP 
cleavage suggesting that although TRAIL may be a major Nur77-induced gene in Panc-
28 cells, other pro-apoptotic genes may also be induced and these are currently being 
investigated.  We also observed in xenograft experiments that DIM-C-pPhOCH3 
inhibited tumor growth in athymic nude mice bearing Panc-28 cell xenografts (Fig. 6.7).  
 In summary, results of this study have identified a novel group of C-substituted 
DIMs that activate the orphan receptor Nur77 through the E/F domain.  These results are 
in contrast to previous reports showing that kinase/coactivator-dependent activation of 
Nur77 was primarily AF-1-dependent (460, 478, 479).  It has also been reported that 
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nuclear receptor coactivators interact with the N-terminal A/B but not E/F domains of 
Nur77 and in the absence of C-DIM compounds, coactivator-Nur7(E/F) interactions 
were not observed in this study.  However, DIM-C-pPhCF3, DIM-C-Ph and DIM-C-
pPhOCH3 induced coactivator interactions with the E/F domain of Nur77 (Fig. 6.3) and 
this was consistent with Nur77 (nuclear)-dependent transactivation.  Activation of Nur77 
by selected C-DIMs is associated with decreased cancer cell survival, induction of 
apoptosis, and induced expression of the apoptotis gene/protein TRAIL.  These results 
suggest that C-DIM ligands that activate Nur77 are a potential new class of anticancer 
agents and their activities and mechanisms of action in other cancer cell lines are 
currently being investigated. 
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CHAPTER VII 
2-CYANO-3,12-DIOXOOLEAN-1,9-DIEN-28-OIC ACID (CDDO) AND 
RELATED COMPOUNDS INHIBIT GROWTH OF COLON CANCER CELLS 
THROUGH PEROXISOME PROLIFERATOR-ACTIVATED RECEPTOR γ-
DEPENDENT AND -INDEPENDENT PATHWAYS* 
Introduction 
 2-Cyano-3,12-dioxooleana-1,9-dien-28-oic acid (CDDO) is a synthetic 
triterpenoid-derived compound structurally-related to the pentacyclic triterpenoids 
oleanolic and ursolic acids which exhibit anti-inflammatory and anticarcinogenic 
activities (481-483).  CDDO and related compounds inhibit growth of multiple cancer 
cell lines, induced differentiation and inhibited inducible nitric oxide synthase (iNOS) 
and cyclooxygenase 2 activities (432, 433, 481, 483-486).  CDDO and the methyl ester 
derivative (CDDO-Me) bound peroxisome-proliferator-activated receptor γ (PPARγ) and 
CDDO induced transactivation in CV-1 cells transfected with PPARγ-responsive GAL4-
PPARγ or PPRE (promoter) constructs (487).  CDDO alone or in combination with the 
RXR agonist LG100268 induced 3T3-L1 differentiation, whereas CDDO-Me was 
inactive in this assay.  It was suggested that CDDO was a PPARγ agonist, whereas 
__________________ 
*Reprinted with permission from  “2-Cyano-3,12-dioxoolean-1,9-dien-28-oic acid and 
related compounds inhibit growth of colon cancer cells through peroxisome proliferator-
activated receptor gamma-dependent and -independent pathways” by Chintharlapalli S, 
Papineni S, Konopleva M, Andreef M, Samudio I, Safe S. Mol Pharmacol 2005;68:119-
128. Copyright 2005 by American Society for Pharmacology and Experimental
Therapeutics. All rights reserved.
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 CDDO-Me exhibited partial antagonist activity (487). 
 
 CDDO, CDDO-Me and an imidazole ester (CDDO-Im) decrease cancer cell 
survival, and their cell context-dependent responses and mechanisms of action have been 
investigated (488-495).  These triterpenoid compounds are potent inducers of 
differentiation and apoptosis in leukemia cells; however, their pro-apoptotic effects were 
somewhat variable among different cell lines.  CDDO-Me induced intrinsic apoptotic 
pathways in HL-60 cells and enhanced responses were observed after cotreatment with 
RXR ligands (491).  CDDO-induced apoptosis in HL-60 and U937 cells were inhibited 
by dominant negative PPARγ expression and the PPARγ antagonist N-(4'-aminopyridyl-
2-chloro-5-nitrobenzamide (T007) (494).  CDDO and related compounds also induced 
caspase 8-dependent pathways in leukemia cells (489, 490, 492-494), and this may be 
due, in part, to downregulation of FLIP, an endogenous inhibitor of caspase-8 activation.  
CDDO also induced apoptosis in leukemia cells through enhanced oxidative stress (493) 
and loss of mitochondrial membrane potential (495).  In breast cancer cells, CDDO 
inhibits growth of ER-positive and ER-negative cells and tumor growth in athymic nude 
mouse models and this correlated with modulation of genes associated with cell cycle 
progression, apoptosis and ER stress (496).  In COLO 16 human skin cancer cells, 
CDDO induced apoptosis and this was due, in part, to ER stress and direct mitochondrial 
effects that disrupted calcium homeostasis (497).  CDDO-Me induced both the intrinsic 
and extrinsic apoptosis pathway in lung cancer cell lines (498, 499), and a caspase 8-
dependent apoptotic pathway was activated by CDDO in human osteosarcoma cells 
(500).  CDDO also inhibited growth of several ovarian cancer cell lines that express 
 222
PPARγ and, since cotreatment with the PPARγ antagonist T007 did not block the effects 
of CDDO, it was concluded that this response was PPARγ-independent (363, 501). 
 This study reports the effects of CDDO compound on SW-480 and other colon 
cancer cell lines and investigates the concentration-dependent induction of PPARγ-
dependent and -independent responses.  Growth inhibitory IC50 values for CDDO-Me 
and CDDO-Im were ≤ 0.2 μM in SW-480, HCT-116 and HT-29 colon cancer cells, 
whereas IC50 values for CDDO were ≤ 0.5 μM after 6 days of growth.  CDDO, CDDO-
Im and CDDO-Me also induced PPARγ-dependent transactivation and coactivator-
PPARγ interactions in mammalian two-hybrid assays in SW-480 cells.  In the same cell 
lines, CDDO and related compounds induce PPARγ-dependent upregulation of the 
tumor suppressor gene caveolin-1 and PPARγ-independent apoptosis and these 
responses were activated over distinct and separable concentrations in SW-480 cells. 
Materials and Methods 
Cell culture 
 Human colon cancer cell lines SW480 and HT-29 were provided by M.D. 
Anderson Cancer Center; HCT-116 cells were obtained from American Type Culture 
Collection (Manassas, VA). SW480 and HT-29 cells were maintained in Dulbecco’s 
Modified Eagle’s Medium nutrient mixture F-12 Ham (DMEM:Ham’s F-12; Sigma, St. 
Louis, MO) with phenol red supplemented with 0.22% sodium bicarbonate, 0.011% 
sodium pyruvate and 5% fetal bovine serum (FBS) (Intergen, Purchase, NY) and 10 
ml/L of 100X antibiotic antimycotic solution (Sigma). HCT-116 cells were maintained 
in RPMI-1640 medium (Sigma) supplemented with 0.22% sodium bicarbonate, 0.011% 
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sodium pyruvate, 0.45% glucose, 0.24% HEPES, 10% FBS and 10 ml/L of 100X 
antibiotic antimycotic solution (Sigma).  
Chemicals, reagents, plasmids and antibodies 
 The PPARγ antagonist N-(4'-aminopyridyl)-2-chloro-5-nitrobenzamide (T007) 
was synthesized in this laboratory and confirmed by gas chromatography-mass 
spectrometry.  CCDO compounds were provided by Dr. Edward Sausville 
(Developmental Therapeutics Program, National Cancer Institute, Bethesda, MD) 
through the Rapid Access to Intervention Developmental Program. Horseradish 
peroxidase substrate for Western blot analysis was purchased from NEN Life Science 
Products (Boston, MA). Cell lysis buffer, and luciferase reagent were purchased from 
Promega (Madison, WI), and β-galactosidase (β-gal) reagent was from Tropix (Bedford, 
MA). Small inhibitory RNA (siRNA) duplexes were prepared by Dharmacon Research 
(Lafayette, CO). Previous studies in this laboratory have reported oligonucleotide 
sequences for PPARγ and lamin A/C siRNA (359). The Gal4 reporter containing 5X 
Gal4 DBD (Gal4Luc) was kindly provided by Dr. Marty Mayo (University of North 
Carolina, Chapel Hill, NC). Gal4DBD-PPARγ construct (gPPARγ) was a gift of Dr. 
Jennifer L. Oberfield (Glaxo Wellcome Research and Development, Research Triangle 
Park, NC) and PPARγ expression plasmid and pM-PPARγ coactivator-1 (PGC1) were 
gifts of Dr. Bruce M. Spiegelman (Harvard University, Boston, MA).  The PPRE-luc 
construct contains three tandem PPARγ response elements (PPREs) with a minimal 
TATA sequence in pGL2. The PPARγ2-VP16 fusion plasmid (VP-PPARγ) contained the 
DEF region of PPARγ (amino acids 183–505) fused to the pVP16 expression vector and 
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the GAL4-coactivator fusion plasmids pM-SRC1, pMSRC2, pMSRC3, pM-DRIP205 
and pM-CARM-1 were kindly provided by Dr. Shigeaki Kato (University of Tokyo, 
Tokyo, Japan).  Antibodies for caveolin-1 (sc-894), PARP (sc-8007), Akt and phospho-
Akt were purchased from Santa Cruz Biotechnology (Santa Cruz, CA).  Monoclonal 
anti-β-actin was purchased from Sigma (St. Louis, MO).  
Cell proliferation assay 
Cells (2 x 104) were plated in 12-well plates and media was replaced the next day 
with DMEM:Ham’s F-12 media containing 2.5% charcoal-stripped FBS  and either 
vehicle (DMSO) or the indicated ligand and dissolved in DMSO.  Fresh media and 
compounds were added every 48 hr.  Cells were counted at the indicated times using a 
Coulter Z1 cell counter.  The proliferation of SW480 cells was also carried out as 
described above using the colorimetric WST1 assay according to the manufacturer's 
instructions (Roche, Mannheim, Germany).  Cells (4000/well) were seeded in 96 well 
plates and assayed after 48 hr.  Each experiment was carried out at least three times and 
results are expressed as means ± SE for each determination. 
Transfection and luciferase assay 
Colon cancer cells (1 x 105) were seeded onto 24-well plates in DME-F12 media 
supplemented with 2.5% charcoal-stripped FBS and grown overnight. Transient 
transfections were performed using LipofectAmine reagent (Invitrogen) according to the 
protocol provided by the manufacturer.  For transfections with siRNA for PPARγ, the 
RNA concentration was 75 nM and Oligofectamine transfection regent (Invitrogen) was 
used.  Cotransfections were performed using Gal4Luc (0.4 μg), β-gal 0.04 μg), 
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Gal4DBD-PPARγ (0.04 μg), VP-PPARγ (0.04 μg), pM SRC1 (0.04 μg), pMSRC2 (0.04 
μg), pMSRC3 (0.04 μg), pMPGC-1 (0.04 μg), pMDRIP205 (0.04 μg) and pMCARM-1 
(0.04 μg). After 5 hr of transfection, the transfection mix was replaced with complete 
media containing either vehicle (DMSO) or the indicated ligand for 20-22 hr. Cells were 
then lysed with 100 μl of 1X reporter lysis buffer and 30 μl of cell extract were used for 
luciferase and β-galactosidase assays.  A Packard Lumicount luminator (Packard 
Instruments Co., Downers Grove, IL) was used to quantitate luciferase and β-
galactosidase activities, and the luciferase activities were normalized to β-galactosidase 
activity. 
Western blot analysis 
 SW480, HT-29 and HCT-116 (3 x 105) cells were seeded in six-well plates in 
DMEM:Ham’s F-12 media containing 2.5% charcoal-stripped FBS for 24 hr and then 
treated with either the vehicle (DMSO) or the indicated compounds. Whole cell lysates 
were obtained using high salt buffer [50 mM HEPES, 500 mM NaCl, 1.5 mM MgCl2, 1 
mM EGTA, 10% glycerol and 1% Triton X-100 pH 7.5 and 5 μl/ml of Protease Inhibitor 
Cocktail (Sigma)]. Protein samples were incubated at 100°C for 2 min, separated on 
10% SDS-PAGE at 120 V for 3-4 hr in 1 X running buffer [25 mM Tris-base, 192 mM 
glycine, and 0.1% SDS (pH 8.3)], and transferred to polyvinylidene difluoride 
membrane (PVDF, Bio-Rad, Hercules, CA) at 0.1 V for 16 hr at 4°C in 1 X transfer 
buffer (48 mM Tris-HCl, 39 mM glycine, and 0.025% SDS). The PVDF membrane was 
blocked in 5% TBST-Blotto [10 mM Tris-HCl, 150 mM NaCl (pH 8.0), 0.05% Triton 
X-100 and 5% non-fat dry milk] with gentle shaking for 30 min and incubated in fresh 
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5% TBST-Blotto with 1:1000 (for caveolin-1), 1:250 (for PARP), 1:5000 (for β-actin) 
primary antibody overnight with gentle shaking at 4°C.  After washing with TBST for 10 
min, the PVDF membrane was incubated with secondary antibody (1:5000) in 5% 
TBST-Blotto for 90 min. The membrane was washed with TBST for 10 min and 
incubated with 10 ml of chemiluminiscence substrate (PerkinElmer Life Sciences) for 
1.0 min and exposed to Kodak X-OMAT AR autoradiography film (Eastman Kodak, 
Rochester, NY). Band intensities were evaluated by scanning laser densitometry (Sharp 
Electronics Corporation, Mahwah, NJ) using Zero-D Scanalytics software (Scanalytics 
Corporation, Billerica, MA).  
Results 
 Initial studies investigated the effects of CDDO, CDDO-Me and CDDO-Im on 
growth of SW-480, HT-29 and HCT-116 colon cancer cells.  Cells were treated with 
different concentrations of the test compounds on days 0, 2 and 4 (media and compounds 
were changed every 2 days) and cell numbers were determined 2, 4 and 6 days after 
treatment.  Significant inhibition of cell proliferation was observed for all compounds 
after treatment for 2 and 4 days, and IC50 values were ≤ 0.2 μM for CDDO-Me and 
CDDO-Im and ≤ 0.5 μM for CDDO in all three cell lines.  Cell survival results after 
treatment with the CDDO compounds (Fig. 7.1) were derived from the growth inhibition 
curves, and the percent cell survival was the ratio of the number of cells in the 
treated/DMSO (solvent) groups at each time point.  Higher concentrations of these 
compounds decreased cell numbers below the initial number of attached cells (i.e. cell 
death) and after 96 hr, the concentrations of CDDO, CDDO-Me and CDDO-Im that 
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induced cell death in all three cell lines were 1.0-2.5, 0.2 and 0.2 μM, respectively.  
CDDO decreased proliferation of SW480 cells using the WST-1 colorimetric assay (Fig. 
7.1D), and cotreatment of CDDO plus 5.0 μM T007 (PPARγ antagonist) significantly 
reversed the growth inhibitory effects of CDDO.  The results demonstrate a role for 
PPARγ in mediating the effects of CDDO in this assay. 
PPARγ-dependent transactivation assays 
 Previous studies showed that CDDO and related compounds activate PPARγ 
(487) and this was further investigated in SW-480 cells transfected a GAL4-PPARγ 
chimericexpression plasmid and a reporter construct (pGAL4) containing 5 tandem 
GAL4 response elements linked to a luciferase reporter gene.  The results (Fig. 7.2A) 
show that CDDO, CDDO-Me and CDDO-Im induced a concentration-dependent 
increase in luciferase activity and significant induction was observed at concentrations as 
low as 0.2, 0.025 and 0.025 μM, respectively.  Both CDDO and CDDO-Me induced a 
maximal 35- to 45-fold increase in luciferase activity; the maximal induced value for 
CDDO-Im was lower (< 30-fold); however, this may be due to toxicity of this compound 
at the higher concentrations or differential recruitment of coactivators or corepressors.  
Ligand-induced transactivation in SW-480 cells transfected with GAL4-PPARγ/pGAL4 
was also inhibited by the PPARγ antagonist T007 (Fig. 7.2B).  Maximal induction of 
luciferase activity by CDDO (2.5 μM), CDDO-Me (0.5 μM) and CDDO-Im (0.5 μM) 
was inhibited in cells cotreated with 5 μM T007.  Similar results were observed at lower 
concentrations of the CDDO compounds and also with the PPARγ antagonist GW9660.  
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The CDDO compounds also induced transactivation in SW-480 cells transfected with a 
construct (PPRE3-luc) containing three tandem PPARγ response elements linked to 
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Fig. 7.1. Effects of CDDO and related esters on colon cancer cell survival and proliferation.  SW-
480 (A), HT-29 (B) and HCT-116 (C) cells were treated with different concentrations of CDDO, 
CDDO-Me or CDDO-Im for 48 or 96 hr, and this percent cell survival was determined as 
described in the Materials and Methods.  Solvent (DMSO)-treated cells survival was set at 100% 
and significantly (p < 0.05) decreased cell numbers after treatment are indicated by an asterisk. 
The percent cell survival is derived from the treated/control (DMSO) cell number ratios.  (D) 
Effects of T007 on CDDO-induced cell proliferation.  SW480 cells were treated with different 
concentrations of CDDO and 5 μM T007 for 48 hr, and cell proliferation was determined 
colorimetrically using the cell proliferation reagent WST-1 as described in the Materials and 
Methods.  Significant (p < 0.05) inhibition of cell proliferation by CDDO is indicated by an 
asterisk (*) and reversal of these effects by 5 μM T007 is indicated (**). 
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Fig. 7.1. Continued 
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Fig. 7.2. PPARγ-dependent transactivation by CDDO, CDDO-Me and CDDO-Im in SW-480 cells. 
Activation of PPARγ-GAL4/pGAL4 (A) and inhibition by T007 (B).  SW-480 cells were 
transfected with PPARγ-GAL4/pGAL4, treated with different concentrations of CDDO 
compounds and luciferase activity determined as described in the Materials and Methods.  In a 
separate experiment, cells were treated with CDDO (2.5 μM), CDDO-Me (0.5 and 1.0 μM), or 
CDDO-Im (0.2 and 0.5 μM) alone or in combination with 5 μM T007.  Significant (p < 0.05) 
induction by CDDO, CDDO-Me and CDDO-Im is indicated by an asterisk and inhibition by T007 
is also indicated (**).  (C) Activation of PPRE3-luc.  SW-480 cells were transfected with PPRE3-
luc, treated with CDDO compounds and luciferase activity determined as described in the 
Materials and Methods.  Significant (p < 0.05) induction is indicated by an asterisk.  (D) RNA 
interference assay.  Cells were transfected with PPRE-luc, treated with the different CDDO 
compounds, and small inhibitory RNA for lamin (non-specific control) or PPARγ and luciferase 
activity determined as described in the Materials and Methods.  Significant (p < 0.05) induction by 
PPARγ agonist (*) and inhibition after cotransfection with iPPARγ (**) is indicated.  All 
experiments (A - D) are expressed as means ± SE for at least three separate determinations for 
each treatment group. 
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firefly luciferase.  The results (Fig. 7.2C) show that CDDO, CDDO-Me and CDDO-Im 
significantly induce transactivation at concentrations of 1.0, 0.2 and 0.2 μM, 
respectively, and maximal induction  (> 30-fold) was observed for CDDO-Me.  
Transactivation induced by CDDO compounds in SW-480 cells transfected with PPRE-
luc was inhibited after cotransfection with iPPARγ (Fig. 7.2D), and this correlates with 
comparable inhibition of PPARγ-dependent gene expression induced by other PPARγ 
agonists using iPPARγ (393).  These results confirm that CDDO, CDDO-Me and 
CDDO-Im activate PPARγ-dependent transactivation in SW-480 colon cancer cells. 
Induction of PPARγ-coactivator interactions by CDDO and related compounds 
 Previous reports show that different classes of PPARγ agonist induce structure-
dependent interactions of PPARγ with coactivators in mammalian two hybrid 
experiments (363, 393) and therefore the effects of CDDO compounds were investigated 
in a mammalian two hybrid assay in SW-480 cells transfected with pGAL4, VP-PPARγ 
and GAL4-coactivators/GAL4-SMRT (corepressor).  The results show that CDDO, 
CDDO-Me and CDDO-Im induce VP-PPARγ - pM coactivator interactions in SW-480 
cells transfected with SRC-1, SRC-2, TRAP 220, CARM-1 and PGC-1 (Fig. 7.3).  In 
contrast, CDDO and CDDO-Me but not CDDO-Im enhanced PPARγ-SRC-3 interaction; 
however, it is possible that higher concentrations of CDDO-Im would induce 
transactivation.  We also investigated interactions with the corepressor SMRT and the 
results indicate that all three compound increased transactivation but CDDO-Im was  
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Fig 7.3. CDDO-, CDDO-Me- and CDDO-Im-induced PPARγ-coactivator interactions in SW-480 
cells.  Ligand-induced interactions with SRC-1 (A), SRC-2 (B), SRC-3 (C), TRAP 220 (D), PGC-
1(E), CARM-1 (F), and SMRT (G).  Cells were transfected with VP-PPARγ and GAL4-
coactivator chimeric expression plasmids, treated with the CDDO compounds, and luciferase 
activity determined as described in the Materials and Methods.  Results are expressed as means ±
SE for at least three separate determinations for each treatment group and significant (p < 0.05) 
induction as indicated by an asterisk. 
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significantly more active than CDDO or CDDO-Im.  These results confirm that CDDO 
and related esters induce interactions between VP-PPARγ with pM-coactivators in SW-
480 cells and differences between compounds were primarily concentration-dependent. 
CDDO compounds induce caveolin-1 in colon cancer cells 
 Caveolin-1 is a tumor suppressor gene in colon cancer cells and previous reports 
show that PPARγ agonists induce this response in some colon cancer cell lines (364, 
393).  The results illustrated in Figure 7.4A show that after treatment of SW-480 cells 
with CDDO (0.25 - 0.5 μM), CDDO-Me (0.025 - 0.1 μM) and CDDO-Im (0.5 - 0.1 μM) 
for 3 days, caveolin-1 was induced by all three compounds.  In contrast, induction of 
PARP cleavage, a marker of apoptosis was not observed at these concentrations.  A 
slight increase in p27 was observed, and cyclin D1 was unchanged by these treatments.  
In a separate experiment, SW-480 cells were treated with the CDDO compounds or 
T007 alone and in combination for 3 days and caveolin-1 protein expression was 
determined (Figs. 7.4B – 7.4D).  The results show that 5 μM T007 alone did not affect 
levels of caveolin-1 protein; however, in cells cotreated with CDDO, CDDO-Me or 
CDDO-Im plus T007, there was a decrease in caveolin-1 protein expression compared to 
cells treated with the CDDO compounds alone.  These results complement the 
transactivation studies and demonstrate that induction of caveolin-1 by the CDDO 
compounds was inhibited by the PPARγ antagonist T007.  Induction of caveolin-1 by 
CDDO, CDDO-Me and CDDO-Im was also determined in HT-29 (Fig. 7.5A) and HCT-
116 (Fig. 5B) cells, and induction was observed in both colon cancer cell lines, The  
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Fig 7.4. Induction of caveolin-1, Akt phosphorylation, and PARP cleavage by CDDO and related 
esters in SW-480 cells.  (A) Induction of caveolin-1 and PARP cleavage.  SW-480 cells were 
treated with CDDO, CDDO-Me and CDDO-Im for 3 days and caveolin-1 and PARP cleavage 
proteins were determined by Western blot analysis of whole cell lysates as described in the 
Materials and Methods.  T007 inhibition of caveolin-1 induction by CDDO (B), CDDO-Me (C), 
and CDDO-Im (D).  Cells were treated with the compounds alone or in combination with 5 μM 
T007 as described in (A), and whole cell lysates were analyzed by Western blot analysis.  β-Actin 
served as a loading control for these experiments.  (E)  CDDO compounds induce Akt 
phosphorylation.  Cells were treated with the CDDO compounds as described in (A), and 
Akt/phospho-Akt were determined by Western blot analysis as described in the Materials and 
Methods. 
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Fig. 7.5. Induction of caveolin-1 and PARP cleavage by CDDO compounds in colon cancer cell 
lines.  Induction by CDDO, CDDO-Me and CDDO-Im in HT-29 (A) and HCT-116 (B) cells. 
Cells were treated with different concentrations of CDDO and related esters for 3 days, and whole 
cell lysates were analyzed by Western blot analysis as described in the Materials and Methods. 
(C) Higher concentrations of CDDO, CDDO-Me and CDDO-Im induce PPARγ-independent 
PARP cleavage in SW-480 cells.  SW-480 cells were treated for 1 day with the indicated doses of 
CDDO compounds alone or in combination with 5.0 μM T007 and PARP cleavage was 
determined by Western blot analysis of whole cell lysates as described in the Materials and 
Methods.  β-Actin served as a loading control. 
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effects of caveolin-1 induction by CDDO compounds on levels of phospho-Erk in 
SW480 cells were minimal.  However, these compounds induced phosphatidylinositol-3-
kinase (PI3-K)-dependent phosphorylation of Akt (Fig. 7.4E), and this was consistent 
with results of a recent study in human 293 and HeLa cells overexpressing caveolin-1 
(398).  PARP cleavage was minimal or not observed at the concentrations of CDDO 
compounds used in this experiment. 
 Cell survival studies (Fig. 7.1) indicated that higher concentrations of CDDO and  
related esters induced cell death and therefore we further investigated induction of PARP 
cleavage in SW-480 cells treated with 0.5 - 2.5 μM CDDO and 0.2 - 1.0 μM CDDO-Me 
and CDDO-Im for 1 day (Fig. 7.5C).  Longer treatment (i.e. 3 days) could not be 
determined due to extensive cell death and minimal cell survival.  These results 
demonstrate that the higher concentrations of CDDO and related esters induced PARP 
cleavage and this was consistent with the cell survival studies.  In contrast, the PPARγ 
antagonist T007 did not inhibit induced PARP cleavage, suggesting that this response 
was PPARγ-independent.  Moreover, at these higher concentrations, there was also a 
significant downregulation of cyclin D1, and this response was also not affected by T007 
(data not shown).  These results demonstrate that CDDO and related esters induce 
PPARγ-dependent and -independent responses associated with growth inhibition/cell 
death in colon cancer cells, and these mechanistic differences are concentration-
dependent. 
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Discussion 
 PPARγ is expressed in tumors from multiple tissues and cancer cell lines (257), 
and chemicals that activate PPARγ have been extensively investigated for their efficacy 
in cancer chemotherapy [reviewed in (355, 357, 383-385, 502)].  PPARγ agonists 
typically decrease cancer cell survival due to induction of differentiation genes and 
apoptosis and modulation of genes/proteins linked to G1 → S phase progression.  It is 
somewhat paradoxical that induction of these responses by PPARγ agonists, such as the 
thiazolidinediones (TZDs), 15-deoxy-Δ12,14-prostaglandin J2 (PGJ2), and CDDO 
compounds, appears to be both PPARγ-dependent and -independent and the relative 
contributions of these pathways are often not well defined.  For example, troglitazone 
inhibits growth and induces apoptosis in colon cancer cell lines and induces early growth 
response-1 (Egr-1) gene expression which in turn activates downstream growth 
inhibitory effects (397).  This response was unique to troglitazone among PPARγ 
agonists and was induced via PPARγ-independent pathways. 
 CDDO, CDDO-Me and CDDO-Im activate PPARγ in transactivation assays and 
CDDO-induced apoptosis was inhibited by dominant negative PPARγ in myeloid HL-60 
cells and by T007 in myeloid U937 cells (494).  In another study, CDDO-Im induced 
differentiation in leukemia cells that was not inhibited by the PPARγ antagonist 
GW9662 (500) and T007 did not affect inhibition of SKOV3 ovarian cancer cell growth 
by CDDO (501).  Thus, it is clear that CDDO and related compounds activate PPARγ-
dependent and -independent pathways that inhibit cancer cell growth and this dual action 
 245
may be beneficial for cancer chemotherapy.  Results of this study demonstrate that 
CDDO, CDDO-Me and CDDO-Im also inhibit growth and survival of colon cancer cells 
(Fig. 7.1) and we have primarily used SW-480 cells as a model for determining 
activation of PPARγ-dependent and -independent pathways by CDDO and related esters. 
 CDDO, CDDO-Me and CDDO-Im activate PPARγ-dependent transactivation 
(Fig. 7.2) and coactivator interactions (Fig. 7.3) and differences between compounds 
were primarily associated with the fold-induction response where induction was lower 
for CDDO-Im due to the higher toxicity of this compound.  Previous studies indicate that 
induced transactivation in the mammalian two hybrid assay using VP-PPARγ and 
GAL4-coactivators was both structure and coactivator-dependent (364, 393).  For 
example, a series of 1,1-bis(3'-indolyl)-1-(p-substitutedphenyl)methanes [methylene-
substituted 1,1-bis(3'-indolyl)methanes (C-DIMs)], that activate PPARγ, primarily 
induced interactions of PPARγ primarily with PGC-1 in colon cancer cell lines (393), 
whereas CDDO, CDDO-Me and CDDO-Im induced interactions with several 
coactivators including SRC-1, SRC-2, CARM-1, TRAP 220 and PGC-1.  The main 
distinguishing feature among the CDDO compounds was the failure of CDDO-Im to 
induce PPARγ-SRC-3 interactions with VP-PPARγ and the relatively high activity of 
CDDO-Im to induce PPARγ interactions with the co-repressor SMRT.  These 
differences among CDDO compounds in PPARγ-dependent interactions with 
coactivators might result in some tissue/cell selectivity in their PPARγ dependent 
responses. 
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 PPARγ agonists such as TZDs, PGJ2 and C-DIMs typically inhibit 
genes/proteins associated with cell cycle progression and differentiation in cancer cell 
lines and these responses may be receptor dependent or independent.  Previous studies in 
colon cancer cell lines with C-DIMs showed that these compounds had minimal effects 
on critical cell cycle proteins cyclin D1, p21 and p27 (393); and similar results were 
observed in this study at the lower concentrations of CDDO compounds.  The induction 
of caveolin-1 by PGJ2, C-DIMs and TZDs has been observed in colon cancer cell lines 
(364, 393) and overexpression of caveolin-1 inhibits colon cancer cell growth in vitro 
and tumor growth in athymic nude mice (364, 375, 393).  Results in Figures 7.4 and 7.5 
show that CDDO, CDDO-Me and CDDO-Im significantly induce caveolin-1 in colon 
cancer cells at concentrations that also inhibit cell growth (Figs. 7.1).  Moreover, in SW-
480 cells, the induced caveolin-1 expression is inhibited by the PPARγ antagonist T007.  
The relatively low concentrations of CDDO, CDDO-Me and CDDO-Im that inhibit SW-
480 cell proliferation induce minimal to non-detectable apoptosis as indicated by PARP 
cleavage (Figs. 7.4, 7.5A and 7.5B).  We also observed that CDDO compounds induced 
PI3-K-dependent Akt phosphorylation which is normally associated with increased cell 
survival.  However, a recent report (398) showed that overexpression of caveolin-1 in 
human 293 and HeLa cells also resulted in upregulation of the PI3-K/Akt pathway which 
sensitized the cells to stress-induced cytotoxicity. 
 In contrast, higher concentrations of CDDO compounds induce apoptosis and 
PARP cleavage; however, this response was PPARγ-independent and not inhibited by 
T007 (Fig. 7.5C).  Moreover, at the higher concentrations of CDDO, CDDO-Me and 
 247
CDDO-Im, there was also a marked decrease in cyclin D1 protein expression which was 
also not inhibited by T007.  Similar results have also been observed in this laboratory 
after treatment of breast cancer cells by PGJ2, TZDs and C-DIMs (359, 361).  These 
data demonstrate that CDDO and related esters inhibit colon cancer cell growth through 
both PPARγ-dependent and -independent pathways which are observed at different 
concentrations and are linked to growth inhibition and cell death, respectively. 
 Previous reports of mechanistic differences regarding the role of PPARγ agonists 
in mediating growth inhibitory responses in different cancer cell lines may be explained, 
in part, by results of this study.  CDDO and related esters are a unique example of a 
specific structural class of PPARγ agonists that induce both PPARγ-dependent (caveolin 
induction) and -independent (apoptosis) responses over a relatively narrow dose range in 
colon cancer cells.  It is possible that the antimitogenic and anticarcinogenic activities of 
PPARγ agonists may be enhanced when the dose ranges for their PPARγ-dependent and 
-independent responses are similar, and this may contribute to the high potencies 
observed for CDDO, CDDO-Me and CDDO-Im in colon cancer cell lines.  Currently, 
we are investigating the dose-dependent effects of thiazolidinediones, CDDO and related 
esters and C-DIMs in different cancer cell lines to determine their relative potencies in 
activating PPARγ-dependent and -independent pathways.  This approach will provide 
important mechanistic insights into the activities of these compounds and their potential 
clinical applications for cancer chemotherapy. 
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CHAPTER VIII 
SUMMARY 
1,1-Bis(3'indolyl)-1-1(p-substitutedphenyl)methanes containing p-
trifluoromethyl (DIM-C-pPhCF3), p-t-butyl (DIM-C-pPhtBu), and p-phenyl (DIM-C-
pPhC6H5) groups induce peroxisome proliferator-activated receptor γ (PPARγ)-mediated 
transactivation in HT-29, HCT-15, HCT-116, RKO and SW480 colon cancer cell lines 
and, KU7 and 253JB-V33 bladder cancer cell lines. Rosiglitazone also induces 
transactivation in these cell lines and inhibited growth of HT-29 cells which express 
wild-type PPARγ, but not HCT-15 cells which express mutant (K422Q) PPARγ.  In 
contrast, DIM-C-pPhCF3, DIM-C-pPhtBu and DIM-C-pPhC6H5 inhibited growth of both 
HT-29 and HCT-15 cells with IC50 (50% growth inhibition) values ranging from 1 to 10 
μM.  Rosiglitazone and diindolylmethane (DIM) analogs did not affect expression of 
cyclin D1, p21 or p27 protein levels or apoptosis in HCT-15 or HT-29 cells but induced 
keratin 18 in both cell lines.  However, rosiglitazone induced caveolins 1 and 2 in HT-29 
but not HCT-15 cells, whereas these differentiation markers were induced by DIM-C-
pPhCF3 and DIM-C-pPhC6H5 in both cell lines.  Since overexpression of caveolin 1 is 
known to suppress colon cancer cell and tumor growth, the growth inhibitory effects of 
rosiglitazone and the DIM compounds are associated with PPARγ-dependent induction 
of caveolins. 
These PPARγ-active compounds also inhibited the proliferation of  KU7 and 
253J-BV bladder cancer cells, and the corresponding IC50 values were 5-10 µM and 1-5 
µM, respectively. In the less responsive KU7 cells, the PPARγ agonists induced 
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caveolin-1 but no changes in the cell cycle proteins cyclin D1, p27, or p21; in 253J-BV 
cells, the PPARγ agonists did not affect caveolin-1, cyclin D1, or p27 expression but did 
induce p21 protein. In KU7 cells, induction of caveolin-1 by each of the PPARγ agonists 
was significantly downregulated after cotreatment with the PPARγ antagonist GW9662. 
DIMC-pPhCF3 (60 mg/kg 3 times a week for 4 weeks) inhibited the growth of implanted 
KU7 orthotopic and subcutaneous tumors by 32% and 60%, respectively, and produced 
a corresponding decrease in proliferation index. Treatment of KU7 cells with DIM-C-
pPhCF3 also elevated caveolin-1 expression by 25-30%, suggesting a role for this protein 
in mediating the antitumorigenic activity of DIM-C-pPhCF3 in bladder cancer.  
The PPARγ-active 1,1-bis-(3'-indolyl)-1-(p-substitutedphenyl)methanes 
containing p-trifluoromethyl (DIM-C-pPhCF3), p-t-butyl (DIM-C-pPhtBu), and phenyl 
(DIM-C-pPhC6H5) substituents had minimal effects on expression of cell cycle proteins 
and did not induce caveolin-1 in HCT-116 cells.  However, these compounds induced 
NSAID-activated gene-1 (NAG-1) and apoptosis in HCT-116 cells and, in time-course 
studies, the PPARγ agonists maximally induced early growth response-1 (Egr-1) protein 
within 2 hr, whereas a longer time course was observed for induction of NAG-1 protein.  
These data, coupled with deletion and mutation analysis of both the Egr-1 and NAG-1 
gene promoters, indicate that activation of NAG-1 by these compounds was dependent 
on prior induction of Egr-1, and induction of these responses were PPARγ-independent.  
Results of kinase inhibitor studies also demonstrated that activation of Egr-1/NAG-1 by 
methylene-substituted diindolylmethanes (C-DIMs) was phosphatidylinositol-3-kinase-
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dependent, and this represents a novel receptor-independent pathway for C-DIM-
induced growth inhibition and apoptosis in colon cancer cells. 
At concentrations from 2.5 - 7.5 μM, the PPARγ agonists induce caveolin-1 and 
phosphorylation of Akt and cotreatment with the PPARγ antagonist GW9662 inhibited 
the induction response in SW480 colon cancer cells.  In contrast, higher concentrations 
(10 μM) of DIM-C-pPhCF3 and DIM-C-pPhC6H5 induce apoptosis which is PPARγ-
independent and this was accompanied by loss of caveolin-1 induction but induction of 
pro-apoptotic nonsteroidal anti-inflammatory drug activated gene-1 (NAG-1).  In 
athymic nude mice bearing SW480 cell xenografts, DIM-C-pPhC6H5 inhibits tumor 
growth at doses of 20 and 40 mg/kg/day and immunohistochemical staining of the 
tumors showed induction of apoptosis and NAG-1 expression.  Thus, the indole-derived 
PPARγ active compounds induce both receptor-dependent and -independent responses in 
SW480 cells which are separable over a narrow range of concentrations and this dual 
mechanism of action enhances their antiproliferative and anticancer activities. 
Nur77 is an orphan receptor and a member of the nerve growth factor-I-B 
subfamily of the nuclear receptor family of transcription factors. Based on the results of 
transactivation assays in pancreatic and other cancer cell lines, we have now identified 
for the first time Nur77 agonists typified by 1,1-bis(3-indolyl)-1-(p-anisyl)methane that 
activate GAL4-Nur77 chimeras expressing wild-type and the ligand binding domain 
(E/F) of Nur77. In Panc-28 pancreatic cancer cells, Nur77 agonists activate the nuclear 
receptor, and downstream responses include decreased cell survival and induction of cell 
death pathways, including tumor necrosis factor-related apoptosis-inducing ligand 
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(TRAIL) and poly(ADP-ribose) polymerase (PARP) cleavage. Moreover, the 
transactivation and apoptotic responses are also induced in other pancreatic, prostate, and 
breast cancer cells that express Nur77. In Panc-28 cells, small inhibitory RNA for Nur77 
reverses ligand-dependent transactivation and induction of TRAIL and PARP cleavage. 
Nur77 agonists also inhibit tumor growth in vivo in athymic mice bearing Panc-28 cell 
xenografts. These results identify compounds that activate Nur77 through the ligand 
binding domain and show that ligand-dependent activation of Nur77 through nuclear 
pathways in cancer cells induces cell death and these compounds are a novel class of 
anticancer agents. 
2-Cyano-3,12-dioxoolean-1,9-dien-28-oic acid (CDDO) and the corresponding 
methyl (CDDO-Me) and imidazole (CDDO-Im) esters induce peroxisome proliferator-
activated receptor gamma (PPARγ)-dependent transactivation in SW-480 colon cancer 
cells, and these responses were inhibited by small inhibitory RNA for PPARγ (iPPARγ).  
Moreover, in a mammalian two-hybrid assay using VP-PPARγ and GAL4-
coactivator/corepressor chimeras and a construct (pGAL4) containing five tandem 
GAL4 response elements, CDDO, CDDO-Me and CDDO-IM induce transactivation and 
PPARγ interaction with multiple coactivators.  A major difference among the three 
PPARγ agonists was the higher activity of CDDO-Im to induce PPARγ interactions with 
the corepressor SMRT.  CDDO, CDDO-Me and CDDO-Im inhibited SW-480, HCT-116 
and HT-29 colon cancer cell proliferation at low concentrations and induced cell death at 
higher concentrations.  Growth inhibition at lower concentrations correlated with 
induction of the tumor suppressor gene caveolin-1 which is known to inhibit colon 
 252
cancer cell growth.  Induction of caveolin-1 by CDDO, CDDO-Me and CDDO-Im was 
inhibited by the PPARγ antagonist N-(4'-aminopyridyl-2-chloro-5-nitrobenzamide 
(T007), whereas higher doses induced apoptosis (PARP cleavage) which was not 
inhibited by T007.  These results illustrate that CDDO-, CDDO-Me and CDDO-Im 
induce both PPARγ-dependent and -independent responses in colon cancer cells and 
activation of these pathways are separable and concentration-dependent for all three 
compounds. 
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